var title_f33_28_34240="Halo nevus 2";
var content_f33_28_34240=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F57744&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F57744&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Halo nevus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An inflamed compound nevus is encircled by a white halo of depigmentation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_28_34240=[""].join("\n");
var outline_f33_28_34240=null;
var title_f33_28_34241="Verruca vulgaris - hand";
var content_f33_28_34241=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F70615&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F70615&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Verruca vulgaris",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A keratotic papule with peripheral hyperpigmentation is present on the hand of this patient with verruca vulgaris (common wart).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_28_34241=[""].join("\n");
var outline_f33_28_34241=null;
var title_f33_28_34242="Patient information: Down syndrome (The Basics)";
var content_f33_28_34242=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15529\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/55/21365\">",
"         Problems caused by Down syndrome",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/56/34690\">",
"          Child with Down syndrome",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/21/25951\">",
"           Transverse palmar crease",
"          </a>",
"          <li>",
"           <a class=\"graphic graphic_table\" href=\"UTD.htm?42/25/43420\">",
"            When to check for health problems in children with Down syndrome",
"           </a>",
"          </li>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?41/57/42897\">",
"         Patient information: Amniocentesis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?38/46/39663\">",
"         Patient information: Chorionic villus sampling (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?30/31/31218\">",
"         Patient information: Newborn appearance (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?10/50/11043\">",
"         Patient information: Should I have a screening test for Down syndrome during pregnancy? (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?28/45/29394\">",
"         Patient information: Down syndrome (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/50/2851\">",
"         Patient information: Should I have a screening test for Down syndrome during pregnancy? (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Down syndrome (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/down-syndrome-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H558705990\">",
"      <span class=\"h1\">",
"       What is Down syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Down syndrome is a life-long condition that a person is born with. It can cause learning problems and medical problems affecting the heart, blood, stomach, and other organs. The learning and medical problems in people with Down syndrome can range from mild to severe.",
"     </p>",
"     <p>",
"      People with Down syndrome have a problem with their chromosomes. Chromosomes are tiny parts of cells that carry the plans that make our bodies the way they are. People with Down syndrome have an extra chromosome. This causes their problems and makes them look a little different than people without Down syndrome.",
"     </p>",
"     <p>",
"      Doctors do not know why some babies are born with Down syndrome. But they do know that a woman has a greater chance of having a baby with Down syndrome as she gets older.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H558705997\">",
"      <span class=\"h1\">",
"       What are the symptoms of Down syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;When a baby with Down syndrome is born, he or she often has:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A flat face (",
"        <a class=\"graphic graphic_picture graphicRef67446 \" href=\"UTD.htm?33/56/34690\">",
"         picture 1",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        Extra skin at the back of the neck",
"       </li>",
"       <li>",
"        Eyes that slant up",
"       </li>",
"       <li>",
"        Loose and floppy muscles",
"       </li>",
"       <li>",
"        Ears that look unusual",
"       </li>",
"       <li>",
"        Only one crease across the palm of the hand (",
"        <a class=\"graphic graphic_picture graphicRef61017 \" href=\"UTD.htm?25/21/25951\">",
"         picture 2",
"        </a>",
"        )",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      As children with Down syndrome get older, they can also have:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A small head or short neck",
"       </li>",
"       <li>",
"        A flat top part of the nose",
"       </li>",
"       <li>",
"        Small or unusual ears",
"       </li>",
"       <li>",
"        Abnormal teeth",
"       </li>",
"       <li>",
"        An open mouth with a tongue that sticks out",
"       </li>",
"       <li>",
"        Short, wide hands",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H558706004\">",
"      <span class=\"h1\">",
"       Is there a test for Down syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Pregnant women can choose to test their baby for Down syndrome before the baby is born. Doctors can do different tests at different times during pregnancy to check if a baby has Down syndrome.",
"     </p>",
"     <p>",
"      A doctor can also do a blood test to check a baby for Down syndrome after it is born if the baby has symptoms of Down syndrome.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H558706011\">",
"      <span class=\"h1\">",
"       What learning problems can be caused by Down syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Babies with Down syndrome can take longer to learn how to sit, walk, and talk.",
"     </p>",
"     <p>",
"      Children with Down syndrome might also have problems with their behavior.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H558706018\">",
"      <span class=\"h1\">",
"       What medical problems can be caused by Down syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A person with Down syndrome can have different types of medical problems (",
"      <a class=\"graphic graphic_figure graphicRef79537 \" href=\"UTD.htm?20/55/21365\">",
"       figure 1",
"      </a>",
"      ). These can affect a person&rsquo;s:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Heart",
"       </li>",
"       <li>",
"        Blood",
"       </li>",
"       <li>",
"        Infection-fighting system",
"       </li>",
"       <li>",
"        Stomach",
"       </li>",
"       <li>",
"        Hormones, which are substances that control the way the body works",
"       </li>",
"       <li>",
"        Bone joints",
"       </li>",
"       <li>",
"        Vision and hearing",
"       </li>",
"       <li>",
"        Skin",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H558706025\">",
"      <span class=\"h1\">",
"       Should children with Down syndrome see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Children with Down syndrome should see a doctor or nurse for regular check-ups. The doctor or nurse will do exams and tests to check for problems that can be caused by Down syndrome (",
"      <a class=\"graphic graphic_table graphicRef50749 \" href=\"UTD.htm?42/25/43420\">",
"       table 1",
"      </a>",
"      ). Then he or she can treat these problems as early as possible.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H558706032\">",
"      <span class=\"h1\">",
"       How is Down syndrome treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors can treat most of the problems that are caused by Down syndrome. For example, a doctor can do surgery to treat a heart problem. Or a child can wear glasses to fix a vision problem.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H558706039\">",
"      <span class=\"h1\">",
"       Can women with Down syndrome get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Women with Down syndrome can get pregnant. If you have a daughter with Down syndrome, talk to her about sex and ways to avoid getting pregnant.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H558706046\">",
"      <span class=\"h1\">",
"       What will life be like for a person with Down syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many people with Down syndrome live happy and full lives. But they usually need help with some day-to-day tasks.",
"     </p>",
"     <p>",
"      Taking care of someone with Down syndrome has its ups and downs. If you have a hard time taking care of someone with Down syndrome, talk with your doctor or nurse. He or she can work with you to get help.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H558706195\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/50/11043?source=see_link\">",
"       Patient information: Should I have a screening test for Down syndrome during pregnancy? (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/57/42897?source=see_link\">",
"       Patient information: Amniocentesis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/46/39663?source=see_link\">",
"       Patient information: Chorionic villus sampling (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/31/31218?source=see_link\">",
"       Patient information: Newborn appearance (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/45/29394?source=see_link\">",
"       Patient information: Down syndrome (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/50/2851?source=see_link\">",
"       Patient information: Should I have a screening test for Down syndrome during pregnancy? (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?33/28/34242?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15529 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-217.117.136.88-94DAD92080-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_28_34242=[""].join("\n");
var outline_f33_28_34242=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H558705990\">",
"      What is Down syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H558705997\">",
"      What are the symptoms of Down syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H558706004\">",
"      Is there a test for Down syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H558706011\">",
"      What learning problems can be caused by Down syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H558706018\">",
"      What medical problems can be caused by Down syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H558706025\">",
"      Should children with Down syndrome see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H558706032\">",
"      How is Down syndrome treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H558706039\">",
"      Can women with Down syndrome get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H558706046\">",
"      What will life be like for a person with Down syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H558706195\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15529\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/55/21365\">",
"      Problems caused by Down syndrome",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/56/34690\">",
"       Child with Down syndrome",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/21/25951\">",
"        Transverse palmar crease",
"       </a>",
"       <li>",
"        <a class=\"graphic graphic_table\" href=\"UTD.htm?42/25/43420\">",
"         When to check for health problems in children with Down syndrome",
"        </a>",
"       </li>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/57/42897?source=related_link\">",
"      Patient information: Amniocentesis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/46/39663?source=related_link\">",
"      Patient information: Chorionic villus sampling (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/45/29394?source=related_link\">",
"      Patient information: Down syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/31/31218?source=related_link\">",
"      Patient information: Newborn appearance (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/50/2851?source=related_link\">",
"      Patient information: Should I have a screening test for Down syndrome during pregnancy? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/50/11043?source=related_link\">",
"      Patient information: Should I have a screening test for Down syndrome during pregnancy? (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_28_34243="Schistosomiasis and glomerular disease";
var content_f33_28_34243=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Schistosomiasis and glomerular disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?33/28/34243/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/28/34243/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?33/28/34243/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/28/34243/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?33/28/34243/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/28/34243/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?33/28/34243/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Schistosomiasis is caused by infection with Schistosoma haematobium, S. mansoni, S. japonicum, S. mekongi, or S. intercalatum. The glomerular disease associated with schistosomiasis will be discussed here. Other issues related to schistosomiasis are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/38/15977?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical features of schistosomiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7398?source=see_link\">",
"     \"Diagnosis of schistosomiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14807?source=see_link\">",
"     \"Treatment and prevention of schistosomiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY OF RENAL INVOLVEMENT AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic infection with Schistosoma mansoni (and, to a lesser degree, other schistosomal species) is associated with glomerular disease in 10 to 15 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34243/abstract/1-7\">",
"     1-7",
"    </a>",
"    ]. Two observations are compatible with a pathogenetic role for schistosomal infection in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34243/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antibodies against schistosomal antigens can often be eluted from the glomeruli.",
"     </li>",
"     <li>",
"      Schistosomal antigens have been detected in the glomeruli by indirect immunofluorescence (in which fluoresceinated anti-schistosomal antibodies are incubated with the renal tissue).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although direct deposition of schistosomal antigens is responsible for the initial glomerular injury, hepatic fibrosis induced by chronic hepatosplenic infection plays an important role in the subsequent disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34243/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Circulating schistosomal immune complexes are normally removed by the Kupffer cells in the liver; in the presence of portal hypertension, however, the circulation is partially bypassed, resulting in increased delivery to and deposition in the glomeruli.",
"   </p>",
"   <p>",
"    The observation that patients with overt renal disease have a predominance of IgA deposition in the glomeruli is also compatible with a \"liver effect\" since glomerular IgA deposition is also seen in cirrhosis due to impaired clearance of IgA-containing immune complexes [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34243/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1337?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical presentation and diagnosis of IgA nephropathy\", section on 'Cirrhosis and other forms of severe liver disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A confounding factor is that many patients with liver and renal involvement are coinfected with hepatitis C virus, particularly in endemic areas [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34243/abstract/7\">",
"     7",
"    </a>",
"    ]. Given that both schistosomiasis and hepatitis C virus can result in liver and renal disease, it is frequently difficult to distinguish the relative contributions of each to organ system abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICOPATHOLOGIC MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with schistosoma-associated glomerular disease can present with a wide variety of manifestations, ranging from asymptomatic albuminuria and normal renal function to end-stage renal disease (ESRD) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34243/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. There are five histologic classes of disease, with frequent switching from one to another based upon changes in the underlying disease as well as associated comorbid conditions.",
"   </p>",
"   <p>",
"    This classification system is referred to as AFRAN, which is an acronym for the African Association of Nephrology [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34243/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Class I is mesangial proliferative glomerulonephritis, resulting from deposition of parasitic antigens and antibodies. Such patients usually have a benign, self-limited course.",
"     </li>",
"     <li>",
"      Class II is an exudative glomerulonephritis, with neutrophils and monocytes as well as deposition of IgG and complement. This lesion is commonly observed with dual infection with schistosoma and salmonella species. Affected patients usually present with an acute febrile illness, as well as signs and symptoms of salmonella infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/19/14649?source=see_link\">",
"       \"Microbiology and epidemiology of salmonellosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Class III is a membranoproliferative glomerulonephritis (MPGN), and class IV is a",
"      <span class=\"nowrap\">",
"       proliferative/sclerosing",
"      </span>",
"      lesion. These classes of disease, which constitute the vast majority of the observed renal lesions in this disease, are commonly associated with Schistosomal mansoni infection, liver disease, and glomerular and peritubular IgA deposits [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34243/abstract/2-5,7\">",
"       2-5,7",
"      </a>",
"      ]. Most patients present with the nephrotic syndrome, hypertension, and a plasma creatinine concentration between 1 and 2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (88 and 176",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34243/abstract/4\">",
"       4",
"      </a>",
"      ]. It is unclear why blacks appear to preferentially develop focal segmental glomerulosclerosis in this setting. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/40/14985?source=see_link\">",
"       \"Noncirrhotic portal hypertension: Portal fibrosis and schistosomiasis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43833?source=see_link\">",
"       \"Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Class V is renal amyloidosis, which results from chronic inflammation due to prolonged infection. Such patients present with significant proteinuria, including the nephrotic syndrome and renal insufficiency. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/29/13784?source=see_link\">",
"       \"Renal amyloidosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, heavy proteinuria can also be associated with other histologic patterns, including mesangial proliferation, membranous nephropathy, and focal segmental glomerulosclerosis (which may reflect healing of previous injury) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34243/abstract/2,3,6\">",
"     2,3,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One authority has proposed a new class of schistosomal glomerulopathy, class VI, which represents renal involvement with combined helminthic and hepatitis C viral infection [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34243/abstract/7\">",
"     7",
"    </a>",
"    ]. The renal lesion associated with this process may include mesangial proliferation, amyloidosis, apoptotic cells, and immune complex deposition. However, it is unclear whether this presents a clearly distinct pathogenic process that is unique to infection with schistosomiasis and hepatitis C virus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37353?source=see_link\">",
"     \"Renal disease associated with hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     THERAPY AND PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progression to end-stage renal disease (ESRD) is common in patients with classes III to V schistosomal glomerulopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34243/abstract/3,4,7\">",
"     3,4,7",
"    </a>",
"    ]. Therapy has been attempted with both antiparasitic drugs and immunosuppressive agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34243/abstract/4,5,7\">",
"     4,5,7",
"    </a>",
"    ]. This regimen does not appear to be effective, as three-quarters of patients progress to renal failure or have persistent renal insufficiency at four- to six-year follow-up; these results are similar to a parallel group with apparently idiopathic membranoproliferative glomerulonephritis (MPGN) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34243/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By comparison, combined antihelmintic and antibacterial treatment is usually associated with complete recovery in patients with class II disease [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34243/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, the majority of those with class I disease usually experience spontaneous recovery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14807?source=see_link\">",
"     \"Treatment and prevention of schistosomiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/40/14985?source=see_link\">",
"     \"Noncirrhotic portal hypertension: Portal fibrosis and schistosomiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10841761\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Schistosomiasis is caused by infection with Schistosoma haematobium, S. mansoni, S. japonicum, S. mekongi, or S. intercalatum. Chronic infection with Schistosoma mansoni (and to a lesser degree other schistosomal species) is associated with glomerular disease in 10 to 15 percent of patients. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology of renal involvement and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Glomerular injury is caused by the deposition of schistosomal antigens and circulating schistosomal immune complexes. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology of renal involvement and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The AFRAN classification system enumerates five histologic classes of disease (I through V), including mesangial proliferative glomerulonephritis (I), exudative glomerulonephritis (II), membranoproliferative glomerulonephritis (MPGN) (III), a",
"      <span class=\"nowrap\">",
"       proliferative/sclerosing",
"      </span>",
"      lesion (IV), and renal amyloidosis (V). Most patients have classes I through IV lesions. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinicopathologic manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with classes I through IV lesions generally present with the nephrotic syndrome, hypertension, and a plasma creatinine concentration between 1 and 2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (88 and 176",
"      <span class=\"nowrap\">",
"       micromol/L).",
"      </span>",
"      Patients with class V lesions present with significant proteinuria and renal insufficiency. Progression to end-stage renal disease (ESRD) is common in patients with classes III to V lesions. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinicopathologic manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Therapy and prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The response to treatment depends on the class. Therapy with both antiparasitic drugs and immunosuppressive agents does not appear to be effective for patients with classes III to V disease. However, combined antihelmintic and antibacterial treatment is usually associated with complete recovery in patients with class II disease, and the majority of patients with class I disease usually have a spontaneous recovery. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Therapy and prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34243/abstract/1\">",
"      KDIGO. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl 2012; 2:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34243/abstract/2\">",
"      Barsoum RS. Schistosomal glomerulopathies. Kidney Int 1993; 44:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34243/abstract/3\">",
"      Sobh MA, Moustafa FE, el-Housseini F, et al. Schistosomal specific nephropathy leading to end-stage renal failure. Kidney Int 1987; 31:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34243/abstract/4\">",
"      Martinelli R, Noblat AC, Brito E, Rocha H. Schistosoma mansoni-induced mesangiocapillary glomerulonephritis: influence of therapy. Kidney Int 1989; 35:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34243/abstract/5\">",
"      Ott BR, Libbey NP, Ryter RJ, Trebbin WM. Treatment of schistosome-induced glomerulonephritis. A case report and review of the literature. Arch Intern Med 1983; 143:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34243/abstract/6\">",
"      Nussenzveig I, De Brito T, Carneiro CR, Silva AM. Human Schistosoma mansoni-associated glomerulopathy in Brazil. Nephrol Dial Transplant 2002; 17:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34243/abstract/7\">",
"      Barsoum R. The changing face of schistosomal glomerulopathy. Kidney Int 2004; 66:2472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34243/abstract/8\">",
"      Barsoum R, Nabil M, Saady G, et al. Immunoglobulin-A and the pathogenesis of schistosomal glomerulopathy. Kidney Int 1996; 50:920.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3057 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-217.117.136.88-D8E73D39BC-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_28_34243=[""].join("\n");
var outline_f33_28_34243=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10841761\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY OF RENAL INVOLVEMENT AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICOPATHOLOGIC MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      THERAPY AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10841761\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1337?source=related_link\">",
"      Clinical presentation and diagnosis of IgA nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43833?source=related_link\">",
"      Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7398?source=related_link\">",
"      Diagnosis of schistosomiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/38/15977?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical features of schistosomiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/19/14649?source=related_link\">",
"      Microbiology and epidemiology of salmonellosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/40/14985?source=related_link\">",
"      Noncirrhotic portal hypertension: Portal fibrosis and schistosomiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/29/13784?source=related_link\">",
"      Renal amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37353?source=related_link\">",
"      Renal disease associated with hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14807?source=related_link\">",
"      Treatment and prevention of schistosomiasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_28_34244="Systemic sclerosis (scleroderma) and pregnancy";
var content_f33_28_34244=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Systemic sclerosis (scleroderma) and pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?33/28/34244/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/28/34244/contributors\">",
"     Bonnie L Bermas, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?33/28/34244/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/28/34244/contributors\">",
"     John S Axford, DSc, MD, FRCP, FRCPCH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/28/34244/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?33/28/34244/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/28/34244/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?33/28/34244/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic sclerosis (SSc; scleroderma) is an uncommon illness with an annual incidence of 1 to 2 per 100,000 individuals in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34244/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The peak onset is between the ages of 30 and 50. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29224?source=see_link\">",
"     \"Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As of 1971, only 12 cases of pregnancy in women with SSc had been reported. Mortality among these patients was alarmingly high: four patients died (three from renal and pulmonary disease and one from a postpartum viral infection) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34244/abstract/3\">",
"     3",
"    </a>",
"    ]. The incidence of pregnancy in women with SSc is increasing since a greater number of women are choosing to have children later in life.",
"   </p>",
"   <p>",
"    This topic will review issues of fertility and pregnancy outcome among patients with SSc, as well as the impact of pregnancy upon disease activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FERTILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is difficult to draw any clear conclusions concerning fertility in women with SSc. In the 1950s, women with SSc were thought to have diminished fertility because of the low incidence of pregnancy in those with preexisting disease [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34244/abstract/4\">",
"     4",
"    </a>",
"    ]. However, subsequent studies showed mixed results with respect to pregnancy rates and to the frequency of pregnancy difficulties among women with SSc, both prior to and after the diagnosis.",
"   </p>",
"   <p>",
"    The following findings were noted in different observational studies of women with SSc who were of child-bearing age:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A nonsignificant threefold increase in risk of the combined end-point of infertility and spontaneous abortion compared with controls in a retrospective analysis of events prior to the diagnosis of SSc [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34244/abstract/5\">",
"       5",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A higher incidence of infertility and a longer time to conceive prior to the diagnosis of SSC compared with healthy controls (odds ratio 2.3 and 2.6, respectively) but not compared with women with primary Raynaud phenomenon [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34244/abstract/6\">",
"       6",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Significantly more live births prior to the onset of SSc and significantly fewer live births after the onset of SSC compared with women in the general population [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34244/abstract/7\">",
"       7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      No difference in fertility among women with SSc compared with patients with rheumatoid arthritis and compared with healthy controls [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34244/abstract/8\">",
"       8",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The conclusions that can be drawn from these studies are limited by their reliance upon patient recall and by a failure to usually distinguish whether women had difficulty conceiving or did not desire pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SPONTANEOUS ABORTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with the information available concerning SSc and fertility, somewhat more conclusive data have been published relating to the rate of spontaneous abortion in women who become pregnant prior to an eventual diagnosis of SSc. Multiple studies (but not all) suggest that such women have an increased risk [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34244/abstract/5,9,10\">",
"     5,9,10",
"    </a>",
"    ]. As an example, the rate of spontaneous miscarriage among pregnant women, both prior to and subsequent to a diagnosis of SSc, was assessed in one study of 14 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34244/abstract/9\">",
"     9",
"    </a>",
"    ]. The rate of spontaneous miscarriage was significantly higher among those who became pregnant prior to disease diagnosis when compared with control individuals (22 versus 14 percent). Pregnant patients with preexisting SSc also had a significantly increased rate of spontaneous abortions. A similar risk (relative risk 2.1) was noted in another report of nearly 270 women with SSc [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34244/abstract/5\">",
"     5",
"    </a>",
"    ]. In contrast to these findings, a third study found an increased number of elective (but not spontaneous) abortions among patients who became pregnant after disease onset, compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34244/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, miscarriage appears to be more common among those who eventually develop SSc, but it remains unclear whether spontaneous abortions occur more frequently among those already diagnosed with the disorder. Data concerning the abortion rate among patients with a preexisting diagnosis of SSc are also clouded by the paucity of information regarding medication use during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34244/abstract/11\">",
"     11",
"    </a>",
"    ]. Whether a history of a spontaneous abortion may predispose a woman to subsequently develop SSc is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34244/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PREGNANCY OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of SSc upon pregnancy outcome is unknown. One study compared outcomes in women with SSc with those in women with rheumatoid arthritis (RA) and in control individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34244/abstract/10\">",
"     10",
"    </a>",
"    ]. A nonsignificant trend toward an increased rate of premature births among patients with SSc, compared with the other two groups, was observed. In addition, there was an increased incidence of infants small for gestational age born to women with SSc, but there was no statistically significant increase in fetal death [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34244/abstract/10,12\">",
"     10,12",
"    </a>",
"    ]. An expanded study by the same group of investigators retrospectively obtained reproductive histories in 214 women with SSc and compared them with 167 women with rheumatoid arthritis and with 105 neighborhood controls [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34244/abstract/8\">",
"     8",
"    </a>",
"    ]. The patients with SSc had more premature births and more infants small for gestational age after disease onset; however, the effect of age on these results was not analyzed.",
"   </p>",
"   <p>",
"    These studies are flawed because the impact of medication use and of other risk factors for prematurity was not assessed. Immunosuppressive agents used in patients with SSc, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , may cause premature rupture of the membranes, as well as infants small for gestational age [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34244/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There have been several case reports of SSc involving the cervix and perineum [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34244/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. In this setting, vaginal delivery can be difficult, and elective cesarean delivery may be required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     IMPACT OF PREGNANCY UPON DISEASE ACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few data are available concerning the impact of pregnancy upon the activity of SSc. Most of the published information is skewed toward case reports of poor outcomes. As an example, one report of two patients with three pregnancies found that two of the pregnancies were complicated by hypertension and that one was complicated by congestive heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34244/abstract/15\">",
"     15",
"    </a>",
"    ]. By comparison, another study found that the frequency of general complications, such as hypertension, was similar in patients with SSc and in those with RA [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34244/abstract/10\">",
"     10",
"    </a>",
"    ]. Pregnancy also had no adverse effect upon long-term survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     SSc renal crisis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal disease is common in patients with SSc [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34244/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35801?source=see_link\">",
"     \"Scleroderma renal crisis\"",
"    </a>",
"    .) In the pregnant patient, however, it is extremely difficult to distinguish renal dysfunction due to SSc from that resulting from preeclampsia and eclampsia. One review of the literature, for example, found that seven of nine patients initially thought to have preeclampsia actually had renal biopsy findings more consistent with SSc renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34244/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=see_link\">",
"     \"Preeclampsia: Clinical features and diagnosis\"",
"    </a>",
"    .) Another possible differential in the postpartum period is hemolytic-uremic syndrome; this disorder",
"    <strong>",
"     cannot",
"    </strong>",
"    be distinguished histologically from SSc kidney. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33479?source=see_link\">",
"     \"Acute kidney injury (acute renal failure) in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whether pregnancy is associated with an increased incidence of renal crisis among patients with preexisting SSc is unclear. One study of women with SSc found no enhanced incidence of renal crisis in pregnant women when compared with those who did not become pregnant [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34244/abstract/10\">",
"     10",
"    </a>",
"    ]. Some investigators, however, believe that renal crisis is more common among those with early diffuse disease [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34244/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An extremely high morbidity has been observed among those who develop renal crisis during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34244/abstract/12\">",
"     12",
"    </a>",
"    ]. The use of angiotensin-converting enzyme (ACE) inhibitors was beneficial in one case report, but ACE inhibitors are contraindicated during pregnancy because of the risk to the fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34244/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy\"",
"    </a>",
"    .) Thus, patients with SSc and active renal disease should be counseled regarding the high morbidity and mortality associated with pregnancy. For patients who develop renal crisis during pregnancy, intensive medical support, including dialysis and fetal monitoring in the intensive care unit, should be utilized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     OTHER CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Difficulties in delivery secondary to skin fibrosis and the aggravation of relatively minor symptoms may also occur among pregnant patients with SSc. As an example, the increased abdominal pressure in pregnancy may exacerbate dyspepsia due to esophageal dysmotility. Some symptoms, however, may diminish; symptoms of Raynaud phenomenon generally lessen because of the vasodilatation of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34244/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25040535\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is difficult to draw clear conclusions concerning fertility in women with systemic sclerosis (SSc), due to the very limited data that are available. Studies have shown mixed results with respect to pregnancy rates and to the frequency of pregnancy difficulties among women with SSc, both prior to and after the diagnosis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Fertility'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multiple studies (but not all) suggest that women who become pregnant prior to an eventual diagnosis of SSc have an increased risk of spontaneous abortion. However, it is unclear whether spontaneous abortions occur more frequently among those already diagnosed with the disorder. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Spontaneous abortion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The effect of SSc upon pregnancy outcome is unknown. Limited study data have suggested a possible increased risk of premature births and of infants small for gestational age after disease onset; however, the impact of medication use, of age, and of other risk factors for prematurity on these results is not known. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pregnancy outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is unclear whether pregnancy affects disease activity or is associated with an increased incidence of renal crisis among patients with preexisting SSc, as very limited data are available. However, extremely high morbidity has been observed among those who develop renal crisis during pregnancy, and patients with SSc and active renal disease should be counseled regarding the high morbidity and mortality associated with pregnancy. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Impact of pregnancy upon disease activity'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'SSc renal crisis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptoms of Raynaud phenomenon generally lessen during pregnancy because of vasodilatation. However, difficulties in delivery secondary to skin fibrosis and the aggravation of relatively minor symptoms, such as dyspepsia, may occur among pregnant patients with SSc. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Other considerations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34244/abstract/1\">",
"      Medsger TA Jr, Masi AT. Epidemiology of progressive systemic sclerosis. Clin Rheum Dis 1979; 5:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34244/abstract/2\">",
"      S&aacute;nchez-Guerrero J, Colditz GA, Karlson EW, et al. Silicone breast implants and the risk of connective-tissue diseases and symptoms. N Engl J Med 1995; 332:1666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34244/abstract/3\">",
"      Knupp MZ, O'Leary JA. Pregnancy and scleroderma. Systemic sclerosis. J Fla Med Assoc 1971; 58:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34244/abstract/4\">",
"      LEINWAND I, DURYEE AW, RICHTER MN. Scleroderma; based on a study of over 150 cases. Ann Intern Med 1954; 41:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34244/abstract/5\">",
"      Silman AJ, Black C. Increased incidence of spontaneous abortion and infertility in women with scleroderma before disease onset: a controlled study. Ann Rheum Dis 1988; 47:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34244/abstract/6\">",
"      Englert H, Brennan P, McNeil D, et al. Reproductive function prior to disease onset in women with scleroderma. J Rheumatol 1992; 19:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34244/abstract/7\">",
"      Bernatsky S, Hudson M, Pope J, et al. Assessment of reproductive history in systemic sclerosis. Arthritis Rheum 2008; 59:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34244/abstract/8\">",
"      Steen VD, Medsger TA Jr. Fertility and pregnancy outcome in women with systemic sclerosis. Arthritis Rheum 1999; 42:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34244/abstract/9\">",
"      Giordano M, Valentini G, Lupoli S, Giordano A. Pregnancy and systemic sclerosis. Arthritis Rheum 1985; 28:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34244/abstract/10\">",
"      Steen VD, Conte C, Day N, et al. Pregnancy in women with systemic sclerosis. Arthritis Rheum 1989; 32:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34244/abstract/11\">",
"      Bermas BL, Hill JA. Effects of immunosuppressive drugs during pregnancy. Arthritis Rheum 1995; 38:1722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34244/abstract/12\">",
"      Steen VD. Scleroderma and pregnancy. Rheum Dis Clin North Am 1997; 23:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34244/abstract/13\">",
"      Bellucci MJ, Coustan DR, Plotz RD. Cervical scleroderma: a case of soft tissue dystocia. Am J Obstet Gynecol 1984; 150:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34244/abstract/14\">",
"      Stenchever MA, Ng AB. Scleroderma of the uterine cervix. Am J Obstet Gynecol 1970; 107:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34244/abstract/15\">",
"      Ballou SP, Morley JJ, Kushner I. Pregnancy and systemic sclerosis. Arthritis Rheum 1984; 27:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34244/abstract/16\">",
"      Traub YM, Shapiro AP, Rodnan GP, et al. Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases. Medicine (Baltimore) 1983; 62:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34244/abstract/17\">",
"      Black CM, Stevens WM. Scleroderma. Rheum Dis Clin North Am 1989; 15:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34244/abstract/18\">",
"      Baethge BA, Wolf RE. Successful pregnancy with scleroderma renal disease and pulmonary hypertension in a patient using angiotensin converting enzyme inhibitors. Ann Rheum Dis 1989; 48:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34244/abstract/19\">",
"      Karlen JR, Cook WA. Renal scleroderma and pregnancy. Obstet Gynecol 1974; 44:349.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7558 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-180.241.123.62-A90D1A112B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_28_34244=[""].join("\n");
var outline_f33_28_34244=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25040535\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FERTILITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SPONTANEOUS ABORTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PREGNANCY OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      IMPACT OF PREGNANCY UPON DISEASE ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SSc renal crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      OTHER CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25040535\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33479?source=related_link\">",
"      Acute kidney injury (acute renal failure) in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29224?source=related_link\">",
"      Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=related_link\">",
"      Preeclampsia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35801?source=related_link\">",
"      Scleroderma renal crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=related_link\">",
"      Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_28_34245="Treatment of acute interstitial nephritis";
var content_f33_28_34245=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of acute interstitial nephritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?33/28/34245/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/28/34245/contributors\">",
"     Abhijit V Kshirsagar, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/28/34245/contributors\">",
"     Ronald J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?33/28/34245/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/28/34245/contributors\">",
"     Paul M Palevsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?33/28/34245/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/28/34245/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?33/28/34245/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute interstitial nephritis (AIN) classically presents as acute renal failure after the use of known offending drugs and is associated with the typical urinary findings of pyuria, hematuria, and white cell casts [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34245/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Less frequently, AIN is secondary to infection or sarcoidosis. Signs of systemic allergy such as a maculopapular rash, peripheral eosinophilia, and eosinophiluria are present in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34245/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Proteinuria is common, but excretion is usually less than 1",
"    <span class=\"nowrap\">",
"     g/day.",
"    </span>",
"    However, nephrotic range proteinuria may occur and presumably reflects cytokine-induced injury to the glomerulus. It is most often seen with AIN caused by nonsteroidal antiinflammatory drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34245/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Histologically, AIN is characterized by the infiltration of T-cells, macrophages, and plasma cells in the interstitial compartment.",
"   </p>",
"   <p>",
"    The treatment of AIN due to drugs will be reviewed here. The manifestations and diagnosis of AIN and the approach to the management of patients diagnosed with infection-induced AIN, tubulointerstitial nephritis and uveitis, and renal sarcoidosis are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27209?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute interstitial nephritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20486?source=see_link\">",
"     \"Tubulointerstitial nephritis and uveitis (TINU syndrome)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40438?source=see_link\">",
"     \"Renal disease in sarcoidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For drug-induced AIN, prognostic data are most available for methicillin, which is no longer available because it was estimated to cause AIN in up to 17 percent of patients who were treated for more than 10 days [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34245/abstract/2,9\">",
"     2,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recovery of renal function was observed in the great majority of cases of AIN due to methicillin, either with discontinuation of the offending drug or with glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34245/abstract/2,9,10\">",
"     2,9,10",
"    </a>",
"    ]. The proportion recovering kidney function appears to be lower in AIN due to drugs other than methicillin [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34245/abstract/2,10-12\">",
"     2,10-12",
"    </a>",
"    ]. The prognosis of AIN due to other inciting factors (eg, sarcoidosis, infection) is not well described. Acute dialysis is often required [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34245/abstract/13-15\">",
"     13-15",
"    </a>",
"    ], but only about 10 percent of patients remain dialysis-dependent [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34245/abstract/3,4,11\">",
"     3,4,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recovery of kidney function is often incomplete with persistent elevation of the serum creatinine concentration in up to 40 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34245/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. As an example, in a review of published series of AIN in which many patients had a peak serum creatinine &gt;5.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (500",
"    <span class=\"nowrap\">",
"     &micro;mol/L),",
"    </span>",
"    the serum creatinine at the end of follow-up was less than 1.2 and 1.7",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (110 and 150",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    in 49 and 68 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34245/abstract/2\">",
"     2",
"    </a>",
"    ]. The final serum creatinine concentration did not correlate with the maximum value during AIN.",
"   </p>",
"   <p>",
"    Clinical indicators of a decreased likelihood of recovery include prolonged renal failure (greater than three weeks), AIN associated with NSAID use, and certain histologic findings (including interstitial granulomas, interstitial fibrosis, and tubular atrophy) on kidney biopsy",
"   </p>",
"   <p>",
"    Biomarkers for acute kidney injury such as kidney injury molecule-1 (KIM-1) and urinary neutrophil gelatinase-associated lipocalin (NGAL) may provide additional prognostic information but are not used clinically for this purpose at this time [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34245/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Discontinuation of the potential causative agent is a mainstay of therapy, and immunosuppressive therapy has been employed if there is no subsequent improvement in kidney function. The optimal therapy of AIN is unknown, since there are no randomized controlled trials or large observational studies. Conclusions cannot be readily drawn from available reports, as patient populations differ and results are discordant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     General issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following theoretical considerations provide a context for the approach to the management of AIN:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most cases of AIN are allergic reactions as suggested by the following: the majority of the immune reactions are directly to drugs or drug-induced antigens; systemic manifestations of hypersensitivity are often present; AIN is not a dose-dependent phenomenon and only a small percentage of patients develop the condition; AIN typically improves following cessation of the drug; and AIN may rapidly recur with accidental re-exposure to the drug or a closely related antigen.",
"     </li>",
"     <li>",
"      T-cells may have an important pathogenetic role in the development of AIN as suggested from the following observations: the timeframe of illness presentation, 10 to 14 days after exposure to the drug, is typical of a T-cell mediated syndrome; the interstitial infiltrate in the kidney is composed primarily of lymphocytes [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34245/abstract/9,18\">",
"       9,18",
"      </a>",
"      ]; and most patients demonstrate activation of lymphocytes against drug haptens [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34245/abstract/19-21\">",
"       19-21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given these considerations, the most important aspect of therapy of AIN is cessation of the potentially offending agent (or treatment of the underlying infection).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Glucocorticoid therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppressive therapy has been employed to treat AIN that persists despite discontinuation of the offending agent. However, the benefits of therapy are inconclusive, since the available data are conflicting, and there are no randomized controlled trials.",
"   </p>",
"   <p>",
"    Improvement in kidney function following glucocorticoid therapy for AIN has been suggested by several uncontrolled reports [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34245/abstract/2,9,13,22\">",
"     2,9,13,22",
"    </a>",
"    ]. The following illustrate these findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One series evaluated 14 patients with methicillin-induced AIN who had an average peak serum creatinine of 8",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (704",
"      <span class=\"nowrap\">",
"       &micro;mol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34245/abstract/9\">",
"       9",
"      </a>",
"      ]. The eight patients treated with glucocorticoids recovered more quickly (9 versus 54 days) and had a lower final plasma creatinine concentration (1.4 versus 1.9",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [123 versus 167",
"      <span class=\"nowrap\">",
"       &micro;mol/L])",
"      </span>",
"      than the six who received no therapy.",
"     </li>",
"     <li>",
"      One series evaluated 27 patients with biopsy-proven AIN; 15 were drug-induced (one methicillin, two",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      , three NSAIDS, three",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"       cimetidine",
"      </a>",
"      , rest other), nine were associated with infection, and three were idiopathic [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34245/abstract/22\">",
"       22",
"      </a>",
"      ]. The 10 patients who did not improve following discontinuation of the drug or treatment of the infection (cause of AIN not specified) were given glucocorticoids within 5 to 20 days of biopsy (intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      3",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      for three days, or oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      40 to 60",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for three to four weeks). In six patients, serum creatinine normalized within approximately one month, and the remaining four had partial improvement in kidney function.",
"     </li>",
"     <li>",
"      A retrospective multicenter study examined the effects of steroids on the recovery of renal function in 52 patients with biopsy-proven drug-induced AIN compared to nine untreated patients with AIN [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34245/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. Despite the low number of control patients, significant benefits with steroids included a lower percentage of dialysis by 18 months (4 versus 44 percent) and lower serum creatinine level (2.1 versus 3.7",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [186 and 327",
"      <span class=\"nowrap\">",
"       &micro;mol/L]).",
"      </span>",
"      Among treated patients, those who started steroids within seven days of withdrawal of the offending drug were significantly more likely to recover renal function than those who received steroids after this period (odds ratio 6.6, 95% CI 1.3-33.6).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other retrospective series demonstrated no benefit from glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34245/abstract/2,4,10,14,15\">",
"     2,4,10,14,15",
"    </a>",
"    ]. One report, for example, included 42 cases of biopsy-proven AIN (44, 33, and 7 percent due to nonsteroidal antiinflammatory drugs [NSAIDs], antibiotics, and proton pump inhibitors, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34245/abstract/4\">",
"     4",
"    </a>",
"    ]. Twenty-six patients were treated with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    for three days followed by oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (initial dose 0.75",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day tapered over three to six weeks), and the remaining 16 were not treated. Baseline serum creatinine was somewhat higher in the glucocorticoid group (7.9 versus 6.2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [700 versus 545",
"    <span class=\"nowrap\">",
"     &micro;mol/L]).",
"    </span>",
"    There was no difference in serum creatinine between the two groups at 1, 6, and 12 months (at one year, the mean serum creatinine was 1.60",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (144",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    in both groups).",
"   </p>",
"   <p>",
"    There are several possible explanations for a lack of effect from glucocorticoids in the negative studies: the patients treated with steroids had more severe disease as manifested by higher maximum serum creatinine concentrations; a significant proportion of the patients had NSAID-associated AIN, which is less likely to respond to glucocorticoid therapy; and steroids are not effective in the treatment of AIN [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34245/abstract/2,4,8\">",
"     2,4,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the potential for benefit and the relative safety of short-term therapy, it seems reasonable to treat patients with corticosteroids if they do not have significant improvement in the serum creatinine within three to seven days after discontinuation of the offending agent.",
"   </p>",
"   <p>",
"    In such cases, a renal biopsy is preferred to confirm AIN, as well as to exclude other possible diseases or interstitial nephritis with significant chronic damage (eg, marked interstitial fibrosis, tubular atrophy, and minimal or no acute inflammation), in which case immunosuppressive therapy might not be indicated. An empiric trial of glucocorticoid therapy is a reasonable alternative in patients with a strongly suggestive history of acute drug-induced AIN when kidney biopsy is not feasible.",
"   </p>",
"   <p>",
"    The optimal dose and duration of therapy are unclear. One approach is to administer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    at a dose of 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day (to a maximum of 40 to 60 mg) for a minimum of one to two weeks, beginning a gradual taper after the serum creatinine has returned to or near baseline, for a total therapy duration of two to three months. Most patients will improve in the first one to two weeks.",
"   </p>",
"   <p>",
"    In patients with more severe acute renal failure, therapy may be initiated with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (0.5 to 1",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    for three days).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited experience with treating AIN in patients who are glucocorticoid-dependent (ie, relapse during the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    taper), glucocorticoid-resistant (as with NSAID-induced disease), or cannot tolerate glucocorticoids. There are case reports and small series using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (MMF) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34245/abstract/25,26\">",
"     25,26",
"    </a>",
"    ], and anecdotal use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The largest reported experience included eight patients with biopsy-proven AIN who had received glucocorticoids for at least six months and could not discontinue therapy without worsening of the serum creatinine; MMF was given for 13 to 34 months [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34245/abstract/25\">",
"     25",
"    </a>",
"    ]. All were able to discontinue corticosteroids and only two patients had no improvement in serum creatinine (one who was ANCA-positive and one with AIN of unknown etiology). The applicability of these results to drug-induced AIN is limited, since only two patients had AIN known to be due to drugs.",
"   </p>",
"   <p>",
"    MMF may be considered only in patients who are glucocorticoid-dependent, glucocorticoid-resistant, or unable to tolerate glucocorticoid therapy and have biopsy-proven AIN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?15/22/15713?source=see_link\">",
"       \"Patient information: Acute interstitial nephritis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    Most cases of AIN due to drugs improve spontaneously, although kidney function may not return to baseline. The rate of recovery of AIN due to other inciting factors is less clear. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Prognosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    It is essential that the potentially offending agent be immediately discontinued. No additional intervention is required in patients who have minimal elevations in the serum creatinine or those who begin to recover within three to seven days. For patients who do not fulfill these criteria, we recommend obtaining a kidney biopsy (unless already done) to confirm the diagnosis.",
"   </p>",
"   <p>",
"    For patients with biopsy-confirmed AIN who do not have significant chronic damage, we recommend therapy with glucocorticoids (",
"    <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"     Grade 1C",
"    </a>",
"    ). Therapy may also be instituted in patients with a strongly suggestive history of drug-induced AIN in whom a biopsy cannot be performed. An exception to this general recommendation is AIN due to NSAID therapy, which appears to be much less likely to respond to glucocorticoid therapy. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Glucocorticoid therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    One possible regimen is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    at a dose of 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day (to a maximum of 40 to 60 mg) for a minimum of one to two weeks, beginning a gradual taper after the serum creatinine has returned to or near baseline, for a total therapy duration of two to three months.",
"   </p>",
"   <p>",
"    The optimal approach to the therapy of biopsy-proven AIN is not known in patients who are glucocorticoid-dependent (ie, relapse during the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    taper), glucocorticoid-resistant, or cannot tolerate glucocorticoids. The largest experience has been with MMF. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Other agents'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34245/abstract/1\">",
"      Davison AM, Jones CH. Acute interstitial nephritis in the elderly: a report from the UK MRC Glomerulonephritis Register and a review of the literature. Nephrol Dial Transplant 1998; 13 Suppl 7:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34245/abstract/2\">",
"      Rossert J. Drug-induced acute interstitial nephritis. Kidney Int 2001; 60:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34245/abstract/3\">",
"      Baker RJ, Pusey CD. The changing profile of acute tubulointerstitial nephritis. Nephrol Dial Transplant 2004; 19:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34245/abstract/4\">",
"      Clarkson MR, Giblin L, O'Connell FP, et al. Acute interstitial nephritis: clinical features and response to corticosteroid therapy. Nephrol Dial Transplant 2004; 19:2778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34245/abstract/5\">",
"      Corwin HL, Korbet SM, Schwartz MM. Clinical correlates of eosinophiluria. Arch Intern Med 1985; 145:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34245/abstract/6\">",
"      Nolan CR 3rd, Anger MS, Kelleher SP. Eosinophiluria--a new method of detection and definition of the clinical spectrum. N Engl J Med 1986; 315:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34245/abstract/7\">",
"      Abraham PA, Keane WF. Glomerular and interstitial disease induced by nonsteroidal anti-inflammatory drugs. Am J Nephrol 1984; 4:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34245/abstract/8\">",
"      Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1984; 310:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34245/abstract/9\">",
"      Galpin JE, Shinaberger JH, Stanley TM, et al. Acute interstitial nephritis due to methicillin. Am J Med 1978; 65:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34245/abstract/10\">",
"      Schwarz A, Krause PH, Kunzendorf U, et al. The outcome of acute interstitial nephritis: risk factors for the transition from acute to chronic interstitial nephritis. Clin Nephrol 2000; 54:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34245/abstract/11\">",
"      Laberke HG, Bohle A. Acute interstitial nephritis: correlations between clinical and morphological findings. Clin Nephrol 1980; 14:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34245/abstract/12\">",
"      Kida H, Abe T, Tomosugi N, et al. Prediction of the long-term outcome in acute interstitial nephritis. Clin Nephrol 1984; 22:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34245/abstract/13\">",
"      Handa SP. Drug-induced acute interstitial nephritis: report of 10 cases. CMAJ 1986; 135:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34245/abstract/14\">",
"      Bhaumik SK, Kher V, Arora P, et al. Evaluation of clinical and histological prognostic markers in drug-induced acute interstitial nephritis. Ren Fail 1996; 18:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34245/abstract/15\">",
"      Koselj M, Kveder R, Bren AF, Rott T. Acute renal failure in patients with drug-induced acute interstitial nephritis. Ren Fail 1993; 15:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34245/abstract/16\">",
"      Liangos O, Tighiouart H, Perianayagam MC, et al. Comparative analysis of urinary biomarkers for early detection of acute kidney injury following cardiopulmonary bypass. Biomarkers 2009; 14:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34245/abstract/17\">",
"      Kuwabara T, Mori K, Mukoyama M, et al. Urinary neutrophil gelatinase-associated lipocalin levels reflect damage to glomeruli, proximal tubules, and distal nephrons. Kidney Int 2009; 75:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34245/abstract/18\">",
"      Ooi BS, Jao W, First MR, et al. Acute interstitial nephritis. A clinical and pathologic study based on renal biopsies. Am J Med 1975; 59:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34245/abstract/19\">",
"      Joh K, Aizawa S, Yamaguchi Y, et al. Drug-induced hypersensitivity nephritis: lymphocyte stimulation testing and renal biopsy in 10 cases. Am J Nephrol 1990; 10:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34245/abstract/20\">",
"      Shibasaki T, Ishimoto F, Sakai O, et al. Clinical characterization of drug-induced allergic nephritis. Am J Nephrol 1991; 11:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34245/abstract/21\">",
"      Spanou Z, Keller M, Britschgi M, et al. Involvement of drug-specific T cells in acute drug-induced interstitial nephritis. J Am Soc Nephrol 2006; 17:2919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34245/abstract/22\">",
"      Buysen JG, Houthoff HJ, Krediet RT, Arisz L. Acute interstitial nephritis: a clinical and morphological study in 27 patients. Nephrol Dial Transplant 1990; 5:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34245/abstract/23\">",
"      Gonz&aacute;lez E, Guti&eacute;rrez E, Galeano C, et al. Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. Kidney Int 2008; 73:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34245/abstract/24\">",
"      Appel GB. The treatment of acute interstitial nephritis: More data at last. Kidney Int 2008; 73:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34245/abstract/25\">",
"      Preddie DC, Markowitz GS, Radhakrishnan J, et al. Mycophenolate mofetil for the treatment of interstitial nephritis. Clin J Am Soc Nephrol 2006; 1:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34245/abstract/26\">",
"      Zuliani E, Zwahlen H, Gilliet F, Marone C. Vancomycin-induced hypersensitivity reaction with acute renal failure: resolution following cyclosporine treatment. Clin Nephrol 2005; 64:155.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7233 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-652B83C886-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_28_34245=[""].join("\n");
var outline_f33_28_34245=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      General issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Glucocorticoid therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27209?source=related_link\">",
"      Clinical manifestations and diagnosis of acute interstitial nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/22/15713?source=related_link\">",
"      Patient information: Acute interstitial nephritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40438?source=related_link\">",
"      Renal disease in sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20486?source=related_link\">",
"      Tubulointerstitial nephritis and uveitis (TINU syndrome)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_28_34246="Ofloxacin (systemic): Pediatric drug information";
var content_f33_28_34246=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ofloxacin (systemic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?1/41/1688?source=see_link\">",
"    see \"Ofloxacin (systemic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/29/30165?source=see_link\">",
"    see \"Ofloxacin (systemic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F9496286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9496295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Oflox&reg;;",
"     </li>",
"     <li>",
"      Novo-Ofloxacin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10512947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Quinolone",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10513028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/41/1688?source=see_link\">",
"      see \"Ofloxacin (systemic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children:",
"     <b>",
"      Note:",
"     </b>",
"     Limited information regarding ofloxacin use in pediatric patients is currently available in the literature; some centers recommend doses of 15 mg/kg/day divided every 12 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Chronic bronchitis (acute exacerbation), community-acquired pneumonia, skin and skin structure infections (uncomplicated): 400 mg every 12 hours for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Urethral and cervical gonorrhea (acute, uncomplicated): 400 mg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cervicitis/urethritis (nongonococcal) due to",
"     <i>",
"      C. trachomatis",
"     </i>",
"     or mixed infections due to",
"     <i>",
"      C. trachomatis",
"     </i>",
"     and",
"     <i>",
"      N. gonorrhoeae",
"     </i>",
"     : 300 mg every 12 hours for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Pelvic inflammatory disease: 400 mg every 12 hours for 10-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cystitis (uncomplicated): 200 mg every 12 hours for 3-7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     UTI (complicated): 200 mg every 12 hours for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Prostatitis: 300 mg every 12 hours for 6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-50 mL/minute: Administer usual dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute: Administer half the usual dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     Severe impairment: Maximum dose: 400 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9497986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 200 mg, 300 mg, 400 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9496347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F9496293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088599.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088599.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10513033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May administer ofloxacin tablets with or without food; avoid antacids, vitamins with iron or minerals, sucralfate, or didanosine; use within 2 hours of administration; drink plenty of fluids to maintain proper hydration and urine output",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10513025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store tablets at room temperature.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10512984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acute bacterial exacerbations of chronic bronchitis, community-acquired pneumonia, uncomplicated skin and skin structure infections, urethral and cervical gonorrhea (acute, uncomplicated), urethritis and cervicitis (nongonococcal), pelvic inflammatory disease, uncomplicated cystitis, complicated urinary tract infections, and prostatitis caused by susceptible organisms including",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     ,",
"     <i>",
"      S. aureus",
"     </i>",
"     ,",
"     <i>",
"      S. pyrogenes",
"     </i>",
"     ,",
"     <i>",
"      C. koseri",
"     </i>",
"     ,",
"     <i>",
"      E. aerogenes",
"     </i>",
"     , E",
"     <i>",
"      . coli",
"     </i>",
"     ,",
"     <i>",
"      H. influenzae",
"     </i>",
"     ,",
"     <i>",
"      K. pneumoniae",
"     </i>",
"     ,",
"     <i>",
"      N. gonorrhoeae",
"     </i>",
"     ,",
"     <i>",
"      P. mirabilis",
"     </i>",
"     ,",
"     <i>",
"      C. trachomatis",
"     </i>",
"     , and",
"     <i>",
"      P. aeruginosa",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F9497561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: dizziness, fatigue, headache, insomnia, nervousness, pyrexia, sleep disorders, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, abnormal taste, appetite decreased, constipation, diarrhea, flatulence, GI distress, nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: External genital pruritus in women, vaginitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Visual disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pharyngitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Trunk pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Anaphylaxis reactions, anxiety, blurred vision, chills, cognitive change, cough, depression, dream abnormality, ecchymosis, edema, erythema nodosum, euphoria, extremity pain, hallucinations, hearing acuity decreased, hepatic dysfunction, hepatic failure (some fatal), hepatitis, hyper-/hypoglycemia, hypertension, interstitial nephritis, intracranial pressure increased, lightheadedness, malaise, myasthenia gravis exacerbation, palpitation, paresthesia, peripheral neuropathy, photophobia, photosensitivity, pneumonitis, pseudotumor cerebri, psychotic reactions, rhabdomyolysis, seizure, Stevens-Johnson syndrome, syncope, tendonitis and tendon rupture, thirst, tinnitus, torsade de pointes, Tourette's syndrome, toxic epidermal necrolysis, vasculitis, vasodilation, vertigo, weakness, weight loss",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10512985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ofloxacin, any component, or other quinolones; not recommended for use in pregnant women or during breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10512988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with known or suspected CNS disorders, seizure disorders, severe cerebral arteriosclerosis or renal impairment; modify dosage in patients with renal impairment. The use of quinolones has been linked to peripheral neuropathy (rare); discontinue if symptoms of sensory or sensorimotor neuropathy occur. Rare cases of torsade de pointes have been reported in patients taking ofloxacin so use with caution in patients on concurrent therapy with Class Ia or Class III antiarrhythmics or in patients with known prolongation of QT interval, bradycardia, cardiomyopathy, hypokalemia, or hypomagnesemia. Avoid excessive sunlight and take precautions to limit exposure (eg, loose-fitting clothing, sunscreen); may rarely cause moderate to severe phototoxicity reactions. Discontinue use if phototoxicity occurs.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10512986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral formulation not recommended for use in children &lt;18 years of age; ofloxacin has caused osteochondrosis in immature rats and dogs. Fluoroquinolones have caused arthropathy with erosions of the cartilage in weight-bearing joints of immature animals; Achilles tendonitis and tendon rupture have been reported with fluoroquinolones in patients of all ages",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; risk increased in patients taking concomitant corticosteroids, patients &gt;60 years of age, and in patients with kidney, heart, or lung transplants. Fluoroquinolones, including ofloxacin, may exacerbate muscle weakness associated with myasthenia gravis",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; cases of severe exacerbations, including the need for ventilatory support and deaths have been reported; avoid use in patients with myasthenia gravis. Prolonged use may result in superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea and pseudomembranous colitis; CNS stimulation and increased intracranial pressure (including pseudotumor cerebi) may occur resulting in tremors, restlessness, confusion, hallucinations (rare), depression, nightmares, suicidal ideation, or convulsive seizures; serious and occasionally fatal hypersensitivity and/or anaphylactic reactions have been reported often following the first dose. Hypersensitivity reactions have been accompanied by cardiovascular collapse, hypotension/shock, seizure, loss of consciousness, tingling, angioedema, airway obstruction, dyspnea, urticaria, itching, and skin reactions. If these reactions occur, discontinue ofloxacin.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9497653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9497654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of quinolones.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Sodium Bicarbonate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bendamustine: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Bendamustine. Concentrations of the active metabolites of bendamustine may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Calcium Chloride.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Quinolone Antibiotics may enhance the adverse/toxic effect of Corticosteroids (Systemic). Risk of tendon-related side effects, including tendonitis and rupture, may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inhibitors (Strong) may decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Didanosine: May decrease the serum concentration of Quinolone Antibiotics. Quinolone Antibiotics may decrease the serum concentration of Didanosine. Management: Administer oral quinolones at least 2 hours before or 6 hours after didanosine. Monitor for decreased therapeutic effects of quinolones, particularly if doses cannot be separated as recommended. This does not apply to unbuffered enteric coated didanosine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: May enhance the hyperglycemic effect of Quinolone Antibiotics. Insulin may enhance the hypoglycemic effect of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: May decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of Quinolone Antibiotics. Management: Administer oral quinolone antibiotics at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: May decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Quinolone Antibiotics. Specifically, polyvalent cations in multivitamin products may decrease the absorption of orally administered quinolone antibiotics. Management: Interactions can be minimized by administering the oral quinolone at least 2 hours before, or 6 hours after, the dose of a multivitamin that contains polyvalent cations (i.e., calcium, iron, magnesium, selenium, zinc).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Quinolone Antibiotics may decrease the serum concentration of Mycophenolate. Specifically, quinolones may decrease concentrations of the active metabolite of mycophenolate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Pirfenidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinapril: May decrease the serum concentration of Quinolone Antibiotics. Management: Separate doses of quinapril and oral quinolones by at least 2 hours in order to reduce the risk of interaction. Monitor for reduced efficacy of the quinolone if these products are used concomitantly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sevelamer: May decrease the absorption of Quinolone Antibiotics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Strontium Ranelate: May decrease the serum concentration of Quinolone Antibiotics. Management: In order to minimize any potential impact of strontium ranelate on quinolone antibiotic concentrations, it is recommended that strontium ranelate treatment be interrupted during quinolone therapy.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: May decrease the serum concentration of Quinolone Antibiotics. Management: Administer oral quinolones at least 2 hours before or 6 hours after the sucralfate dose.  Greater separation of doses may further lessen the risk for a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Quinolone Antibiotics may enhance the hypoglycemic effect of Sulfonylureas. This appears to be particularly concerning early in the course of combination therapy. Quinolone Antibiotics may diminish the hypoglycemic effect of Sulfonylureas. With longer-term combination, there is a greater risk of hyperglycemia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Quinolone Antibiotics may decrease the metabolism of Theophylline Derivatives. Ciprofloxacin and enoxacin are of greatest concern.  Theophylline/quinolone therapy might augment the seizure-producing potential of each of the individual agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Varenicline: Quinolone Antibiotics may increase the serum concentration of Varenicline.  Management: Monitor for increased varenicline adverse effects with concurrent use of levofloxacin or other quinolone antibiotics, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Quinolone Antibiotics may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zinc Salts: May decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Zinc Chloride.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F10513024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Calcium, dairy products, iron, mineral supplements, and enteral products may decrease ofloxacin concentrations.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9496354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9496355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in some animal studies; therefore, the manufacturer classifies ofloxacin as pregnancy category C. Ofloxacin crosses the placenta and produces measurable concentrations in the amniotic fluid. An increased risk of teratogenic effects has not been observed in animals or humans following ofloxacin use during pregnancy; however, because of concerns of cartilage damage in immature animals, ofloxacin should only be used during pregnancy if a safer option is not available. Serum concentrations of ofloxacin may be lower during pregnancy than in nonpregnant patients.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10513034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients receiving concurrent ofloxacin and theophylline should have serum levels of theophylline monitored; monitor INR in patients receiving warfarin; monitor blood glucose in patients receiving antidiabetic agents; monitor renal, hepatic, hematopoietic function, and electrolytes periodically; number and type of stools/day for diarrhea",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10513026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ofloxacin inhibits DNA gyrase (bacterial topoisomerase II) thereby inhibiting relaxation of supercoiled DNA and promoting breakage of DNA strands. DNA gyrase maintains the superhelical structure of DNA and is required for DNA replication, transcription, repair, recombination, and transposition.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10513027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Well-absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Widely distributed into body tissues and fluids, including blister fluid, cervix, lung, ovary, prostatic tissue, skin, and sputum; crosses the placenta; excreted into breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     : 2.4-3.5 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 20% to 32%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: 98%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life, biphasic: 4-7.4 hours and 20-25 hours; prolonged with renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, serum concentration: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: 68% to 90% is excreted unchanged in urine; 4% to 8% excreted in feces; &lt;10% is metabolized",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10513035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/29/30165?source=see_link\">",
"      see \"Ofloxacin (systemic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Drink plenty of fluids; may cause dizziness or lightheadedness and impair ability to perform activities requiring mental alertness or physical coordination; notify physician if tendon pain or swelling, burning, tingling, numbness, or weakness develops, or if palpitations, chest pains, signs of allergy occurs; burning, tingling, numbness, or weakness develop; difficulty breathing, or persistent diarrhea occurs. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Alghasham AA and Nahata MC, &ldquo;Clinical Use of Fluoroquinolones in Children,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2000, 34(3):347-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?33/28/34246/abstract-text/10917383 /pubmed\" id=\"10917383 \" target=\"_blank\">",
"        10917383",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16032 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-6A22C7A760-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_28_34246=[""].join("\n");
var outline_f33_28_34246=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9496286\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9496295\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512947\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10513028\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9497986\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9496347\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9496293\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10513033\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10513025\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512984\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9497561\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512985\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512988\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512986\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9497653\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9497654\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10513024\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9496354\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9496355\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10513034\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10513026\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10513027\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10513035\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16032\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16032|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/2/31780?source=related_link\">",
"      Ofloxacin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/20/30020?source=related_link\">",
"      Ofloxacin (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/55/21363?source=related_link\">",
"      Ofloxacin (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/30/484?source=related_link\">",
"      Ofloxacin (otic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/6/16484?source=related_link\">",
"      Ofloxacin (otic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/42/20131?source=related_link\">",
"      Ofloxacin (otic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/41/1688?source=related_link\">",
"      Ofloxacin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/29/30165?source=related_link\">",
"      Ofloxacin (systemic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_28_34247="Prenatal sonographic diagnosis of fetal abdominal wall defects";
var content_f33_28_34247=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prenatal sonographic diagnosis of fetal abdominal wall defects",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?33/28/34247/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/28/34247/contributors\">",
"     Ana Monteagudo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?33/28/34247/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/28/34247/contributors\">",
"     Louise Wilkins-Haug, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/28/34247/contributors\">",
"     Deborah Levine, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?33/28/34247/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/28/34247/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?33/28/34247/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal abdominal wall defects occur in 1 in 2000 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34247/abstract/1\">",
"     1",
"    </a>",
"    ]. The most common abdominal wall defects are gastroschisis and omphalocele; uncommon anomalies include ectopia cordis, limb-body wall complex, cloacal exstrophy, and urachal cyst (",
"    <a class=\"graphic graphic_table graphicRef79143 \" href=\"UTD.htm?2/3/2107\">",
"     table 1",
"    </a>",
"    ). Widespread use of antenatal ultrasound examination and maternal serum alpha-fetoprotein screening has led to increasing detection of these defects in the second trimester of pregnancy. Moreover, with the increased use of first trimester sonography for the assessment of nuchal translucency in screening for Down syndrome, the diagnosis of these defects is shifting to as early as 11 to 14 weeks of gestation. The early gestational scan should be able to detect all cases of omphalocele, gastroschisis, and body stalk anomaly [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34247/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EMBRYOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the 4th to 5th week of development, the flat embryonic disk folds in four directions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    planes: cephalic, caudal, and right and left lateral. Each fold converges at the site of the umbilicus, thus obliterating the extraembryonic coelom. The lateral folds form the lateral portions of the abdominal wall and the cephalic and caudal folds make up the epigastrium and hypogastrium [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34247/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Rapid growth of the intestines and liver also occurs at this time. During the 6th week of development (or eight weeks from the last menstrual period), the abdominal cavity temporarily becomes too small to accommodate all of its contents, resulting in protrusion of the intestines into the residual extraembryonic coelom at the base of the umbilical cord. This temporary herniation is called physiologic midgut herniation (PMH) and is sonographically evident between the 9th to 11th postmenstrual weeks (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54907 \" href=\"UTD.htm?34/20/35141\">",
"     image 1",
"    </a>",
"    ). Reduction of this hernia occurs by the 12th postmenstrual week; beyond the 12th week a midgut herniation is no longer physiological [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34247/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A simple midline omphalocele develops if the extra-embryonic gut fails to return to the abdominal cavity and remains covered by the two-layer amnionic-peritoneal layer into which the umbilicus inserts [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34247/abstract/3,4,6\">",
"     3,4,6",
"    </a>",
"    ]. In contrast to fetal bowel, the liver does not have a physiological migration outside of the abdominal cavity during development. Therefore, the liver is never present in physiologic midgut herniation. However, if the lateral folds fail to close, a large abdominal wall defect is created through which the abdominal cavity contents, including the liver, can herniate [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34247/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The result is a liver-containing omphalocele (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Containing liver'",
"    </a>",
"    below)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SONOGRAPHIC APPROACH TO DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whenever an abdominal wall defect is identified prenatally, five issues should be addressed to help categorize the defect [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34247/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Does the defect include a limiting membrane? A membrane helps to distinguish omphalocele from gastroschisis; however, membranes occasionally rupture in-utero.",
"     </li>",
"     <li>",
"      Where does the umbilical cord insert relative to the defect? Omphalocele and body-stalk defects are connected to the cord, ectopia cordis develops above and bladder exstrophy below the cord insertion, and gastroschisis is paraumbilical. Scoliosis associated with a defect at the cord insertion site suggests body stalk anomaly, rather than omphalocele.",
"     </li>",
"     <li>",
"      Are there extracorporeal organs? Extracorporeal heart or liver is associated with a poor prognosis. With omphaloceles, the risk of aneuploidy is high when the liver is intracorporeal and low when extracorporeal.",
"     </li>",
"     <li>",
"      What is the appearance of the bowel? Dilatation and thickening are more common with gastroschisis than omphalocele. Ascites is often seen with omphalocele.",
"     </li>",
"     <li>",
"      Are there associated malformations? The presence of one abnormality means there is an increased risk of additional anomalies. Both diagnosis and prognosis depend upon accurate characterization of associated malformations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     OMPHALOCELE",
"    </span>",
"    &nbsp;&mdash;&nbsp;An omphalocele is a medial abdominal wall defect into which the abdominal contents herniate (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77707 \" href=\"UTD.htm?14/63/15359\">",
"     image 2",
"    </a>",
"    ). The defect, which is covered by amnion and peritoneum, usually occurs at the base of the umbilical cord with the cord inserting at its apex (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50482 \" href=\"UTD.htm?34/26/35234\">",
"     image 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76612 \" href=\"UTD.htm?38/57/39826\">",
"     image 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59696 \" href=\"UTD.htm?15/33/15889\">",
"     image 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62449 \" href=\"UTD.htm?12/29/12767\">",
"     image 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef60889 \" href=\"UTD.htm?28/50/29472\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef71646 \" href=\"UTD.htm?10/41/10911\">",
"     picture 2",
"    </a>",
"    ). Omphaloceles are categorized as either liver-containing (ie, giant omphalocele) or nonliver-containing (containing only bowel).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Not containing liver",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sonographic diagnosis of a nonliver-containing omphalocele can only be made reliably after 12 postmenstrual weeks; prior to this time it is difficult to differentiate from physiologic midgut herniation [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34247/abstract/5,7\">",
"     5,7",
"    </a>",
"    ]. A chromosomal abnormality, particularly aneuploidies such as trisomy 18, 21, or 13, is present in 40 to 60 percent of fetuses with omphaloceles not containing liver [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34247/abstract/8\">",
"     8",
"    </a>",
"    ]. Therefore, prenatal testing for fetal karyotype should be offered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Containing liver",
"    </span>",
"    &nbsp;&mdash;&nbsp;A liver-containing omphalocele encloses all or part of the liver in the omphalocele sac. Bowel and other organs may also be present in the sac. The sonographic diagnosis of liver-containing omphalocele can be made before the 12th postmenstrual week since herniated liver is",
"    <strong>",
"     never",
"    </strong>",
"    a normal developmental finding.",
"   </p>",
"   <p>",
"    During the first trimester, the liver is homogeneous while the bowel is more echogenic. This difference in sonographic appearance can help differentiate between the two. A liver-containing omphalocele can be diagnosed by transvaginal sonography as early as 9 to 10 postmenstrual weeks if a mass with the consistency of liver measuring greater than 5 to 10 mm in diameter is imaged within the area of physiologic midgut herniation [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34247/abstract/7,9-13\">",
"     7,9-13",
"    </a>",
"    ]. Fetuses with this type of omphalocele typically, but not invariably, have a normal karyotype [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34247/abstract/8,14,15\">",
"     8,14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Associated anomalies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to aneuploidy, omphaloceles have been associated with conditions such as Pentalogy of Cantrell, amniotic band syndrome, schisis association, OEIS syndrome (omphalocele, exstrophy of the bladder, imperforate anus, spinal defects) and Beckwith-Wiedemann syndrome (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59696 \" href=\"UTD.htm?15/33/15889\">",
"     image 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73556 \" href=\"UTD.htm?27/13/27857\">",
"     image 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67270 \" href=\"UTD.htm?42/22/43375\">",
"     image 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34247/abstract/16-20\">",
"     16-20",
"    </a>",
"    ]. The latter syndrome consists of a group of disorders that have in common the following features: omphalocele, macroglossia, visceromegaly, and neonatal hypoglycemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24473?source=see_link\">",
"     \"Beckwith-Wiedemann syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A congenital heart defect accompanies omphalocele in as many as 50 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34247/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. Additional gastrointestinal abnormalities, genitourinary anomalies, neural tube defects, polyhydramnios, and fetal growth restriction also occur with increased frequency in these fetuses [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34247/abstract/11,13\">",
"     11,13",
"    </a>",
"    ]. The prevalence of omphalocele is 10 times higher in fetuses with increased nuchal translucency than in the general population, even in the presence of normal chromosomes [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34247/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The obstetrical and neonatal management of these",
"    <span class=\"nowrap\">",
"     fetuses/infants",
"    </span>",
"    is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38454?source=see_link\">",
"     \"Obstetrical management of omphalocele\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     GASTROSCHISIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastroschisis refers to a full thickness defect in the abdominal wall through which evisceration of the intestines has occurred (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58739 \" href=\"UTD.htm?8/30/8673\">",
"     image 9",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61153 \" href=\"UTD.htm?9/13/9425\">",
"     image 10",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69631 \" href=\"UTD.htm?1/42/1696\">",
"     image 11",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef60889 \" href=\"UTD.htm?28/50/29472\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef61463 \" href=\"UTD.htm?10/38/10851\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34247/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. The defect usually arises to the right of the umbilicus and is generally small (less than 2 cm) compared to the volume of eviscerated bowel.",
"   </p>",
"   <p>",
"    The anterior abdominal wall can be consistently imaged from 9 postmenstrual weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34247/abstract/28\">",
"     28",
"    </a>",
"    ], although the defect has not been diagnosed before the 12th week [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34247/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Late in pregnancy, the eviscerated bowel often appears thickened, matted, and mildly dilated due to chronic exposure to amniotic fluid.",
"   </p>",
"   <p>",
"    The pathogenesis of gastroschisis is thought to be vascular compromise of either the umbilical vein or omphalomesenteric artery leading to an abdominal wall defect [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34247/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. In contrast to nonliver-containing omphalocele, there is no increase in incidence of chromosomal aneuploidy. Coexistent bowel abnormalities, such as malrotation, atresia, stenosis, and ischemia, are common. Associated abnormalities include exstrophy of the urinary bladder, fetal growth restriction, and minor cardiac anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34247/abstract/11,27,31\">",
"     11,27,31",
"    </a>",
"    ]. In contrast to omphalocele, gastroschisis has fewer associated defects [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34247/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The obstetrical and neonatal management of these",
"    <span class=\"nowrap\">",
"     fetuses/infants",
"    </span>",
"    is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/40/35464?source=see_link\">",
"     \"Obstetrical management of gastroschisis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ECTOPIA CORDIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ectopia cordis is a rare defect in which the heart is partially or completely exposed on the surface of the thorax. Up to 80 percent of affected fetuses will have associated intracardiac defects, such as ventricular septal defect (VSD), tetralogy of Fallot (TOF), left ventricular diverticulum (LVD), double outlet right ventricle (DORV), and pulmonary hypoplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34247/abstract/32-35\">",
"     32-35",
"    </a>",
"    ]. The diagnosis has been reported as early as the 12th to 14th week of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34247/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Three-dimensional ultrasound has been useful in better defining the pathology (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56859 \" href=\"UTD.htm?25/17/25874\">",
"     image 12",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34247/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ectopia cordis results from failure of fusion of the lateral folds in the thoracic area during the 6th postmenstrual week [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34247/abstract/39\">",
"     39",
"    </a>",
"    ]. It is classified into four different types: cervical (3 percent), thoracic (60 percent), thoraco-abdominal (7 percent), and abdominal (30 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34247/abstract/33,35,38\">",
"     33,35,38",
"    </a>",
"    ]. Neonatal mortality is very high, especially with complete thoracic ectopia cordis, which, if left untreated, is universally lethal [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34247/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pentalogy of Cantrell",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pentalogy of Cantrell is a rare and complex malformation caused by failure of cephalic body folding (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60660 \" href=\"UTD.htm?43/33/44561\">",
"     image 13",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61828 \" href=\"UTD.htm?2/29/2514\">",
"     image 14",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef58812 \" href=\"UTD.htm?11/11/11443\">",
"     picture 4",
"    </a>",
"    ). It is characterized by:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Median supraumbilical (epigastric) abdominal defect",
"     </li>",
"     <li>",
"      Defect of the lower sternum",
"     </li>",
"     <li>",
"      Deficiency of the diaphragmatic pericardium",
"     </li>",
"     <li>",
"      Deficiency of the anterior diaphragm",
"     </li>",
"     <li>",
"      Intracardiac abnormality",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This malformation has been diagnosed as early as the 10th to 11th postmenstrual week. The diagnosis should be considered if both ectopia cordis and an",
"    <span class=\"nowrap\">",
"     omphalocele/ventral",
"    </span>",
"    abdominal wall defect have been demonstrated as the intracardiac abnormality may be difficult to detect [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34247/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Associated abnormalities include craniofacial defects, trisomy 18, 13, and 21, and cystic hygroma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     BODY STALK ANOMALY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Body stalk anomaly refers to a lethal malformation that occurs from failure of fusion of all four body folds during the 6th postmenstrual week. The main features of this abnormality are large complex cranial defects (eg, encephalocele), facial clefts, body wall defects of the thorax",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    abdomen, and limb defects. The intrathoracic and abdominal organs lie outside the cavity and are contained within a sac, which is covered by amnioperitoneal membrane attached directly to the placenta (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50682 \" href=\"UTD.htm?10/47/10998\">",
"     image 15",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75623 \" href=\"UTD.htm?27/49/28436\">",
"     image 16",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef52215 \" href=\"UTD.htm?11/10/11428\">",
"     picture 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34247/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. The umbilical cord may be totally absent or extremely shortened. Severe kyphoscoliosis is often present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/21/6488?source=see_link\">",
"     \"Obstetrical and neonatal management of body stalk anomalies and cloacal abnormalities\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A combination of scoliosis and omphalocele should suggest this diagnosis, which has been made as early as the 9th postmenstrual week [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34247/abstract/3,40,44-46\">",
"     3,40,44-46",
"    </a>",
"    ]. Differential diagnosis includes amniotic band syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CLOACAL EXSTROPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal caudal folding can cause any or all of the defects observed in cloacal exstrophy: hypogastric omphalocele, meningomyelocele, scoliosis, abnormal genitalia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    herniation of the bladder, kidneys and female reproductive organs into an extracorporeal sac. The herniated bladder consists of two hemibladders (each with its own ureter) separated by intestinal mucosa. Extensive failure of the caudal fold somatic layer leads to absence of the hypogastric wall in front of the allantois, thereby producing urorectal or cloacal exstrophy as well as omphalocele [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34247/abstract/3\">",
"     3",
"    </a>",
"    ]. Greater degrees of cloacal septation will result in imperforate anus and vesico-intestinal, urethral-intestinal, or ureteral-intestinal fistula [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34247/abstract/3,47\">",
"     3,47",
"    </a>",
"    ]. A single umbilical artery is often observed. Other anomalies include abdominal and pelvic defects, spinal abnormalities, and anorectal atresia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/21/6488?source=see_link\">",
"     \"Obstetrical and neonatal management of body stalk anomalies and cloacal abnormalities\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Bladder exstrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bladder exstrophy has a similar embryological origin and defect in the lower abdominal wall as cloacal exstrophy. Mild cases are limited to exstrophy of the urethra and part of the bladder, while severe cases involve diastasis of the symphysis pubis and include malposition of the anal orifice. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24966?source=see_link\">",
"     \"Clinical manifestations and initial management of infants with bladder exstrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11849?source=see_link\">",
"     \"Surgical management and postoperative outcome of children with bladder exstrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Demonstration of a normal urinary bladder excludes the diagnosis of both cloacal and bladder exstrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34247/abstract/48\">",
"     48",
"    </a>",
"    ]. Body stalk anomaly may demonstrate defects of the mid and lower abdomen similar to cloacal exstrophy, but the latter does not have associated craniofacial abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     URACHAL ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The urachus extends from the umbilical cord to the urinary bladder. In the term fetus, it narrows to a fibrous band called the median umbilical ligament. Although not a true abdominal wall defect, failure of urachal regression can result in communication between the anterior abdominal wall and bladder. This abnormality can consist of a complete or partial patent urachus, urachal diverticulum, urachal sinus, urachal cyst, or alternating sinus [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34247/abstract/1\">",
"     1",
"    </a>",
"    ]. A visible communication between the bladder and the cystic mass is a pathognomonic sign of a patent urachus [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34247/abstract/49\">",
"     49",
"    </a>",
"    ]. Common associated anomalies include omphalocele, meningomyelocele, and genitourinary defects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41721?source=see_link&amp;anchor=H16#H16\">",
"     \"Care of the umbilicus and management of umbilical disorders\", section on 'Urachal anomalies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fetal abdominal wall defects occur in 1 in 2000 live births. The most common abdominal wall defects are gastroschisis and omphalocele; uncommon anomalies include ectopia cordis, limb-body wall complex, cloacal exstrophy, and urachal cyst (",
"      <a class=\"graphic graphic_table graphicRef79143 \" href=\"UTD.htm?2/3/2107\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Midgut herniation is no longer physiological after the 12th gestational week. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Embryology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An omphalocele is a median abdominal wall defect into which the abdominal contents herniate. The defect occurs at the base of the umbilical cord with the cord inserting at its apex and is covered by amnion and peritoneum (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef50482 \" href=\"UTD.htm?34/26/35234\">",
"       image 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef76612 \" href=\"UTD.htm?38/57/39826\">",
"       image 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef59696 \" href=\"UTD.htm?15/33/15889\">",
"       image 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef62449 \" href=\"UTD.htm?12/29/12767\">",
"       image 6",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef60889 \" href=\"UTD.htm?28/50/29472\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef71646 \" href=\"UTD.htm?10/41/10911\">",
"       picture 2",
"      </a>",
"      ). Omphaloceles are categorized as either liver-containing (ie, giant omphalocele) or nonliver-containing (containing only bowel). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Omphalocele'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gastroschisis refers to a full thickness defect in the abdominal wall through which evisceration of the intestines has occurred (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef58739 \" href=\"UTD.htm?8/30/8673\">",
"       image 9",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef61153 \" href=\"UTD.htm?9/13/9425\">",
"       image 10",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef69631 \" href=\"UTD.htm?1/42/1696\">",
"       image 11",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef60889 \" href=\"UTD.htm?28/50/29472\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef61463 \" href=\"UTD.htm?10/38/10851\">",
"       picture 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Gastroschisis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ectopia cordis is a rare defect in which the heart is partially or completely exposed on the surface of the thorax. Up to 80 percent of affected fetuses will have associated intracardiac defects. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Ectopia cordis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The main features of body stalk anomaly are large complex cranial defects, facial clefts, body wall defects of the thorax",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      abdomen, and limb defects. The intrathoracic and abdominal organs lie outside the cavity and are contained within a sac, which is covered by amnioperitoneal membrane attached directly to the placenta (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef50682 \" href=\"UTD.htm?10/47/10998\">",
"       image 15",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef75623 \" href=\"UTD.htm?27/49/28436\">",
"       image 16",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef52215 \" href=\"UTD.htm?11/10/11428\">",
"       picture 5",
"      </a>",
"      ). A combination of scoliosis and omphalocele should suggest this diagnosis. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Body stalk anomaly'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Defects observed in cloacal exstrophy may include hypogastric omphalocele, meningomyelocele, scoliosis, abnormal genitalia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      herniation of the bladder, kidneys and female reproductive organs into an extracorporeal sac. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Cloacal exstrophy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A visible communication between the bladder and the cystic mass is a pathognomonic sign of a patent urachus. Common associated anomalies include omphalocele, meningomyelocele, and genitourinary defects. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Urachal abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Nyberg, DA, Mack, LA. Abdominal wall defects. In:Nyberg, DA, Mahony, BS, Pretorius, DH (eds). Diagnostic ultrasound of fetal anomalies. Mosby, St Louis, 1990. p395.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34247/abstract/2\">",
"      Syngelaki A, Chelemen T, Dagklis T, et al. Challenges in the diagnosis of fetal non-chromosomal abnormalities at 11-13 weeks. Prenat Diagn 2011; 31:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34247/abstract/3\">",
"      Duhamel B. Embryology of Exomphalos and Allied Malformations. Arch Dis Child 1963; 38:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34247/abstract/4\">",
"      HUTCHIN P. SOMATIC ANOMALIES OF THE UMBILICUS AND ANTERIOR ABDOMINAL WALL. Surg Gynecol Obstet 1965; 120:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34247/abstract/5\">",
"      Cyr DR, Mack LA, Schoenecker SA, et al. Bowel migration in the normal fetus: US detection. Radiology 1986; 161:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34247/abstract/6\">",
"      Margulis, L. Omphalocele (amnicele). Am J Obstet Gynecol 1945; 49:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34247/abstract/7\">",
"      Curtis JA, Watson L. Sonographic diagnosis of omphalocele in the first trimester of fetal gestation. J Ultrasound Med 1988; 7:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34247/abstract/8\">",
"      van Zalen-Sprock RM, Vugt JM, van Geijn HP. First-trimester sonography of physiological midgut herniation and early diagnosis of omphalocele. Prenat Diagn 1997; 17:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34247/abstract/9\">",
"      Brown DL, Emerson DS, Shulman LP, Carson SA. Sonographic diagnosis of omphalocele during 10th week of gestation. AJR Am J Roentgenol 1989; 153:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34247/abstract/10\">",
"      Gray DL, Martin CM, Crane JP. Differential diagnosis of first trimester ventral wall defect. J Ultrasound Med 1989; 8:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34247/abstract/11\">",
"      Khoury MJ, Erickson JD, Cordero JF, McCarthy BJ. Congenital malformations and intrauterine growth retardation: a population study. Pediatrics 1988; 82:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34247/abstract/12\">",
"      Pagliano M, Mossetti M, Ragno P. Echographic diagnosis of omphalocele in the first trimester of pregnancy. J Clin Ultrasound 1990; 18:658.",
"     </a>",
"    </li>",
"    <li>",
"     Romero, R, et al. Omphalocele. In: Prenatal diagnosis of congenital anomalies, Romero, R, et al. (Eds), Appleton &amp; Lange, Norwalk 1998. p. 220.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34247/abstract/14\">",
"      Benacerraf BR, Saltzman DH, Estroff JA, Frigoletto FD Jr. Abnormal karyotype of fetuses with omphalocele: prediction based on omphalocele contents. Obstet Gynecol 1990; 75:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34247/abstract/15\">",
"      Nyberg DA, Fitzsimmons J, Mack LA, et al. Chromosomal abnormalities in fetuses with omphalocele. Significance of omphalocele contents. J Ultrasound Med 1989; 8:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34247/abstract/16\">",
"      Kasznica J, Maldonado NM. Umbilical cord hernia, single umbilical artery, and lung hypoplasia in Ullrich-Turner syndrome. Am J Med Genet 1995; 57:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34247/abstract/17\">",
"      Ranzini AC, Day-Salvatore D, Turner T, et al. Intrauterine growth and ultrasound findings in fetuses with Beckwith-Wiedemann syndrome. Obstet Gynecol 1997; 89:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34247/abstract/18\">",
"      Saller DN Jr, Dailey JV, Doyle DL, et al. Turner syndrome associated with an omphalocele. Prenat Diagn 1993; 13:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34247/abstract/19\">",
"      Stoll C, Alembik Y, Dott B, Roth MP. Risk factors in congenital abdominal wall defects (omphalocele and gastroschisi): a study in a series of 265,858 consecutive births. Ann Genet 2001; 44:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34247/abstract/20\">",
"      Vasudevan PC, Cohen MC, Whitby EH, et al. The OEIS complex: two case reports that illustrate the spectrum of abnormalities and a review of the literature. Prenat Diagn 2006; 26:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34247/abstract/21\">",
"      Fogel M, Copel JA, Cullen MT, et al. Congenital heart disease and fetal thoracoabdominal anomalies: associations in utero and the importance of cytogenetic analysis. Am J Perinatol 1991; 8:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34247/abstract/22\">",
"      Crawford DC, Chapman MG, Allan LD. Echocardiography in the investigation of anterior abdominal wall defects in the fetus. Br J Obstet Gynaecol 1985; 92:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34247/abstract/23\">",
"      Tulloh RM, Tansey SP, Parashar K, et al. Echocardiographic screening in neonates undergoing surgery for selected gastrointestinal malformations. Arch Dis Child Fetal Neonatal Ed 1994; 70:F206.",
"     </a>",
"    </li>",
"    <li>",
"     Nicolaides, K, Sebire, N, Snijders, R. The 11 - 14 week scan. The diagnosis offetal abnormalities. Diploma in Fetal medicine Series, ed. K. Nicolaides. 1999, New York: The Parthenon Publishing Group. 76-77.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34247/abstract/25\">",
"      Hoyme HE, Higginbottom MC, Jones KL. The vascular pathogenesis of gastroschisis: intrauterine interruption of the omphalomesenteric artery. J Pediatr 1981; 98:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34247/abstract/26\">",
"      Hoyme HE, Jones MC, Jones KL. Gastroschisis: abdominal wall disruption secondary to early gestational interruption of the omphalomesenteric artery. Semin Perinatol 1983; 7:294.",
"     </a>",
"    </li>",
"    <li>",
"     Romero, R, et al. Gastroschisis, In: Prenatal diagnosis of congenital anomalies, Romero, R, et al (Eds), Appleton &amp; Lange, Norwalk 1998. p. 224-5.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34247/abstract/28\">",
"      Timor-Tritsch IE, Monteagudo A, Peisner DB. High-frequency transvaginal sonographic examination for the potential malformation assessment of the 9-week to 14-week fetus. J Clin Ultrasound 1992; 20:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34247/abstract/29\">",
"      Guzman ER. Early prenatal diagnosis of gastroschisis with transvaginal ultrasonography. Am J Obstet Gynecol 1990; 162:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34247/abstract/30\">",
"      Kushnir O, Izquierdo L, Vigil D, Curet LB. Early transvaginal sonographic diagnosis of gastroschisis. J Clin Ultrasound 1990; 18:194.",
"     </a>",
"    </li>",
"    <li>",
"     Sadler, T. Digestive system. In: Langman's Medical Embryology, Williams &amp; Wilkins, Baltimore 1999. p. 237-259.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34247/abstract/32\">",
"      Alphonso N, Venugopal PS, Deshpande R, Anderson D. Complete thoracic ectopia cordis. Eur J Cardiothorac Surg 2003; 23:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34247/abstract/33\">",
"      Amato JJ, Zelen J, Talwalkar NG. Single-stage repair of thoracic ectopia cordis. Ann Thorac Surg 1995; 59:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34247/abstract/34\">",
"      Hornberger LK, Colan SD, Lock JE, et al. Outcome of patients with ectopia cordis and significant intracardiac defects. Circulation 1996; 94:II32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34247/abstract/35\">",
"      Morales JM, Patel SG, Duff JA, et al. Ectopia cordis and other midline defects. Ann Thorac Surg 2000; 70:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34247/abstract/36\">",
"      Bennett TL, Burlbaw J, Drake CK, Finley BE. Diagnosis of ectopia cordis at 12 weeks gestation using transabdominal ultrasonography with color flow Doppler. J Ultrasound Med 1991; 10:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34247/abstract/37\">",
"      Fleming AD, Vintzileos AM, Rodis JF, et al. Diagnosis of fetal ectopia cordis by transvaginal ultrasound. J Ultrasound Med 1991; 10:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34247/abstract/38\">",
"      Mittermayer C, Bernaschek G, Lee A. Diagnosis of ectopia cordis with three-dimensional power Doppler ultrasound in first-trimester pregnancy. Ultrasound Obstet Gynecol 2002; 20:203.",
"     </a>",
"    </li>",
"    <li>",
"     Moore, K. The cardiovascular system. In: The developing human. Clinically oriented embryology, Moore, K (Ed), WB Saunders Company, Philadelphia 1988. p. 286.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34247/abstract/40\">",
"      Hiett AK, Devoe LD, Falls DG 3rd, Martin SA. Ultrasound diagnosis of a twin gestation with concordant body stalk anomaly. A case report. J Reprod Med 1992; 37:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34247/abstract/41\">",
"      Liang RI, Huang SE, Chang FM. Prenatal diagnosis of ectopia cordis at 10 weeks of gestation using two-dimensional and three-dimensional ultrasonography. Ultrasound Obstet Gynecol 1997; 10:137.",
"     </a>",
"    </li>",
"    <li>",
"     Bronshtein, M, Timor-Tritsch, I, S, Rottem. Early detection offetal anomalies. In: Transvaginal Sonography, Timor-Tritsch, I, Rottem, S, (Eds), Chapman &amp; Hall, New York 1991. p. 327.",
"    </li>",
"    <li>",
"     Romero, R, et al. Body stalk anomaly, In: Prenatal diagnosis of congenital anomalies, Romero, R, et al. (Eds), Appleton &amp; Lange, Norwalk 1998. p. 226.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34247/abstract/44\">",
"      Becker R, Runkel S, Entezami M. Prenatal diagnosis of body stalk anomaly at 9 weeks of gestation. Case report. Fetal Diagn Ther 2000; 15:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34247/abstract/45\">",
"      Daskalakis G, Sebire NJ, Jurkovic D, et al. Body stalk anomaly at 10-14 weeks of gestation. Ultrasound Obstet Gynecol 1997; 10:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34247/abstract/46\">",
"      Ginsberg NE, Cadkin A, Strom C. Prenatal diagnosis of body stalk anomaly in the first trimester of pregnancy. Ultrasound Obstet Gynecol 1997; 10:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34247/abstract/47\">",
"      Gosden C, Brock DJ. Prenatal diagnosis of exstrophy of the cloaca. Am J Med Genet 1981; 8:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34247/abstract/48\">",
"      Wilcox DT, Chitty LS. Non-visualisations of the fetal bladder: aetiology and management. Prenat Diagn 2001; 21:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34247/abstract/49\">",
"      Sepulveda W, Bower S, Dhillon HK, Fisk NM. Prenatal diagnosis of congenital patent urachus and allantoic cyst: the value of color flow imaging. J Ultrasound Med 1995; 14:47.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 408 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-60.18.131.125-8F74BD76B3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_28_34247=[""].join("\n");
var outline_f33_28_34247=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EMBRYOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SONOGRAPHIC APPROACH TO DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      OMPHALOCELE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Not containing liver",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Containing liver",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Associated anomalies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      GASTROSCHISIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ECTOPIA CORDIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pentalogy of Cantrell",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      BODY STALK ANOMALY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CLOACAL EXSTROPHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Bladder exstrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      URACHAL ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/408\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/408|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?34/20/35141\" title=\"diagnostic image 1\">",
"      Prenatal ultrasound images of physiologic midgut herniation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?14/63/15359\" title=\"diagnostic image 2\">",
"      Ultrasound of omphalocele and cystic hygroma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?34/26/35234\" title=\"diagnostic image 3\">",
"      Normal cord insertion by U-S",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/57/39826\" title=\"diagnostic image 4\">",
"      Norml cord insert color doppler",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/33/15889\" title=\"diagnostic image 5\">",
"      Ultrasound of an omphalocele",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?12/29/12767\" title=\"diagnostic image 6\">",
"      Omphalocele 3D ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?27/13/27857\" title=\"diagnostic image 7\">",
"      Ultrasound of protruding tongue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/22/43375\" title=\"diagnostic image 8\">",
"      U-S enlarged fetal kidneys",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/30/8673\" title=\"diagnostic image 9\">",
"      Ultrasound gastroschisis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?9/13/9425\" title=\"diagnostic image 10\">",
"      Color Doppler cord gastroschisi",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/42/1696\" title=\"diagnostic image 11\">",
"      Gastroschisis 3D ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/17/25874\" title=\"diagnostic image 12\">",
"      Ultrasound of ectopia cordis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?43/33/44561\" title=\"diagnostic image 13\">",
"      U-S pentalogy of Cantrell",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/29/2514\" title=\"diagnostic image 14\">",
"      Doppler pentalogy of Cantrell",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/47/10998\" title=\"diagnostic image 15\">",
"      U-S body stalk malformation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?27/49/28436\" title=\"diagnostic image 16\">",
"      Sonogram short umbilical cord",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/408|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/50/29472\" title=\"picture 1\">",
"      Neonate with gastroschisi",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/41/10911\" title=\"picture 2\">",
"      Neonate with omphalocele",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/38/10851\" title=\"picture 3\">",
"      Neonatal gastroschisis 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/11/11443\" title=\"picture 4\">",
"      Abortus pentalogy of Cantrell",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/10/11428\" title=\"picture 5\">",
"      Neonate body stalk malformation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/408|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/3/2107\" title=\"table 1\">",
"      Prevalence of body fold defects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24473?source=related_link\">",
"      Beckwith-Wiedemann syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41721?source=related_link\">",
"      Care of the umbilicus and management of umbilical disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24966?source=related_link\">",
"      Clinical manifestations and initial management of infants with bladder exstrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/21/6488?source=related_link\">",
"      Obstetrical and neonatal management of body stalk anomalies and cloacal abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/40/35464?source=related_link\">",
"      Obstetrical management of gastroschisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38454?source=related_link\">",
"      Obstetrical management of omphalocele",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11849?source=related_link\">",
"      Surgical management and postoperative outcome of children with bladder exstrophy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_28_34248="Airway management of pregnant women at delivery";
var content_f33_28_34248=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Airway management of pregnant women at delivery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?33/28/34248/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/28/34248/contributors\">",
"     Michaela K Farber, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/28/34248/contributors\">",
"     Lorraine Chow, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/28/34248/contributors\">",
"     Bhavani-Shankar Kodali, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?33/28/34248/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/28/34248/contributors\">",
"     David L Hepner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?33/28/34248/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/28/34248/contributors\">",
"     Kari G Doucette, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?33/28/34248/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H14530966\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of the airway in pregnancy requires careful consideration of physiologic, mechanical, and situational factors. Airway swelling, decreased gastric motility, and the need to establish airway protection emergently in the setting of fetal distress can all contribute to difficult endotracheal intubation and increase the risk of maternal morbidity and mortality. Early placement of a labor epidural in patients with a potentially difficult airway is a preventative approach that may avoid the need for airway manipulation in the event of an urgent or emergent cesarean delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14530973\">",
"    <span class=\"h1\">",
"     INCIDENCE OF DIFFICULT AND FAILED INTUBATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Difficult intubation has been reported in 1.3 to 16.3 percent of obstetric intubations [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/1\">",
"     1",
"    </a>",
"    ]. In one large series of 2633 general anesthetics in pregnancy or postpartum over a 20-year period, difficult tracheal intubation was encountered in 4.7 percent of",
"    <span class=\"nowrap\">",
"     pregnant/postpartum",
"    </span>",
"    women",
"    <span class=\"nowrap\">",
"     (123/2633)",
"    </span>",
"    and 5.7 percent of women",
"    <span class=\"nowrap\">",
"     (60/1052)",
"    </span>",
"    undergoing cesarean delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Failed intubation is much less common. Two of the largest retrospective studies on the rate of failed intubation in obstetrics reviewed data from 1993-1998 [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/3\">",
"     3",
"    </a>",
"    ] and 1999-2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/4\">",
"     4",
"    </a>",
"    ] and reported failed intubation rates of 1:249 and 1:238 general anesthetics, respectively. This is nearly 10 times the rate observed in general surgical patients (1:2330) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/5\">",
"     5",
"    </a>",
"    ]. Other studies have reported fewer failed intubations (1:750 to 1:1500), possibly because of higher overall rates of general anesthesia at these centers, more senior coverage, immediately available trainee supervision, and more vigilant airway assessment and risk stratification [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/2,6,7\">",
"     2,6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95478368\">",
"    <span class=\"h2\">",
"     Maternal mortality related to anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A report from the Confidential Enquiries into Maternal and Child Health for 2006-2008 noted seven deaths directly attributed to anesthesia; two of these deaths were from failure to ventilate the lungs [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/8\">",
"     8",
"    </a>",
"    ]. There were four deaths from postoperative anesthesia-related complications (opioid toxicity during patient-controlled analgesia, transfusion reaction, cardiac arrest and aspiration during recovery from general anesthesia) and one death from leukoencephalitis after spinal anesthesia. Anesthetic management contributed to the outcome in 18 additional deaths.",
"   </p>",
"   <p>",
"    In an analysis comparing anesthesia-related deaths in the United States from 1991-2002 versus 1979-1990, maternal case fatality rates for general anesthesia at cesarean delivery fell from 16.8 to 6.5 per million general anesthetics, while maternal mortality case fatality rates for regional anesthesia at cesarean delivery rose from 2.5 to 3.8 per million regional anesthetics [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In women who received general anesthesia, about two-thirds of deaths associated were caused by intubation failure or induction problems; for women whose deaths were associated with regional anesthesia, 26 percent were caused by high spinal or epidural block, followed by respiratory failure (19 percent), and drug reaction (19 percent). The reduction in maternal mortality with general anesthesia is likely related to introduction of advanced airway protocols and rescue airway devices (eg, laryngeal mask airway).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14530980\">",
"    <span class=\"h1\">",
"     REASONS FOR DIFFICULT INTUBATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Difficult intubation has been attributed to anatomic and physiological changes of pregnancy, situational stress, and the low volume of cases resulting in diminished clinician experience [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/1\">",
"     1",
"    </a>",
"    ]. It is difficult to accurately predict which patients will have difficult intubation at emergency cesarean delivery; no method of assessment is highly sensitive [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18552?source=see_link&amp;anchor=H7#H7\">",
"     \"The difficult airway in adults\", section on 'Identification of the difficult airway'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14530989\">",
"    <span class=\"h2\">",
"     Anatomic changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prepregnancy, antepartum, and intrapartum factors all affect the airway and can increase the cumulative risk for a difficult intubation. A short neck, receding mandible, protruding maxillary incisors, morbid obesity pregnancy weight gain, and oropharyngeal edema from fluid retention can all play a role in difficult intubation.",
"   </p>",
"   <p>",
"    Anesthesiologists caring for pregnant women should be aware of the potential worsening of the maternal airway as gestation advances. In a study that used the modified Mallampati classification (",
"    <a class=\"graphic graphic_figure graphicRef75229 \" href=\"UTD.htm?2/36/2626\">",
"     figure 1",
"    </a>",
"    ) to evaluate maternal airways at both 12 and 38 weeks of gestation, the number of patients with Mallampati class 4 airways increased by 34 percent at 38 weeks, and the increase correlated significantly with weight gain [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/12\">",
"     12",
"    </a>",
"    ]. A high proportion of women in this study had class 4 airways, which the authors attributed to placing the head in the neutral position rather than the extended position.",
"   </p>",
"   <p>",
"    Labor and delivery can also have adverse effects on the airway (",
"    <a class=\"graphic graphic_picture graphicRef87272 \" href=\"UTD.htm?35/62/36832\">",
"     picture 1",
"    </a>",
"    ). When acoustic reflectometry was utilized to evaluate airway changes at the onset and at the end of labor using the modified Mallampati classification, significant decreases in oral volume and pharyngeal area and volume were observed: the modified Mallampati classification increased by one grade in 33 percent of parturients and by two grades in 5 percent of parturients [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/13\">",
"     13",
"    </a>",
"    ]. These changes did not correlate with longer duration of labor or greater volume of fluids administered, and was not fully reversed 48 hours postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14530996\">",
"    <span class=\"h2\">",
"     Emergent intubation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common indication for emergent endotracheal intubation of a pregnant patient is emergency cesarean delivery due to a nonreassuring fetal heart rate pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/15\">",
"     15",
"    </a>",
"    ]. Additional indications include a failed regional technique, a high sympathetic blockade from a spinal anesthetic, local anesthetic toxicity, respiratory or neurologic emergencies, and maternal cardiac arrest.",
"   </p>",
"   <p>",
"    During an emergency intubation, there may not be time for careful airway assessment, and resources including induction drugs, airway equipment, and back-up assistance, may not be readily available. Preparation for the unanticipated difficult intubation can alleviate stress and improve performance under pressure. All patients on the labor floor should have their airway assessed and their history reviewed upon admission. Patients with anticipated difficult airway or those with contraindications to neuraxial techniques can be identified early and a plan for general anesthesia formulated, if it becomes necessary. In addition, each operating room on the labor and delivery floor should be checked daily to ensure functional anesthesia airway equipment, availability of induction medications in the operating room, and availability of a video laryngoscope and difficult airway equipment [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/1,16\">",
"     1,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14531003\">",
"    <span class=\"h1\">",
"     AIRWAY MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95480329\">",
"    <span class=\"h2\">",
"     Reducing the risk of aspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The obstetric patient is at increased risk of aspiration of gastric contents due to hormonal and physical changes in pregnancy and the use of parenteral or neuraxial opioid analgesics. This risk is increased in cases of difficult or failed intubation or full stomach during non-elective emergent situations, and can be reduced by fasting and use of pharmacologic prophylaxis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14531012\">",
"    <span class=\"h3\">",
"     Fasting guidelines for laboring patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Society of Anesthesiologists (ASA) practice guidelines for obstetric anesthesia and the American College of Obstetricians and Gynecologists (ACOG) Committee Opinion allow for oral intake of modest amounts of clear liquids for patients with uncomplicated labor [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Gastric emptying of solid foods during labor is delayed and intake should be avoided, especially when parenteral or neuraxial opioids are given. Patients with increased risk factors for aspiration (eg, morbid obesity, diabetes, difficult airway) or patients at increased risk for operative delivery (eg, preeclampsia, multiple gestations) may require further restrictions of oral intake, which is determined on an individual basis [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14531019\">",
"    <span class=\"h3\">",
"     Fasting guidelines for elective cesarean delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;For elective cesarean delivery, the fasting guidelines are similar to those for other elective procedures based on the ASA Practice Guidelines for Preoperative Fasting [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/16\">",
"     16",
"    </a>",
"    ]. It is appropriate to allow clear liquids until two hours prior to an elective procedure. The volume of liquid is less important than the type of liquid ingested. Six hours is recommended for a light meal (eg, toast and clear liquid) and eight hours for fatty or fried meals prior to any elective surgical procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gastric emptying of water in healthy, term pregnant, non-laboring patients is not delayed after ingestion of 300 mL of water compared to an overnight fast [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. This is a consistent finding among both normal-weight and obese parturients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14531026\">",
"    <span class=\"h3\">",
"     Pharmacologic and mechanical prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative administration of nonparticulate acids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    ) or H",
"    <sub>",
"     2",
"    </sub>",
"    receptor antagonists are effective in decreasing gastric acidity, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    reduces peripartum nausea and vomiting. The ASA Practice Guidelines for obstetric anesthesia recommend administering pharmacologic aspiration prophylaxis to parturients requiring general or neuraxial anesthesia when clinically indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/2/39977?source=see_link&amp;anchor=H9#H9\">",
"     \"Anesthesia for cesarean delivery\", section on 'Reduction of gastric acidity/volume'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cricoid pressure should be applied at the onset of induction and maintained until confirmation of endotracheal intubation. If difficulty with intubation arises, cricoid pressure should be maintained during rescue mask ventilation. A maximum force of 40N does not distort laryngeal anatomy [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14531033\">",
"    <span class=\"h2\">",
"     Preoxygenation",
"    </span>",
"    &nbsp;&mdash;&nbsp;During apnea, oxygen requirements are supplied by the functional residual capacity (FRC) of the lungs. In pregnancy, FRC decreases and oxygen requirements increase, decreasing the time to desaturation during apnea. In a simulator model of rapid sequence induction at term gestation, labor, morbid obesity (BMI &gt;50",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ),",
"    </span>",
"    and sepsis accelerated both preoxygenation and desaturation during apnea [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/37/32340?source=see_link\">",
"     \"Respiratory tract changes during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Three minutes of tidal volume breathing is superior to 4 deep",
"    <span class=\"nowrap\">",
"     breaths/30",
"    </span>",
"    seconds, but equivalent to 8 deep",
"    <span class=\"nowrap\">",
"     breaths/60",
"    </span>",
"    seconds [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. In acute obstetric emergencies when there is limited time for preoxygenation, 8 deep",
"    <span class=\"nowrap\">",
"     breaths/60",
"    </span>",
"    seconds provides optimal protection against oxygen desaturation during apnea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14531040\">",
"    <span class=\"h2\">",
"     Patient positioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proper patient positioning maximizes the chance of successful intubation and may be the most important factor for successful direct laryngoscopy in the parturient, especially in cases of morbid obesity. The neck should be slightly flexed and elevated at the cervico-thoracic junction to align the laryngeal and pharyngeal axes, while the head should be extended at the atlanto-occipital joint to align the pharyngeal and oral axes. The optimal position for direct laryngoscopy occurs when the external auditory meatus is aligned horizontally with the sternal notch. This process can be achieved by elevation of the upper back and shoulders with blankets or with a pre-formed intubation ramp [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/24\">",
"     24",
"    </a>",
"    ]. It is essential to maintain at least 15 degrees of left uterine displacement during this time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14531047\">",
"    <span class=\"h2\">",
"     Airway equipment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Basic and advanced airway equipment should be readily available for use by experienced personnel. A universal system to notify additional anesthesia personnel in the event that assistance is needed is also recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/25\">",
"     25",
"    </a>",
"    ]. Airway equipment can be divided into two groups for basic and difficult intubation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95480434\">",
"    <span class=\"h3\">",
"     Basic intubation equipment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Basic airway equipment",
"    <strong>",
"    </strong>",
"    should be readily available at each anesthesia machine or cart and includes [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/16,20,24-26\">",
"     16,20,24-26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Masks (varying sizes)",
"     </li>",
"     <li>",
"      Oral airways (7 to 10 cm)",
"      <span class=\"nowrap\">",
"       +/-",
"      </span>",
"      nasal airways",
"     </li>",
"     <li>",
"      Laryngoscopes &ndash; straight and curved blades (#3, 4), regular and short handles",
"      <span class=\"nowrap\">",
"       +/-",
"      </span>",
"      McCoy blade",
"     </li>",
"     <li>",
"      Tracheal tubes (varying sizes)",
"     </li>",
"     <li>",
"      Stylets",
"     </li>",
"     <li>",
"      Gum elastic bougie",
"     </li>",
"     <li>",
"      Lubricating jelly",
"     </li>",
"     <li>",
"      Magill forceps",
"     </li>",
"     <li>",
"      Laryngeal mask airway (LMA)",
"     </li>",
"     <li>",
"      Standard monitoring equipment (ECG, non-invasive blood pressure, carbon dioxide [CO",
"      <sub>",
"       2",
"      </sub>",
"      ] analyzer, oxygen [O",
"      <sub>",
"       2",
"      </sub>",
"      ] monitor, pulse oximeter)",
"     </li>",
"     <li>",
"      Suction device",
"     </li>",
"     <li>",
"      Self-inflating bag and mask for positive-pressure ventilation",
"     </li>",
"     <li>",
"      Medications for blood pressure support, muscle relaxation and hypnosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95480472\">",
"    <span class=\"h3\">",
"     Difficult intubation equipment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Equipment for difficult intubation is specialized and should be kept in one location and checked regularly [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/15,16,27\">",
"     15,16,27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Flexible fiberoptic bronchoscope",
"     </li>",
"     <li>",
"      Video laryngoscope (eg, Glidescope, C-Mac)",
"     </li>",
"     <li>",
"      At least one device suitable for emergency nonsurgical airway ventilation, including but not limited to: lightwand, jet ventilator, Combitube, Intubating LMA, ProSeal LMA (PLMA)",
"     </li>",
"     <li>",
"      Jet ventilation apparatus",
"     </li>",
"     <li>",
"      Cricothyrotomy kit",
"     </li>",
"     <li>",
"      Retrograde intubation equipment",
"     </li>",
"     <li>",
"      Ventilating tube exchangers",
"     </li>",
"     <li>",
"      Topical anesthetics and vasoconstrictors",
"     </li>",
"     <li>",
"      Exhaled CO2 detector",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95480872\">",
"    <span class=\"h2\">",
"     Video laryngoscopes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The video laryngoscope provides a better view of the larynx than conventional direct laryngoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/28\">",
"     28",
"    </a>",
"    ] and increases the success of intubation, while minimizing the concern for airway swelling and tissue friability that occur with repeated attempts at intubation. Cormack-Lehane laryngoscopy grades (",
"    <a class=\"graphic graphic_figure graphicRef55034 \" href=\"UTD.htm?34/2/34863\">",
"     figure 2",
"    </a>",
"    ) are better with use of videolaryngoscopy compared to conventional laryngoscopy (incidence of Cormack-Lehane grade I or II views 90.2 versus 63.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another useful aspect of videolaryngoscopy is that it allows the assistant to see what the laryngoscopist is doing. Video-assisted instruction improves success rate for tracheal intubation in novices with minimal intubation training [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95480947\">",
"    <span class=\"h2\">",
"     Equipment for failed intubation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Equipment that should be readily available in the event of failed intubation includes:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95480582\">",
"    <span class=\"h3\">",
"     Laryngeal mask airway",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laryngeal mask airways (LMAs) are not used routinely in pregnant patients out of concern for risk of aspiration. However, there are numerous case reports documenting safe LMA use after failed intubation for cesarean deliveries, with rapid improvement of hypoxia and no evidence of pulmonary aspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. As an example, in a prospective study of 1067 patients undergoing elective cesarean delivery, no episodes of hypoxia (defined as SpO",
"    <sub>",
"     2",
"    </sub>",
"    &lt;90 percent), aspiration, regurgitation, laryngospasm, bronchospasm, or gastric insufflation occurred in patients fasted overnight, managed with rapid sequence induction, and ventilated through a classic LMA with cricoid pressure maintained until delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/34\">",
"     34",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15079?source=see_link\">",
"     Vecuronium",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    were administered after delivery.",
"   </p>",
"   <p>",
"    The intubating LMA is a good option in women with a difficult airway because of its ability to act both as an effective ventilatory device and a conduit for blind or fiberoptic intubation [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/35\">",
"     35",
"    </a>",
"    ]. The intubating LMA consists of a rigid, anatomically curved tube that facilitates endotracheal intubation through the LMA. The ProSeal LMA is modified to facilitate ventilation and contains a gastric access port that allows the passage of a 14 French orogastric tube to allow suction of gastric contents or passive drainage of stomach contents. The ProSeal LMA allows for more reliable positive pressure ventilation than the classic LMA and may be advantageous in the obstetric patient [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. More definitive data are needed before this device can be considered as an alternative to endotracheal intubation for cesarean delivery requiring general anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/38\">",
"     38",
"    </a>",
"    ]. However, the LMA remains a critical rescue airway device for failed intubation during anesthesia for both obstetric and non-obstetric patients [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14531068\">",
"    <span class=\"h3\">",
"     Transtracheal jet ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transtracheal jet ventilation (TTJV) is performed by inserting a 14 or 16 gauge intravenous cannula into the cricothyroid membrane, and is faster than conventional tracheostomy. The cannula can be attached to a jet injector that provides ventilation with 100 percent O",
"    <sub>",
"     2",
"    </sub>",
"    pressurized to 50 pounds per square inch [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/26\">",
"     26",
"    </a>",
"    ]. High airway pressures may be required to overcome the decreased lung compliance seen in pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/15\">",
"     15",
"    </a>",
"    ]. One person should be dedicated to holding the catheter in place, and a more definitive airway should be established prior to proceeding with surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major risk of transtracheal jet ventilation is barotrauma; therefore, full exhalation must be ensured.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14531075\">",
"    <span class=\"h1\">",
"     APPROACH TO THE DIFFICULT AIRWAY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Principles of approach to the potentially difficult airway begin with preferential application of regional anesthesia to prevent the need for intubation. If intubation becomes necessary, then use of a failed intubation algorithm and availability of difficult airway equipment are useful. Implementation of a mandatory training program for all personnel at regular intervals also serves to improve and maintain skills [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14531084\">",
"    <span class=\"h2\">",
"     Difficult airway algorithms and drills",
"    </span>",
"    &nbsp;&mdash;&nbsp;The widespread use of neuraxial techniques during labor and cesarean deliveries has significantly reduced the need for general anesthesia and airway manipulation. Accordingly, both trainees and staff in obstetric anesthesia have less exposure to obstetric airway management [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Simulator training can be used to increase trainee awareness and preparedness for emergency obstetric airway management [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/43\">",
"     43",
"    </a>",
"    ]. Many centers utilize simulation routinely.",
"   </p>",
"   <p>",
"    Airway drills and algorithms prepare the entire anesthesia team for the unanticipated obstetric airway emergency. Several algorithms for the management of the obstetric airway have been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/15,20,24,26,36,39\">",
"     15,20,24,26,36,39",
"    </a>",
"    ]. The ASA difficult airway algorithm provides a standardized approach to the difficult airway and aims to decrease morbidity and mortality. A similar approach should be applied to the obstetric patient, with adaptations relevant to this patient population [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/15\">",
"     15",
"    </a>",
"    ]. Four significant differences have been identified:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most obstetric cases are emergent rather than elective",
"     </li>",
"     <li>",
"      Maternal, uterine, and fetal physiologies need to be taken into account",
"     </li>",
"     <li>",
"      Both the condition of the mother and the condition of the fetus need to be assessed and weighed in decision-making",
"     </li>",
"     <li>",
"      Spontaneous breathing is preferred in the non-obstetric patient",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14531091\">",
"    <span class=\"h2\">",
"     Anticipated difficult intubation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following algorithm is for management of an anticipated difficult airway in pregnant women (",
"    <a class=\"graphic graphic_algorithm graphicRef78812 \" href=\"UTD.htm?27/47/28413\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In the patient with a known or anticipated difficult airway, the anesthetic options for cesarean delivery include neuraxial anesthesia or awake intubation followed by general anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/15\">",
"     15",
"    </a>",
"    ]. The need for quick onset of surgical anesthesia is not a contraindication to a regional technique. General anesthesia and endotracheal intubation may be required in situations such as a nonreassuring fetal heart rate pattern, massive hemorrhage, local anesthetic toxicity, high spinal anesthetic, failed regional anesthesia, or maternal cardiac arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although awake intubation is time-consuming, an advantage is maintenance of muscle tone with a natural airway [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/39\">",
"     39",
"    </a>",
"    ]. The success of awake intubation relies largely on operator experience and adequate topical anesthesia of the airway. Awake intubation techniques include fiberoptic and non-fiberoptic techniques (eg, direct laryngoscopy, video laryngoscope, ILMA). Blind nasal intubation should be avoided in pregnancy due to hyperemic nasal mucosa with an increased risk of epistaxis.",
"   </p>",
"   <p>",
"    When administering topical anesthesia to the airway, extra care must be taken to avoid local anesthetic toxicity because increased vascularity of the oropharyngeal mucosa enhances the uptake of topical anesthetics [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/15\">",
"     15",
"    </a>",
"    ]. Thus, it is particularly important to adhere to established local anesthetic toxicity dose limitations in pregnant women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14531098\">",
"    <span class=\"h2\">",
"     Unanticipated difficult intubation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following algorithm is for management of an unanticipated difficult airway in pregnant women (",
"    <a class=\"graphic graphic_algorithm graphicRef60775 \" href=\"UTD.htm?13/17/13599\">",
"     algorithm 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    When intubation is difficult, mask ventilation should be attempted to ensure oxygenation and ventilation while maintaining cricoid pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/15\">",
"     15",
"    </a>",
"    ]. Assistance should be requested early in this situation, and maternal and fetal status should be re-evaluated in conjunction with the obstetric team [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of an oropharyngeal airway may improve the success of mask ventilation. Nasopharyngeal airways should be avoided due to the risk of epistaxis potentially worsening an already difficult airway. Repeated laryngoscopy attempts can cause edema and trauma and may result in an inability to ventilate.",
"   </p>",
"   <p>",
"    If the mother is in immediate jeopardy (eg, hemorrhage from uterine rupture or placental abruption, cardiac arrest) and ventilation is possible, proceeding with the cesarean delivery may optimize the outcome for both the mother and the baby [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/39\">",
"     39",
"    </a>",
"    ]. Controversy exists when the maternal condition is stable, but there is life-threatening fetal compromise. In this case, the risk versus benefit of proceeding with surgery with an unsecured airway and the potential risk of pulmonary aspiration must be weighed against the benefits of prompt delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/44\">",
"     44",
"    </a>",
"    ]. Placement of an LMA early after an unanticipated difficult intubation and signs of fetal distress provide maternal oxygenation and allow for prompt delivery. Correct placement of an LMA with unobstructed ventilation is essential prior to a surgical incision (see",
"    <a class=\"local\" href=\"#H95480582\">",
"     'Laryngeal mask airway'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14531105\">",
"    <span class=\"h3\">",
"     Cannot intubate, can ventilate, no fetal distress",
"    </span>",
"    &nbsp;&mdash;&nbsp;If initial attempts at laryngoscopy are unsuccessful, we suggest atraumatic manipulations such as optimizing the sniffing position, application of external laryngeal pressure, changing to an alternative laryngoscope blade, utilizing a new technique (eg, videolaryngoscopy or lightwand), use of a gum elastic bougie, or participation by a more experienced laryngoscopist [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/36,44\">",
"     36,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If intubation is still unsuccessful, mask ventilation should continue and the patient should be awakened if surgery is not urgently indicated. After awakening, the pathway of &ldquo;anticipated difficult intubation&rdquo; can be followed (see",
"    <a class=\"local\" href=\"#H14531091\">",
"     'Anticipated difficult intubation'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14531112\">",
"    <span class=\"h3\">",
"     Cannot intubate, can ventilate, fetal distress",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the fetus is in acute distress, surgery can proceed even if intubation has failed, provided that oxygenation and ventilation can be maintained [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/26\">",
"     26",
"    </a>",
"    ]. If general anesthesia without a secure airway is performed, the patient can be allowed to resume spontaneous ventilation or be paralyzed with muscle relaxation and ventilated by hand [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/36\">",
"     36",
"    </a>",
"    ]. The absence of muscle relaxation may inhibit exposure of the surgical field and fetal extraction. The use of LMA, intubating LMA, or ProSeal LMA should be considered in this situation (see",
"    <a class=\"local\" href=\"#H95480582\">",
"     'Laryngeal mask airway'",
"    </a>",
"    above). Cricoid pressure may need to be released temporarily to achieve correct positioning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14531119\">",
"    <span class=\"h3\">",
"     Cannot intubate, cannot ventilate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two-person mask ventilation achieves better mask seal and tidal volume than one-person mask ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/39\">",
"     39",
"    </a>",
"    ]. If ventilation is still not adequate, another supraglottic device (LMA, Combitube) or one of the following techniques: transtracheal jet ventilation (see",
"    <a class=\"local\" href=\"#H14531068\">",
"     'Transtracheal jet ventilation'",
"    </a>",
"    above), cricothyrotomy (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4905?source=see_link\">",
"     \"Emergent surgical cricothyrotomy (cricothyroidotomy)\"",
"    </a>",
"    ), or tracheostomy (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/42/11945?source=see_link\">",
"     \"Overview of tracheostomy\"",
"    </a>",
"    ), should be attempted [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/26\">",
"     26",
"    </a>",
"    ]. LMA is the rescue tool of choice; aspiration is the main potential complication [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/15\">",
"     15",
"    </a>",
"    ]. If attempts to ventilate are successful, the risks and benefits of proceeding with surgery should be discussed with the obstetric team.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14531126\">",
"    <span class=\"h2\">",
"     Extubation of the patient with a difficult airway",
"    </span>",
"    &nbsp;&mdash;&nbsp;Care must be taken when extubating the patient with a difficult airway. Airway compromise during emergence in the post-anesthesia period has become the main cause of airway tragedies in the obstetric population [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/45\">",
"     45",
"    </a>",
"    ]. This is especially important if the parturient is obese, has a history of obstructive sleep apnea (OSA), has received large amounts of intravenous fluid or blood products, has undergone a lengthy surgical procedure, or has an underlying disease process that increases the risk of airway edema, such as preeclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These patients should be monitored in a high-dependency area with continuous pulse oximetry. Routine measures prior to extubation should include suctioning of gastric contents, clearing the oropharynx of secretions and blood, giving 100 percent oxygen for at least three to five minutes, and possibly the head-up position to improve FRC [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/29,46\">",
"     29,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14531133\">",
"    <span class=\"h1\">",
"     SELECTED PATIENT POPULATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14531142\">",
"    <span class=\"h2\">",
"     Morbidly obese parturient",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared to normal weight women, the morbidly obese parturient is at increased risk of cesarean delivery, emergency cesarean delivery, failed epidural, and difficult intubation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/11/29882?source=see_link\">",
"     \"The impact of obesity on fertility and pregnancy\"",
"    </a>",
"    .) In a prospective study, difficult tracheal intubation occurred in 6 of 17 morbidly obese women compared with 0 of 8 normal weight women [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest early neuraxial analgesia and heightened vigilance of epidural blockade for morbidly obese laboring parturients [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/48\">",
"     48",
"    </a>",
"    ]. Conversion of a labor epidural to a regional anesthetic is preferable to general anesthesia to avoid airway difficulty in this population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14531149\">",
"    <span class=\"h2\">",
"     Preeclamptic/eclamptic parturient",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of preeclampsia is believed to compound airway challenges, although this has never been systematically reported. The airway in preeclamptic patients may have greater upper airway narrowing and heightened airway reactivity compared to non-preeclamptic parturients [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34248/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14531156\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pregnant women are at higher risk of difficult intubation and aspiration than nonpregnant women. (See",
"      <a class=\"local\" href=\"#H14530973\">",
"       'Incidence of difficult and failed intubation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The percent of women with Mallampati IV classification increases as gestation advances and during labor. Therefore, the airway should be re-examined prior to providing anesthesia to a patient who has been in labor. (See",
"      <a class=\"local\" href=\"#H14530989\">",
"       'Anatomic changes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients on the labor floor should undergo airway assessment and history review upon admission. Patients with anticipated difficult airway or those with contraindications to neuraxial techniques can be identified early and a plan for general anesthesia formulated, if it becomes necessary. (See",
"      <a class=\"local\" href=\"#H14530996\">",
"       'Emergent intubation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Optimum airway management involves reducing the risk of aspiration, preoxygenation, optimum patient positioning, and availability of appropriate equipment for difficult intubation. (See",
"      <a class=\"local\" href=\"#H14531003\">",
"       'Airway management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A video laryngoscope provides a better view of the larynx than conventional direct laryngoscopy and increases the success of intubation. (See",
"      <a class=\"local\" href=\"#H95480872\">",
"       'Video laryngoscopes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The ProSeal laryngeal mask airway is recommended as a primary rescue airway device in obstetric anesthesia. Aspiration is the main potential complication. (See",
"      <a class=\"local\" href=\"#H95480582\">",
"       'Laryngeal mask airway'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The approach to the potentially difficult airway begins with preferential application of regional anesthesia to prevent the need for intubation. If intubation becomes necessary, then use of a failed intubation algorithm (",
"      <a class=\"graphic graphic_algorithm graphicRef78812 \" href=\"UTD.htm?27/47/28413\">",
"       algorithm 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef60775 \" href=\"UTD.htm?13/17/13599\">",
"       algorithm 2",
"      </a>",
"      ) is useful. (See",
"      <a class=\"local\" href=\"#H14531075\">",
"       'Approach to the difficult airway'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Airway compromise during emergence in the post-anesthesia period is an increasing cause of airway tragedies in the obstetric population. Risk factors include obesity, history of obstructive sleep apnea, administration of large volumes of intravenous fluid or blood products, lengthy surgical procedure, or an underlying disease process that increases the risk of airway edema. (See",
"      <a class=\"local\" href=\"#H14531126\">",
"       'Extubation of the patient with a difficult airway'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/1\">",
"      Douglas MJ, Preston RL. The obstetric airway: things are seldom as they seem. Can J Anaesth 2011; 58:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/2\">",
"      McKeen DM, George RB, O'Connell CM, et al. Difficult and failed intubation: Incident rates and maternal, obstetrical, and anesthetic predictors. Can J Anaesth 2011; 58:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/3\">",
"      Barnardo PD, Jenkins JG. Failed tracheal intubation in obstetrics: a 6-year review in a UK region. Anaesthesia 2000; 55:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/4\">",
"      Rahman K, Jenkins JG. Failed tracheal intubation in obstetrics: no more frequent but still managed badly. Anaesthesia 2005; 60:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/5\">",
"      Samsoon GL, Young JR. Difficult tracheal intubation: a retrospective study. Anaesthesia 1987; 42:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/6\">",
"      Djabatey EA, Barclay PM. Difficult and failed intubation in 3430 obstetric general anaesthetics. Anaesthesia 2009; 64:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/7\">",
"      Rocke DA, Murray WB, Rout CC, Gouws E. Relative risk analysis of factors associated with difficult intubation in obstetric anesthesia. Anesthesiology 1992; 77:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/8\">",
"      Cooper GM, McClure JH. Anaesthesia chapter from Saving mothers' lives; reviewing maternal deaths to make pregnancy safer. Br J Anaesth 2008; 100:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/9\">",
"      Hawkins JL, Chang J, Palmer SK, et al. Anesthesia-related maternal mortality in the United States: 1979-2002. Obstet Gynecol 2011; 117:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/10\">",
"      Hawkins JL, Koonin LM, Palmer SK, Gibbs CP. Anesthesia-related deaths during obstetric delivery in the United States, 1979-1990. Anesthesiology 1997; 86:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/11\">",
"      Basaranoglu G, Columb M, Lyons G. Failure to predict difficult tracheal intubation for emergency caesarean section. Eur J Anaesthesiol 2010; 27:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/12\">",
"      Pilkington S, Carli F, Dakin MJ, et al. Increase in Mallampati score during pregnancy. Br J Anaesth 1995; 74:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/13\">",
"      Kodali BS, Chandrasekhar S, Bulich LN, et al. Airway changes during labor and delivery. Anesthesiology 2008; 108:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/14\">",
"      Boutonnet M, Faitot V, Katz A, et al. Mallampati class changes during pregnancy, labour, and after delivery: can these be predicted? Br J Anaesth 2010; 104:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/15\">",
"      Vasdev GM, Harrison BA, Keegan MT, Burkle CM. Management of the difficult and failed airway in obstetric anesthesia. J Anesth 2008; 22:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/16\">",
"      American Society of Anesthesiologists Task Force on Obstetric Anesthesia. Practice guidelines for obstetric anesthesia: an updated report by the American Society of Anesthesiologists Task Force on Obstetric Anesthesia. Anesthesiology 2007; 106:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/17\">",
"      Committee on Obstetric Practice, American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 441: Oral intake during labor. Obstet Gynecol 2009; 114:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/18\">",
"      Wong CA, Loffredi M, Ganchiff JN, et al. Gastric emptying of water in term pregnancy. Anesthesiology 2002; 96:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/19\">",
"      Wong CA, McCarthy RJ, Fitzgerald PC, et al. Gastric emptying of water in obese pregnant women at term. Anesth Analg 2007; 105:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/20\">",
"      Harmer M. Difficult and failed intubation in obstetrics. Int J Obstet Anesth 1997; 6:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/21\">",
"      McClelland SH, Bogod DG, Hardman JG. Pre-oxygenation and apnoea in pregnancy: changes during labour and with obstetric morbidity in a computational simulation. Anaesthesia 2009; 64:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/22\">",
"      Baraka AS, Taha SK, Aouad MT, et al. Preoxygenation: comparison of maximal breathing and tidal volume breathing techniques. Anesthesiology 1999; 91:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/23\">",
"      Chiron B, Laffon M, Ferrandiere M, et al. Standard preoxygenation technique versus two rapid techniques in pregnant patients. Int J Obstet Anesth 2004; 13:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/24\">",
"      Davies JM, Weeks S, Crone LA, Pavlin E. Difficult intubation in the parturient. Can J Anaesth 1989; 36:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/25\">",
"      Lewin SB, Cheek TG, Deutschman CS. Airway management in the obstetric patient. Crit Care Clin 2000; 16:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/26\">",
"      Ezri T, Szmuk P, Evron S, et al. Difficult airway in obstetric anesthesia: a review. Obstet Gynecol Surv 2001; 56:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/27\">",
"      American Society of Anesthesiologists Task Force on Management of the Difficult Airway. Practice guidelines for management of the difficult airway: an updated report by the American Society of Anesthesiologists Task Force on Management of the Difficult Airway. Anesthesiology 2003; 98:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/28\">",
"      Sun DA, Warriner CB, Parsons DG, et al. The GlideScope Video Laryngoscope: randomized clinical trial in 200 patients. Br J Anaesth 2005; 94:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/29\">",
"      Stroumpoulis K, Pagoulatou A, Violari M, et al. Videolaryngoscopy in the management of the difficult airway: a comparison with the Macintosh blade. Eur J Anaesthesiol 2009; 26:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/30\">",
"      Howard-Quijano KJ, Huang YM, Matevosian R, et al. Video-assisted instruction improves the success rate for tracheal intubation by novices. Br J Anaesth 2008; 101:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/31\">",
"      Awan R, Nolan JP, Cook TM. Use of a ProSeal laryngeal mask airway for airway maintenance during emergency Caesarean section after failed tracheal intubation. Br J Anaesth 2004; 92:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/32\">",
"      McCrirrick A. The laryngeal mask airway for failed intubation at caesarean section. Anaesth Intensive Care 1991; 19:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/33\">",
"      Bailey SG, Kitching AJ. The Laryngeal mask airway in failed obstetric tracheal intubation. Int J Obstet Anesth 2005; 14:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/34\">",
"      Han TH, Brimacombe J, Lee EJ, Yang HS. The laryngeal mask airway is effective (and probably safe) in selected healthy parturients for elective Cesarean section: a prospective study of 1067 cases. Can J Anaesth 2001; 48:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/35\">",
"      Vaida SJ, Pott LM, Budde AO, Gaitini LA. Suggested algorithm for management of the unexpected difficult airway in obstetric anesthesia. J Clin Anesth 2009; 21:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/36\">",
"      Kuczkowski KM, Reisner LS, Benumof JL. Airway problems and new solutions for the obstetric patient. J Clin Anesth 2003; 15:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/37\">",
"      Halaseh BK, Sukkar ZF, Hassan LH, et al. The use of ProSeal laryngeal mask airway in caesarean section--experience in 3000 cases. Anaesth Intensive Care 2010; 38:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/38\">",
"      Dyer RA, James MF, Butwick AJ, Carvalho B. The Proseal laryngeal mask airway and elective caesarean section. Anaesth Intensive Care 2011; 39:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/39\">",
"      Munnur U, Suresh MS. Airway problems in pregnancy. Crit Care Clin 2004; 20:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/40\">",
"      Biro P. Difficult intubation in pregnancy. Curr Opin Anaesthesiol 2011; 24:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/41\">",
"      Palanisamy A, Mitani AA, Tsen LC. General anesthesia for cesarean delivery at a tertiary care hospital from 2000 to 2005: a retrospective analysis and 10-year update. Int J Obstet Anesth 2011; 20:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/42\">",
"      Tsen LC, Pitner R, Camann WR. General anesthesia for cesarean section at a tertiary care hospital 1990-1995: indications and implications. Int J Obstet Anesth 1998; 7:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/43\">",
"      Goodwin MW, French GW. Simulation as a training and assessment tool in the management of failed intubation in obstetrics. Int J Obstet Anesth 2001; 10:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/44\">",
"      Munnur U, de Boisblanc B, Suresh MS. Airway problems in pregnancy. Crit Care Med 2005; 33:S259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/45\">",
"      Mhyre JM, Riesner MN, Polley LS, Naughton NN. A series of anesthesia-related maternal deaths in Michigan, 1985-2003. Anesthesiology 2007; 106:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/46\">",
"      Hignett R, Fernando R, McGlennan A, et al. A randomized crossover study to determine the effect of a 30&deg; head-up versus a supine position on the functional residual capacity of term parturients. Anesth Analg 2011; 113:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/47\">",
"      Hood DD, Dewan DM. Anesthetic and obstetric outcome in morbidly obese parturients. Anesthesiology 1993; 79:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/48\">",
"      Soens MA, Birnbach DJ, Ranasinghe JS, van Zundert A. Obstetric anesthesia for the obese and morbidly obese patient: an ounce of prevention is worth more than a pound of treatment. Acta Anaesthesiol Scand 2008; 52:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/49\">",
"      Izci B, Riha RL, Martin SE, et al. The upper airway in pregnancy and pre-eclampsia. Am J Respir Crit Care Med 2003; 167:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34248/abstract/50\">",
"      Siddiqui S, Goodman N, McKenna S, et al. Pre-eclampsia is associated with airway hyperresponsiveness. BJOG 2008; 115:520.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16690 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-201.211.0.116-5E7A61E86A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_28_34248=[""].join("\n");
var outline_f33_28_34248=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14531156\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14530966\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14530973\">",
"      INCIDENCE OF DIFFICULT AND FAILED INTUBATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95478368\">",
"      Maternal mortality related to anesthesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14530980\">",
"      REASONS FOR DIFFICULT INTUBATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14530989\">",
"      Anatomic changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14530996\">",
"      Emergent intubation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14531003\">",
"      AIRWAY MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95480329\">",
"      Reducing the risk of aspiration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14531012\">",
"      - Fasting guidelines for laboring patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14531019\">",
"      - Fasting guidelines for elective cesarean delivery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14531026\">",
"      - Pharmacologic and mechanical prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14531033\">",
"      Preoxygenation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14531040\">",
"      Patient positioning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14531047\">",
"      Airway equipment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H95480434\">",
"      - Basic intubation equipment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H95480472\">",
"      - Difficult intubation equipment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95480872\">",
"      Video laryngoscopes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95480947\">",
"      Equipment for failed intubation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H95480582\">",
"      - Laryngeal mask airway",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14531068\">",
"      - Transtracheal jet ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14531075\">",
"      APPROACH TO THE DIFFICULT AIRWAY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14531084\">",
"      Difficult airway algorithms and drills",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14531091\">",
"      Anticipated difficult intubation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14531098\">",
"      Unanticipated difficult intubation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14531105\">",
"      - Cannot intubate, can ventilate, no fetal distress",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14531112\">",
"      - Cannot intubate, can ventilate, fetal distress",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14531119\">",
"      - Cannot intubate, cannot ventilate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14531126\">",
"      Extubation of the patient with a difficult airway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14531133\">",
"      SELECTED PATIENT POPULATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14531142\">",
"      Morbidly obese parturient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14531149\">",
"      Preeclamptic/eclamptic parturient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14531156\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/16690\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/16690|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?27/47/28413\" title=\"algorithm 1\">",
"      Management of anticipated difficult airway in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?13/17/13599\" title=\"algorithm 2\">",
"      Management of unanticipated difficult airway in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/16690|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/36/2626\" title=\"figure 1\">",
"      Modified Mallampati airway classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/2/34863\" title=\"figure 2\">",
"      Cormack Lehane laryngoscopy grade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/16690|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/62/36832\" title=\"picture 1\">",
"      Maternal airway pre- and post-labor",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/2/39977?source=related_link\">",
"      Anesthesia for cesarean delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4905?source=related_link\">",
"      Emergent surgical cricothyrotomy (cricothyroidotomy)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/42/11945?source=related_link\">",
"      Overview of tracheostomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/37/32340?source=related_link\">",
"      Respiratory tract changes during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18552?source=related_link\">",
"      The difficult airway in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/11/29882?source=related_link\">",
"      The impact of obesity on fertility and pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_28_34249="Comorbidities and complications of type 2 diabetes mellitus in children and adolescents";
var content_f33_28_34249=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Comorbidities and complications of type 2 diabetes mellitus in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?33/28/34249/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/28/34249/contributors\">",
"     Lori Laffel, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/28/34249/contributors\">",
"     Britta Svoren, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?33/28/34249/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/28/34249/contributors\">",
"     Joseph I Wolfsdorf, MB, BCh",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?33/28/34249/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/28/34249/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?33/28/34249/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 28, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children and adolescents with type 2 diabetes are at increased risk for associated comorbidities that include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypertension",
"     </li>",
"     <li>",
"      Dyslipidemia",
"     </li>",
"     <li>",
"      Nonalcoholic fatty liver disease (NAFLD)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adult patients with type 2 diabetes, especially those with poor glycemic control, hypertension and dyslipidemia, are at increased risk for vascular complications. Although data in children and adolescents with type 2 diabetes are limited, they suggest that children and adolescents are also at increased risk for vascular disease similar to that seen in adults with type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34249/abstract/1\">",
"     1",
"    </a>",
"    ]. Glycemic control among adolescents with type 2 diabetes is often poor. Studies in several populations report that less than half of the adolescents with type 2 diabetes regularly attend follow-up visits [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34249/abstract/1\">",
"     1",
"    </a>",
"    ]. One study reported mean glycated hemoglobin concentrations of 12 percent, even among patients involved in active follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34249/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both diabetic ketoacidosis and hyperosmolar hyperglycemia are acute complications in adolescent patients with type 2 disease [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34249/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The comorbidities and complications of type 2 diabetes mellitus in children and adolescents are presented here. The epidemiology, presentation, diagnosis, and management of type 2 diabetes in children and adolescents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/25/4506?source=see_link\">",
"     \"Epidemiology, presentation, and diagnosis of type 2 diabetes mellitus in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36329?source=see_link\">",
"     \"Management of type 2 diabetes mellitus in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     COMORBIDITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children and adolescents with type 2 diabetes are at risk for comorbid conditions including hypertension, dyslipidemia, and nonalcoholic fatty liver disease (NAFLD). These disorders may be present before the diagnosis of type 2 diabetes and, like type 2 diabetes, are associated with excessive weight. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/25/4506?source=see_link\">",
"     \"Epidemiology, presentation, and diagnosis of type 2 diabetes mellitus in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary hypertension (also known as essential hypertension) was once considered uncommon in children. However, with the increasing prevalence of obesity, primary hypertension is the most common cause of hypertension in adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34249/abstract/5\">",
"     5",
"    </a>",
"    ]. Hypertension is a known risk factor for cardiovascular disease in adults. Autopsy studies in children and young adults who died of noncardiovascular causes have demonstrated that childhood hypertension is associated with early development of atherosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34249/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. As the number of cardiovascular risk factors (hypertension, obesity, and dyslipidemia) increased, so did the severity of atherosclerotic changes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=see_link\">",
"     \"Definition and diagnosis of hypertension in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26938?source=see_link\">",
"     \"Secondary factors and progression of chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37685?source=see_link\">",
"     \"Cardiovascular risks of hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Primary hypertension is common in patients with pediatric type 2 diabetes. Observational studies of adolescents with type 2 diabetes reported hypertension in 17 to 32 percent of patients at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34249/abstract/1,8-10\">",
"     1,8-10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=see_link\">",
"     \"Glycemic control and vascular complications in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of medical care in adults with diabetes mellitus\", section on 'Blood pressure control'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with type 2 diabetes, blood pressure should be measured at each health care visit because hypertension increases the risk of vascular complications [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34249/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of prehypertension or hypertension is based on blood pressure measurements obtained on three separate occasions, as defined by the National High Blood Pressure Education Program Working Group [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34249/abstract/12\">",
"     12",
"    </a>",
"    ]. Measurements are compared to normative data classified as percentiles based upon gender, age, and height. The evaluation of hypertension in children and adolescents is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=see_link\">",
"     \"Definition and diagnosis of hypertension in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prehypertension is defined as systolic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diastolic BP &ge;90",
"      <sup>",
"       th",
"      </sup>",
"      percentile but &lt;95",
"      <sup>",
"       th",
"      </sup>",
"      percentile (or between",
"      <span class=\"nowrap\">",
"       120/80",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       130/80",
"      </span>",
"      mmHg, if 90",
"      <sup>",
"       th",
"      </sup>",
"      percentile exceeds that value), measured on three or more separate occasions.",
"     </li>",
"     <li>",
"      Hypertension is defined as systolic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diastolic BP &ge;95",
"      <sup>",
"       th",
"      </sup>",
"      percentile (or",
"      <span class=\"nowrap\">",
"       &gt;130/80",
"      </span>",
"      mmHg, if 95",
"      <sup>",
"       th",
"      </sup>",
"      percentile exceeds that value), measured on three or more separate occasions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Age- and height-specific blood pressure percentiles may be determined using a calculator for boys (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) and girls (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=see_link\">",
"     calculator 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The goal for blood pressure control is for both systolic and diastolic blood pressure to be below the 90th percentile.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prehypertension &mdash; For children with diabetes and prehypertension, non-pharmacologic treatment, consisting of diet, salt restriction, exercise, and weight reduction, is used initially to manage prehypertension. If the prehypertension is not responsive to these measures within three to six months, pharmacologic therapy is initiated [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34249/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hypertension &mdash; For children with diabetes and hypertension, pharmacologic treatment should be initiated as soon as the diagnosis is confirmed. The threshold for initiating pharmacologic treatment are lower than those used for children without diabetes [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34249/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27626?source=see_link&amp;anchor=H4#H4\">",
"       \"Treatment of hypertension in children and adolescents\", section on 'Nonpharmacologic therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data are lacking regarding the most effective antihypertensive agents in children and adolescents with type 2 diabetes. Angiotensin converting enzyme (ACE) inhibitors are generally recommended for initial treatment because they reduce the risk of renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34249/abstract/13\">",
"     13",
"    </a>",
"    ]; angiotensin II receptor blockers (ARBs) are also a reasonable choice [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34249/abstract/12,14,15\">",
"     12,14,15",
"    </a>",
"    ]. Therapy is initiated at the lowest recommended dose and increased until the blood pressure goal (&lt;90th percentile) is reached. Serum creatinine and potassium should be checked monthly during the first two to three months because ACE inhibitors and ARBs can reduce renal function and cause hyperkalemia. ACE inhibitors are teratogenic; patients should be counseled to avoid pregnancy, and these drugs and should be discontinued immediately if a pregnancy is discovered. Alternative agents should be considered for females at risk for pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25224?source=see_link\">",
"     \"Renin-angiotensin system inhibition in the treatment of hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If ACE inhibitors or ARBs are contraindicated (ie, pregnancy) or not well tolerated by the patient, therapeutic alternatives include thiazide diuretics, calcium-channel inhibitors,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a beta-blocker. Beta-blockers can impair hypoglycemia awareness and may not be the best choice in patients who are at risk for hypoglycemia (ie, patients receiving exogenous insulin or oral insulin secretagogues). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=see_link\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Dyslipidemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dyslipidemia is defined as lipoprotein disorders that promote the development of atherosclerosis and include the following abnormalities: (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18138?source=see_link&amp;anchor=H15#H15\">",
"     \"Lipoprotein classification; metabolism; and role in atherosclerosis\", section on 'Lipoproteins and atherosclerosis'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased low-density lipoprotein cholesterol (LDL-C)",
"     </li>",
"     <li>",
"      Decreased high-density lipoprotein cholesterol (HDL-C)",
"     </li>",
"     <li>",
"      Increased triglycerides (TG)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with type 2 diabetes, insulin resistance, relative insulin deficiency, and obesity are associated with hypertriglyceridemia, low serum HDL-C, and, occasionally, high serum LDL-C concentration. Although dyslipidemia is not as common in pediatric patients as in adult patients with type 2 diabetes, a substantial proportion of young patients with type 2 diabetes have abnormal serum lipids. In a cross-sectional, population-based study conducted in six centers throughout the United States, 33 percent of 283 patients with type 2 diabetes (between 10 and 20 years of age) had total cholesterol concentrations &gt;200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34249/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In adults with type 2 diabetes, clinical trials of statin therapy, which lowers LDL-C concentration, reduced the risk of cardiovascular disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\", section on 'Treatment in diabetes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27226?source=see_link&amp;anchor=H12#H12\">",
"     \"Prevalence of and risk factors for coronary heart disease in diabetes mellitus\", section on 'Dyslipidemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar data demonstrating the beneficial effect of statin therapy in childhood type 2 diabetes are lacking. However, because the genesis of atherosclerosis begins in childhood and dyslipidemia can occur in pediatric type 2 diabetes, it is generally accepted that children and adolescents with type 2 diabetes are at increased risk for dyslipidemia and cardiovascular disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the above observations and data from adult trials, the American Diabetes Association (ADA) in association with the American Academy of Pediatrics (AAP) developed guidelines for the screening and treatment of dyslipidemia in pediatric type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34249/abstract/17\">",
"     17",
"    </a>",
"    ]. The American Heart Association has published recommendations to guide decisions regarding treatment of high-risk lipid abnormalities in children and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34249/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/49/23320?source=see_link\">",
"     \"Overview of the management of the child at risk for atherosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ADA guidelines for screening include (",
"    <a class=\"graphic graphic_table graphicRef75008 \" href=\"UTD.htm?34/21/35164\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At diagnosis (after glycemic control is well established), a lipid profile is obtained, preferably in the fasting state. The profile should include measurements of total cholesterol, LDL-C, HDL-C, and TG. Lipid profiles should be repeated at least every two years.",
"     </li>",
"     <li>",
"      Targeted goals for lipid levels are:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      LDL-C &lt;100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.6",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      HDL-C &gt;35",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.9",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      TG &lt;150",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.7",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In adults, screening criteria and treatment goals differ for men and women, whereas in children and adolescents there are no differences in screening and targeted lipid levels based upon gender. If, on the initial screen, goals are met, screening should be repeated in two years.",
"   </p>",
"   <p>",
"    Of note, the ADA LDL-C goal for children with diabetes is lower than the goal of &lt;130",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.36",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    recommended for the general pediatric population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;If goals for lipid levels are not met, non-pharmacologic therapy (diet, exercise, improved glycemic control, and weight reduction) is recommended as the first intervention. The American Heart Association (AHA) step 2 diet is suggested as an initial lifestyle modification [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34249/abstract/13,19\">",
"     13,19",
"    </a>",
"    ]. This diet prescribes a daily intake of dietary cholesterol &lt;200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and saturated fat &lt;7 percent of the total calories.",
"   </p>",
"   <p>",
"    Follow-up fasting lipid profiles should be obtained at three months and again at six months after the start of non-pharmacologic therapy. If treatment goals are achieved, non-pharmacologic therapy should be maintained and the lipid profile repeated annually.",
"   </p>",
"   <p>",
"    After six months of non-pharmacologic therapy, drug therapy is recommended in children older than 10 years of age:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If LDL-C remains above 160",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (4.14",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      If LDL-C is between 130",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.36",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      and 159",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (4.14",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      and they have another cardiovascular risk factor (eg, family history, hypertension, or smoking)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with LDL-C between 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.59",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and 130",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.36",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    management focuses on maximizing nonpharmacologic intervention.",
"   </p>",
"   <p>",
"    The goal of pharmacologic therapy is an LDL &lt;100",
"    <span class=\"nowrap\">",
"     mg/dl.",
"    </span>",
"    HMG-CoA reductase inhibitors (statins) are generally recommended as first-line therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34249/abstract/13,18\">",
"     13,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Statins &mdash; Clinical trials have demonstrated the effectiveness and safety of statins in treating adolescents with familial hypercholesterolemia [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34249/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. Initially, the lowest recommended dose is started and increased depending on the LDL-C measurements and side effects. Side effects include hepatic and renal dysfunction and muscle injury. Statins are teratogenic and should not be used in females at risk for pregnancy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32314?source=see_link&amp;anchor=H11#H11\">",
"       \"Statins: Actions, side effects, and administration\", section on 'Side effects'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Resins (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/27/1462?source=see_link\">",
"       cholestyramine",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/38/36453?source=see_link\">",
"       colestipol",
"      </a>",
"      hydrochloride) &mdash; These agents, which sequester bile, had been recommended as the initial pharmacologic agent. However, compliance with this class of medication is poor due to dosing frequency and adverse gastrointestinal effects.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ADA recommends that elevated TG &gt;150",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.69",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    be managed by maximizing glycemic control and weight reduction. In rare cases with TG &gt;1000",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (11.3",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    fibric acid medication is suggested because of an increased risk of pancreatitis with severe hypertriglyceridemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/39/7800?source=see_link\">",
"     \"Lipid lowering with fibric acid derivatives\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Nonalcoholic fatty liver disease (NAFLD)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity and type 2 diabetes are associated with a clinical spectrum of liver abnormalities collectively known as nonalcoholic fatty liver disease (NAFLD). NAFLD is the most common cause of liver disease in children, and is particularly common in children with type 2 diabetes. Serum alanine aminotransferase is elevated more than twice normal in about 20 percent of youth with type 2 diabetes, and in most cases this is attributable to NAFLD [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34249/abstract/1\">",
"     1",
"    </a>",
"    ]. Abnormalities include hepatic steatosis (increased liver fat without inflammation) and nonalcoholic steatohepatitis (NASH, increased liver fat with inflammation). NASH may lead to fibrosis, cirrhosis, and liver failure if untreated. However, for patients with simple steatosis or mild steatohepatitis, the likelihood and risk factors for progression to more severe liver disease are unknown.",
"   </p>",
"   <p>",
"    The clinical manifestations, prevalence, and pathogenesis of NAFLD are discussed separately in greater detail. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37674?source=see_link&amp;anchor=H15#H15\">",
"     \"Comorbidities and complications of obesity in children and adolescents\", section on 'Nonalcoholic fatty liver disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/44/16073?source=see_link\">",
"     \"Pathogenesis of nonalcoholic fatty liver disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38105?source=see_link&amp;anchor=H6#H6\">",
"     \"Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Routine care of children and adolescents with type 2 diabetes should include abdominal examination for hepatomegaly and monitoring serum aminotransferase concentrations to screen for liver disease. If abnormalities are detected, other causes of hepatic dysfunction should be excluded. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38105?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If no other cause is identified, a trial of gradual weight reduction is recommended. Consultation with a gastroenterologist is recommended if the hepatic abnormalities persist after weight reduction or if advanced liver disease is present. In those patients who do not respond to weight reduction, a liver biopsy can be obtained to confirm the diagnosis.",
"   </p>",
"   <p>",
"    There have been no large trials of therapy for NAFLD in children with type 2 diabetes. Currently, treatment is based upon gradual weight reduction and improving insulin resistance while maintaining excellent glycemic control. Excessively rapid weight loss can predispose to hepatic fibrosis. Alcohol consumption should also be avoided.",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/59/13238?source=see_link\">",
"     metformin",
"    </a>",
"    is contraindicated in patients with liver disease because of an increased risk of developing lactic acidosis, there has been no reported toxicity in several small observational studies of metformin in patients with NASH. Because of the small numbers of treated patients and the quality of the reports, no specific recommendations can be made for the use of metformin in the treatment of NAFLD or NASH in children. However, because metformin is often the agent of first-choice to treat type 2 diabetes, it is reasonable to proceed with metformin therapy as long as serum aminotransferase levels are closely monitored and the drug is discontinued if there is significant elevation of serum aminotransferase. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23882?source=see_link&amp;anchor=H54339426#H54339426\">",
"     \"Natural history and management of nonalcoholic fatty liver disease in adults\", section on 'Metformin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     HYPERGLYCEMIA AND DKA",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with diabetes, hyperglycemia occurs when insulin levels are inadequate to maintain normal blood glucose concentrations. If hyperglycemia is not identified and treated, either diabetic ketoacidosis (DKA) or a hyperosmolar hyperglycemic state (HHS) may develop. DKA and HHS differ in magnitude of dehydration and degree of ketosis (and acidosis).",
"   </p>",
"   <p>",
"    Although DKA is more common in patients with type 1 diabetes, it also can occur in patients with type 2 disease [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34249/abstract/9,22\">",
"     9,22",
"    </a>",
"    ]. About 10 to 25 percent of adolescents with type 2 diabetes present with ketoacidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34249/abstract/1\">",
"     1",
"    </a>",
"    ]. Differentiating between the two types of diabetes in children and adolescents is important for management decisions and is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/25/4506?source=see_link\">",
"     \"Epidemiology, presentation, and diagnosis of type 2 diabetes mellitus in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HHS is uncommon in adolescents, with 65 case reports as of 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34249/abstract/23\">",
"     23",
"    </a>",
"    ]. Recognition of HHS is important because it is characterized by more severe dehydration than DKA, with high morbidity and mortality if not adequately treated. Management of HHS is discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/48/15114?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\", section on 'Fluid replacement'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Successful treatment of DKA and HHS requires correction of dehydration, hyperglycemia, and electrolyte imbalances; identification of comorbid precipitating events; and frequent patient monitoring. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/25/4506?source=see_link&amp;anchor=H12#H12\">",
"     \"Epidemiology, presentation, and diagnosis of type 2 diabetes mellitus in children and adolescents\", section on 'Diabetic ketoacidosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41480?source=see_link\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7626?source=see_link\">",
"     \"Treatment and complications of diabetic ketoacidosis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     VASCULAR COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adult patients with poorly controlled type 2 diabetes have an increased risk of vascular disease. In a randomized clinical trial (United Kingdom Prospective Diabetes Study), adult patients treated with intensive therapy had lower A1C levels and a decreased risk of microvascular disease (nephropathy and retinopathy), (",
"    <a class=\"graphic graphic_figure graphicRef52273 \" href=\"UTD.htm?36/32/37389\">",
"     figure 1",
"    </a>",
"    ). In addition, observational studies and secondary analyses of clinical trials suggest an increased risk of macrovascular disease (coronary artery, peripheral, and cerebral vascular disease) with poor glycemic control. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=see_link\">",
"     \"Glycemic control and vascular complications in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar data are lacking in children and adolescents with type 2 diabetes. No epidemiologic data, outside of populations with a very high prevalence of diabetes, or clinical trial data, as noted above, are available to determine whether and to what extent children with type 2 diabetes develop complications over time. However, there is increasing evidence of progressive retinopathy, nephropathy, and changes indicative of premature aging of the cardiovascular system [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34249/abstract/1\">",
"     1",
"    </a>",
"    ]. Because hyperglycemia increases the risk of vascular sequelae in childhood type 1 diabetes and in adult type 2 disease, it is generally accepted that children and adolescents with type 2 diabetes are also at increased risk for vascular complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism by which poor glycemic control predisposes to vascular disease is incompletely understood. The pathologic processes that cause vascular disease in either type 2 or type 1 diabetes are thought to be the same and are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11817?source=see_link\">",
"     \"Glycemic control and vascular complications in type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In summary, pathogenesis of diabetic vascular complications include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Accumulation of advanced glycosylation end products in plasma that contribute to microvascular disease",
"     </li>",
"     <li>",
"      Accumulation of cellular",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/33/32275?source=see_link\">",
"       sorbitol",
"      </a>",
"      , which interferes with cellular metabolism because of a rise in cell osmolality and a decrease in intracellular myoinositol",
"     </li>",
"     <li>",
"      End-organ response with activation of cytokines, profibrotic elements, vascular growth factors, inflammation, and protein kinase C. Specific end organ responses include mesangial matrix expansion and glomerular hypertension in the kidney, and impairment of retinal blood flow and microthrombus formation in the eye. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/63/30714?source=see_link&amp;anchor=H8#H8\">",
"       \"Overview of diabetic nephropathy\", section on 'Pathogenesis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30422?source=see_link\">",
"       \"Pathogenesis of diabetic retinopathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/60/41928?source=see_link\">",
"       \"Pathogenesis and prevention of diabetic polyneuropathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Microvascular complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microvascular complications of diabetes include retinopathy, nephropathy, and neuropathy (peripheral and autonomic). Studies of these complications in type 2 diabetes have been performed mostly in adult patients.",
"   </p>",
"   <p>",
"    In one longitudinal population-based study, 20 percent of 178 Pima Indians diagnosed with type 2 diabetes before 20 years of age developed nephropathy over 25 years [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34249/abstract/24\">",
"     24",
"    </a>",
"    ]. This incidence was not different from those with adult-onset type 2 diabetes. In a subsequent report, patients with diabetes diagnosed before 20 years of age compared to those diagnosed after 20 years of age had a higher incidence of endstage renal disease (25 versus 4.6 per 1000 person-years) and a higher mortality rate between the ages of 25 and 55 years (15.4 versus 7.3 deaths per 1000 person-years) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34249/abstract/25\">",
"     25",
"    </a>",
"    ]. In a subset analysis that adjusted for sex, mean arterial pressure, body mass index, plasma blood glucose concentration, smoking, and hypoglycemic and antihypertensive medication, results appeared to be mainly due to the longer duration of diabetes in those diagnosed before 20 years of age.",
"   </p>",
"   <p>",
"    In contrast, the risk of developing retinopathy was lower in patients diagnosed before 20 years of age compared to those diagnosed later in life. By an average age of 30 years, 57 percent of patients developed nephropathy and 45 percent developed retinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34249/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In adults, randomized clinical trials show that improved glycemic control and control of hypertension delay the progression of microvascular disease. Similar data are lacking in children and adolescents.",
"   </p>",
"   <p>",
"    Based upon the above observations, the major goal of preventing microvascular sequelae in pediatric type 2 diabetes is to identify patients with early microvascular disease and initiate treatment that reverses the process, or delays",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prevents further progression of disease.",
"   </p>",
"   <p>",
"    In our practice, we screen all patients with type 2 diabetes for microvascular complications to identify those with microvascular disease and initiate treatment when complications are discovered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Retinopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetes-associated retinopathy is a progressive disorder that affects the microvasculature of the retina. Most patients develop the mildest form of retinopathy (non-proliferative retinopathy). This can progress to an intermediate stage (pre-proliferative) and in some patients progresses to proliferative retinopathy, which carries a high risk of visual loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/11/36023?source=see_link\">",
"     \"Classification and clinical features of diabetic retinopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Screening allows detection of retinopathy in the non-proliferative stage. At this stage, improving glycemic control can reverse nonproliferative changes and prevent progression. In more severe cases, laser therapy can prevent further progression of disease and visual loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/38/32362?source=see_link\">",
"     \"Prevention and treatment of diabetic retinopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two population studies report that four percent of youth with type 2 diabetes had retinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34249/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. The prevalence was lower than in patients with type 1 diabetes, perhaps because of shorter disease duration. In the absence of adequate data in children with type 2 diabetes, screening for and treatment of diabetic retinopathy are modeled on the strategies used in adults with type 2 diabetes.",
"   </p>",
"   <p>",
"    In our practice, all children and adolescents with type 2 diabetes are screened by direct ophthalmoscopy of dilated fundi by well-trained personnel. The first examination is at the time of diagnosis. Timing of subsequent examinations is determined by the presence and severity of retinopathy at the initial examination. If the examination is normal, screening is performed annually. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42501?source=see_link\">",
"     \"Screening for diabetic retinopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Nephropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetes-associated nephropathy is a progressive disorder of the microvasculature of the kidney. Microalbuminuria, defined as persistent albumin excretion between 30 and 300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (20 to 200",
"    <span class=\"nowrap\">",
"     mcg/min),",
"    </span>",
"    is the earliest stage of nephropathy. In youth with diabetes, microalbuminuria predicts progression of nephropathy to overt proteinuria [albumin excretion &gt;300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (200",
"    <span class=\"nowrap\">",
"     mcg/min)],",
"    </span>",
"    which can be accompanied by systemic hypertension and impaired glomerular filtration [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34249/abstract/28\">",
"     28",
"    </a>",
"    ]. Some patients with overt proteinuria will progress to end-stage renal disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42777?source=see_link\">",
"     \"Microalbuminuria in type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/33/39449?source=see_link\">",
"     \"Microalbuminuria in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/63/30714?source=see_link\">",
"     \"Overview of diabetic nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Microalbuminuria is common among adolescents with type 2 diabetes, occurring in 14 to 22 percent at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34249/abstract/1\">",
"     1",
"    </a>",
"    ]. The finding of microalbuminuria increased to about 60 percent during the next ten years of follow up; the incidence in adolescents with type 2 diabetes is much higher than that seen in the first ten years of type 1 diabetes.",
"   </p>",
"   <p>",
"    In the absence of adequate data in children with type 2 diabetes outside highly vulnerable populations (eg, Pima Indians), screening for and treatment of diabetic nephropathy are modeled on the strategies used in adults with type 2 diabetes.",
"   </p>",
"   <p>",
"    In our practice, all patients with type 2 diabetes are screened annually for microalbuminuria by measuring the microalbumin-to-creatinine ratio in a random urine sample. This is consistent with ADA guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34249/abstract/13\">",
"     13",
"    </a>",
"    ]. Upright posture or exercise can yield false-positive results. Therefore, a first morning void should be obtained for testing. Patients with positive results should have repeat screening on at least two occasions during the subsequent three to six months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/33/39449?source=see_link&amp;anchor=H2#H2\">",
"     \"Microalbuminuria in type 2 diabetes mellitus\", section on 'Detection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment for microalbuminuria includes optimization of glycemic control and the use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers. There is some evidence that these interventions can reverse microalbuminuria and delay or prevent the progression of renal disease. Patients with persistent microalbuminuria (measured on three separate days) should usually be treated with an ACE inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34249/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42777?source=see_link\">",
"     \"Microalbuminuria in type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/33/39449?source=see_link\">",
"     \"Microalbuminuria in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40714?source=see_link\">",
"     \"Treatment of diabetic nephropathy\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetes-associated neuropathy is a progressive disorder that affects both the autonomic (eg, heart rate, postural blood pressure control, pupillary adaption to darkness, and vibratory threshold) and peripheral (eg, nerve conduction and sensory perception) nervous systems. Ten to 18 percent of adult patients have evidence of nerve damage at the time that their diabetes is diagnosed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18551?source=see_link\">",
"     \"Clinical manifestations and diagnosis of diabetic polyneuropathy\"",
"    </a>",
"    .) The prevalence and risk of progression has not been systematically studied among adolescents with type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34249/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar to other microvascular complications, the risk of diabetic neuropathy in adults has been shown to increase with poor glycemic control and duration of disease. Improved glycemic control improves nerve function in adults with diabetes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/43/12986?source=see_link\">",
"     \"Treatment of diabetic neuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon the strategies used in adults with type 2 diabetes, in our practice, we screen patients with type 2 diabetes beginning at puberty by performing a 10-g monofilament exam at specific sites on the foot to detect loss of sensation (",
"    <a class=\"graphic graphic_figure graphicRef52481 \" href=\"UTD.htm?33/55/34687\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34249/abstract/29\">",
"     29",
"    </a>",
"    ]. If the screening examination is abnormal, we recommend referral to a neurologist for further evaluation. If the screening examination is normal, it is repeated yearly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18551?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical manifestations and diagnosis of diabetic polyneuropathy\", section on 'Monitoring'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11464?source=see_link&amp;anchor=H9#H9\">",
"     \"Evaluation of the diabetic foot\", section on 'Pressure sensation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Macrovascular complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In adults with type 2 diabetes, observational studies and secondary analyses of clinical trials showed that poor glycemic control increases the risk of macrovascular disease (coronary artery, peripheral, and cerebral vascular disease). In adolescents with type 2 diabetes, a variety of cardiovascular abnormalities have been documented. These include increased left ventricular wall thickness (22 to 47 percent of patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34249/abstract/1\">",
"     1",
"    </a>",
"    ] and increased arterial stiffness as compared to obese and healthy-weight controls, indicating premature aging of the cardiovascular system [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34249/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In adult clinical trials of type 2 diabetes, however, improving glycemic control has not been shown to reduce the risk of macrovascular sequelae. Subgroup analyses of the United Kingdom Prospective Diabetes Study (UKPDS) suggested that the use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/59/13238?source=see_link\">",
"     metformin",
"    </a>",
"    decreased macrovascular risk when compared to insulin or sulfonylurea therapy, although this finding has been contested. Despite the controversy over the results of the UKPDS study, metformin is often the agent chosen first to treat type 2 diabetes when there are no contraindications for its use. Metformin is the preferred drug because of its efficacy in lowering A1C and minimal risk of hypoglycemic episodes and weight gain, as well as its low expense and ease of use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=see_link&amp;anchor=H24#H24\">",
"     \"Glycemic control and vascular complications in type 2 diabetes mellitus\", section on 'Macrovascular complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypertension and dyslipidemia contribute to the increased risk of macrovascular sequelae in adults. In the United States, almost all children and adolescents with type 2 diabetes have findings of one these cardiovascular risk factors and 20 percent had both [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34249/abstract/31\">",
"     31",
"    </a>",
"    ]. In adults with type 2 diabetes, clinical trials have shown that aggressive treatment and control of hypertension and hyperlipidemia reduce the risk of macrovascular disease. Although data are lacking in pediatric patients, similar management is recommended. In addition, because smoking is another major risk factor for macrovascular disease, smoking cessation should be strongly encouraged in patients with type 2 diabetes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H371142\">",
"    <span class=\"h1\">",
"     PSYCHOLOGICAL COMPLICATIONS",
"    </span>",
"   </p>",
"   <p>",
"    Youth with type 2 diabetes appear to have an increased risk for depression and binge eating. In the baseline data from a multicenter study, 26 percent of participants with available data (n=678) endorsed clinical or subclinical symptoms of binge eating on a standardized eating disorder questionnaire [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34249/abstract/32\">",
"     32",
"    </a>",
"    ]. In addition, 15 percent out of 689 participants reported clinically significant depressive symptoms. Because both binge eating and depression interfere with weight loss efforts in youth with obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34249/abstract/33\">",
"     33",
"    </a>",
"    ], identifying and treating these issues may be an important step in management of type 2 diabetes. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Associated comorbidities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children and adolescents with type 2 diabetes are at increased risk for the following associated comorbidities: nonalcoholic fatty liver disease, hypertension, and dyslipidemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary (essential hypertension) is reported in 17 to 32 percent of adolescent patients with type 2 diabetes at presentation. Both type 2 diabetes and hypertension increase the risk for vascular disease. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Hypertension'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that blood pressure be measured at all routine health care visits for pediatric patients with type 2 diabetes (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Prehypertension is defined as systolic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diastolic BP &ge;90th percentile but &lt;95th percentile. Hypertension is defined as systolic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diastolic BP &ge;95th percentile, measured on three or more separate occasions. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Comorbidities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If prehypertension is present, we recommend that non-pharmacologic therapy (diet, salt restriction, exercise, and weight reduction) is used initially (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). If the prehypertension is not responsive to these measures, pharmacologic therapy should be initiated. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Comorbidities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If hypertension is diagnosed in a patient with diabetes, we recommend initiating pharmacologic therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The preferred antihypertensive agent is an angiotensin-converting enzyme (ACE) inhibitor. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Comorbidities'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27626?source=see_link\">",
"       \"Treatment of hypertension in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Dyslipidemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with type 2 diabetes are at increased risk for dyslipidemia, a major risk factor for cardiovascular disease. In our practice, we use the American Diabetes Association guidelines for screening and treatment of dyslipidemia in pediatric patients with type 2 diabetes (",
"    <a class=\"graphic graphic_table graphicRef75008 \" href=\"UTD.htm?34/21/35164\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Dyslipidemia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In all pediatric patients with type 2 diabetes, we suggest that lipid profiles are obtained at diagnosis (after blood glucose control has been well established), and repeated every two years if the prior screen is normal (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest that non-pharmacologic therapy (diet, exercise, improved glycemic control, and weight reduction) is initially used to manage dyslipidemia (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We suggest that pharmacologic therapy is reserved for children over 10 years of age, who fail non-pharmacologic therapy, have elevated low-density lipoprotein cholesterol (&gt;160",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      4.14",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      other cardiovascular risk factors (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Our preferred pharmacologic agent is a statin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Nonalcoholic fatty liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonalcoholic fatty liver disease (NAFLD) is common among children with type 2 diabetes, and is usually the cause of elevated aminotransferase levels. The only established treatment is weight reduction.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/59/13238?source=see_link\">",
"     Metformin",
"    </a>",
"    and other anti-hyperglycemia drugs used for treatment of diabetes, also may cause aminotransferase elevations, but it is reasonable to proceed with metformin therapy as long as serum aminotransferase levels are closely monitored. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Nonalcoholic fatty liver disease (NAFLD)'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Hyperglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both diabetic ketoacidosis and hyperosmolar hyperglycemia can occur in patients with type 2 diabetes. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Hyperglycemia and DKA'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Vascular complications",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In both adults and children, the risk of microvascular complications increases with poor glycemic control and duration of type 2 diabetes. Early detection allows for intervention that may reverse vascular disease or delay further progression. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Vascular complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For pediatric patients with type 2 diabetes, we recommend annual ophthalmologic evaluation to screen for diabetic retinopathy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Retinopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend annual screening for microalbuminuria (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Nephropathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest annual screening for diabetic neuropathy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Annual screening typically is performed with a careful examination of the sensory nerves. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Neuropathy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34249/abstract/1\">",
"      Pinhas-Hamiel O, Zeitler P. Acute and chronic complications of type 2 diabetes mellitus in children and adolescents. Lancet 2007; 369:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34249/abstract/2\">",
"      Dean H. NIDDM-Y in First Nation children in Canada. Clin Pediatr (Phila) 1998; 37:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34249/abstract/3\">",
"      Kitabchi AE, Umpierrez GE, Murphy MB, et al. Management of hyperglycemic crises in patients with diabetes. Diabetes Care 2001; 24:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34249/abstract/4\">",
"      Zeitler P, Solberg P, Pharmacy and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. Food and levothyroxine administration in infants and children. J Pediatr 2010; 157:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34249/abstract/5\">",
"      Sorof J, Daniels S. Obesity hypertension in children: a problem of epidemic proportions. Hypertension 2002; 40:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34249/abstract/6\">",
"      Berenson GS, Srinivasan SR, Bao W, et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med 1998; 338:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34249/abstract/7\">",
"      McGill HC Jr, McMahan CA, Zieske AW, et al. Effects of nonlipid risk factors on atherosclerosis in youth with a favorable lipoprotein profile. Circulation 2001; 103:1546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34249/abstract/8\">",
"      Pinhas-Hamiel O, Dolan LM, Daniels SR, et al. Increased incidence of non-insulin-dependent diabetes mellitus among adolescents. J Pediatr 1996; 128:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34249/abstract/9\">",
"      Scott CR, Smith JM, Cradock MM, Pihoker C. Characteristics of youth-onset noninsulin-dependent diabetes mellitus and insulin-dependent diabetes mellitus at diagnosis. Pediatrics 1997; 100:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34249/abstract/10\">",
"      Rodriguez BL, Dabelea D, Liese AD, et al. Prevalence and correlates of elevated blood pressure in youth with diabetes mellitus: the SEARCH for diabetes in youth study. J Pediatr 2010; 157:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34249/abstract/11\">",
"      Alberti G, Zimmet P, Shaw J, et al. Type 2 diabetes in the young: the evolving epidemic: the international diabetes federation consensus workshop. Diabetes Care 2004; 27:1798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34249/abstract/12\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004; 114:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34249/abstract/13\">",
"      American Diabetes Association. Standards of medical care in diabetes--2011. Diabetes Care 2011; 34 Suppl 1:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34249/abstract/14\">",
"      Miller K. Pharmacological management of hypertension in paediatric patients. A comprehensive review of the efficacy, safety and dosage guidelines of the available agents. Drugs 1994; 48:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34249/abstract/15\">",
"      Type 2 diabetes in children and adolescents. American Diabetes Association. Diabetes Care 2000; 23:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34249/abstract/16\">",
"      Kershnar AK, Daniels SR, Imperatore G, et al. Lipid abnormalities are prevalent in youth with type 1 and type 2 diabetes: the SEARCH for Diabetes in Youth Study. J Pediatr 2006; 149:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34249/abstract/17\">",
"      American Diabetes Association. Management of dyslipidemia in children and adolescents with diabetes. Diabetes Care 2003; 26:2194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34249/abstract/18\">",
"      McCrindle BW, Urbina EM, Dennison BA, et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation 2007; 115:1948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34249/abstract/19\">",
"      Kavey RE, Daniels SR, Lauer RM, et al. American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. Circulation 2003; 107:1562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34249/abstract/20\">",
"      de Jongh S, Ose L, Szamosi T, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin. Circulation 2002; 106:2231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34249/abstract/21\">",
"      Stein EA, Illingworth DR, Kwiterovich PO Jr, et al. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. JAMA 1999; 281:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34249/abstract/22\">",
"      Sapru A, Gitelman SE, Bhatia S, et al. Prevalence and characteristics of type 2 diabetes mellitus in 9-18 year-old children with diabetic ketoacidosis. J Pediatr Endocrinol Metab 2005; 18:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34249/abstract/23\">",
"      Rosenbloom AL. Hyperglycemic hyperosmolar state: an emerging pediatric problem. J Pediatr 2010; 156:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34249/abstract/24\">",
"      Krakoff J, Lindsay RS, Looker HC, et al. Incidence of retinopathy and nephropathy in youth-onset compared with adult-onset type 2 diabetes. Diabetes Care 2003; 26:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34249/abstract/25\">",
"      Pavkov ME, Bennett PH, Knowler WC, et al. Effect of youth-onset type 2 diabetes mellitus on incidence of end-stage renal disease and mortality in young and middle-aged Pima Indians. JAMA 2006; 296:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34249/abstract/26\">",
"      Scott A, Toomath R, Bouchier D, et al. First national audit of the outcomes of care in young people with diabetes in New Zealand: high prevalence of nephropathy in Maori and Pacific Islanders. N Z Med J 2006; 119:U2015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34249/abstract/27\">",
"      Eppens MC, Craig ME, Cusumano J, et al. Prevalence of diabetes complications in adolescents with type 2 compared with type 1 diabetes. Diabetes Care 2006; 29:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34249/abstract/28\">",
"      Kim NH, Pavkov ME, Knowler WC, et al. Predictive value of albuminuria in American Indian youth with or without type 2 diabetes. Pediatrics 2010; 125:e844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34249/abstract/29\">",
"      Boulton AJ, Vinik AI, Arezzo JC, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005; 28:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34249/abstract/30\">",
"      Gungor N, Thompson T, Sutton-Tyrrell K, et al. Early signs of cardiovascular disease in youth with obesity and type 2 diabetes. Diabetes Care 2005; 28:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34249/abstract/31\">",
"      Rodriguez BL, Fujimoto WY, Mayer-Davis EJ, et al. Prevalence of cardiovascular disease risk factors in U.S. children and adolescents with diabetes: the SEARCH for diabetes in youth study. Diabetes Care 2006; 29:1891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34249/abstract/32\">",
"      TODAY Study Group, Wilfley D, Berkowitz R, et al. Binge eating, mood, and quality of life in youth with type 2 diabetes: baseline data from the today study. Diabetes Care 2011; 34:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34249/abstract/33\">",
"      Wildes JE, Marcus MD, Kalarchian MA, et al. Self-reported binge eating in severe pediatric obesity: impact on weight change in a randomized controlled trial of family-based treatment. Int J Obes (Lond) 2010; 34:1143.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5826 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-88.81.100.162-4217E6CC24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_28_34249=[""].join("\n");
var outline_f33_28_34249=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      COMORBIDITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Nonalcoholic fatty liver disease (NAFLD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      HYPERGLYCEMIA AND DKA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      VASCULAR COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Microvascular complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Retinopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Nephropathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Neuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Macrovascular complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H371142\">",
"      PSYCHOLOGICAL COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Associated comorbidities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Nonalcoholic fatty liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Hyperglycemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Vascular complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5826\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5826|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/32/37389\" title=\"figure 1\">",
"      Microvascular endpoint and control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/55/34687\" title=\"figure 2\">",
"      Test sites in diabetic foot",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5826|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/21/35164\" title=\"table 1\">",
"      ADA lipid guideline",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=related_link\" title=\"calculator 1\">",
"      Calculator: Blood pressure percentiles for boys (2 to 17 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=related_link\" title=\"calculator 2\">",
"      Calculator: Blood pressure percentiles for girls (2 to 17 years)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37685?source=related_link\">",
"      Cardiovascular risks of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/11/36023?source=related_link\">",
"      Classification and clinical features of diabetic retinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41480?source=related_link\">",
"      Clinical features and diagnosis of diabetic ketoacidosis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18551?source=related_link\">",
"      Clinical manifestations and diagnosis of diabetic polyneuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37674?source=related_link\">",
"      Comorbidities and complications of obesity in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=related_link\">",
"      Definition and diagnosis of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38105?source=related_link\">",
"      Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/25/4506?source=related_link\">",
"      Epidemiology, presentation, and diagnosis of type 2 diabetes mellitus in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11464?source=related_link\">",
"      Evaluation of the diabetic foot",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11817?source=related_link\">",
"      Glycemic control and vascular complications in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=related_link\">",
"      Glycemic control and vascular complications in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/39/7800?source=related_link\">",
"      Lipid lowering with fibric acid derivatives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18138?source=related_link\">",
"      Lipoprotein classification; metabolism; and role in atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36329?source=related_link\">",
"      Management of type 2 diabetes mellitus in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42777?source=related_link\">",
"      Microalbuminuria in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/33/39449?source=related_link\">",
"      Microalbuminuria in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23882?source=related_link\">",
"      Natural history and management of nonalcoholic fatty liver disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/63/30714?source=related_link\">",
"      Overview of diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=related_link\">",
"      Overview of medical care in adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/49/23320?source=related_link\">",
"      Overview of the management of the child at risk for atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/60/41928?source=related_link\">",
"      Pathogenesis and prevention of diabetic polyneuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30422?source=related_link\">",
"      Pathogenesis of diabetic retinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/44/16073?source=related_link\">",
"      Pathogenesis of nonalcoholic fatty liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27226?source=related_link\">",
"      Prevalence of and risk factors for coronary heart disease in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/38/32362?source=related_link\">",
"      Prevention and treatment of diabetic retinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25224?source=related_link\">",
"      Renin-angiotensin system inhibition in the treatment of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42501?source=related_link\">",
"      Screening for diabetic retinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26938?source=related_link\">",
"      Secondary factors and progression of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32314?source=related_link\">",
"      Statins: Actions, side effects, and administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7626?source=related_link\">",
"      Treatment and complications of diabetic ketoacidosis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/48/15114?source=related_link\">",
"      Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40714?source=related_link\">",
"      Treatment of diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/43/12986?source=related_link\">",
"      Treatment of diabetic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27626?source=related_link\">",
"      Treatment of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=related_link\">",
"      Treatment of hypertension in patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_28_34250="Renal function and nonrenal solid organ transplantation";
var content_f33_28_34250=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Renal function and nonrenal solid organ transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?33/28/34250/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/28/34250/contributors\">",
"     Roy D Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?33/28/34250/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/28/34250/contributors\">",
"     Barbara Murphy, MB, BAO, BCh, FRCPI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?33/28/34250/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/28/34250/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?33/28/34250/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As outcomes following nonrenal solid organ transplantation (SOT) have improved, chronic kidney disease (CKD) has become an increasingly prevalent complication in this population [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. CKD occurs despite advancements in immunosuppression and peri-operative management, as well as attention to cardiovascular risk factors and infectious complications [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/4\">",
"     4",
"    </a>",
"    ]. The development of CKD is associated with enhanced morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues relating to kidney function following nonrenal solid organ transplants, including the evaluation of kidney function prior to nonrenal organ transplantation, are presented in this topic review. A review of calcineurin inhibitor nephrotoxicity is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=see_link\">",
"     \"Cyclosporine and tacrolimus nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREOPERATIVE EVALUATION OF KIDNEY FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a general rule, the preoperative evaluation of kidney function in candidates for nonrenal SOT should focus upon establishing the likelihood of being left with adequate kidney function post-transplant and the chance of progression to end-stage renal disease (ESRD). Patients who are likely to have stage 4 or stage 5 CKD after the early post-transplant period",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    those with established primary renal disease that is likely to progress at a rapid pace (thereby requiring chronic kidney replacement therapy shortly after transplant) should be listed for combined organ transplant. It should be noted that, in an era of ever-increasing organ shortage, in which waiting times for kidneys are lengthening, combined nonrenal and renal organ transplantation should be considered judiciously.",
"   </p>",
"   <p>",
"    The vast majority of patients with normal or mild impairment in kidney function should receive a nonrenal SOT alone. However, normal or near normal serum creatinine levels do not necessarily reflect normal kidney function, especially in states of heart failure or liver disease, where affected patients frequently have poor nutritional status, low muscle mass, weight loss, and edema.",
"   </p>",
"   <p>",
"    The evaluation of renal function in individuals who are to undergo a nonrenal SOT begins with a complete history and physical examination, an accurate measure of renal function, a urinalysis, and kidney imaging study [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/6\">",
"     6",
"    </a>",
"    ]. Based on findings from this initial evaluation, renal biopsy, and other studies may be required.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      History and physical examination &mdash; The level of kidney function and duration of kidney disease prior to organ transplantation is an important risk factor for post-transplant CKD. It is essential to determine what the baseline serum creatinine concentration level was six months to a year prior to the current evaluation as well as the presence or absence of proteinuria at that time. Acute kidney injury (AKI) may be primarily due to deterioration in underlying heart, lung, or liver disease and is frequently compromised by poor effective circulating volume (eg, low cardiac output in advanced heart failure or hepatorenal syndrome in liver candidates). In these situations, kidney function may improve after replacement of the nonrenal failing organ.",
"     </li>",
"     <li>",
"      Measure of renal function &mdash; The serum creatinine level may not accurately reflect renal function especially in patients with advanced liver disease or advanced heart failure. Since the glomerular filtration rate (GFR) is one of the main predictors of renal function following nonrenal SOT, failure to accurately estimate GFR by the use of serum creatinine alone may result in unrealistic expectations of what kidney function will be after the transplant. Patients with a serum creatinine above 1",
"      <span class=\"nowrap\">",
"       mg/dl",
"      </span>",
"      warrant further evaluation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=see_link\">",
"       \"Assessment of kidney function\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      As an example, in a large cohort study, I(125) iothalamate GFR measurements were performed in 1447 liver transplant candidates before transplantation, and comparison of this \"gold standard\" measurement was made to estimate the GFR based upon the serum creatinine concentration using the MDRD, Cockcroft-Gault and Nankivell formulas [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/7\">",
"       7",
"      </a>",
"      ]. The mean pre-transplant creatinine was 1.15",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      and the mean iothalamate GFR was 91",
"      <span class=\"nowrap\">",
"       mL/min.",
"      </span>",
"      Of all formulas, the six-variable MDRD fared best, although it lacked precision in that only 66 percent of estimates were within 30 percent of the measured GFR. When patients were divided into two groups according to GFR more or less than 40",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      all the formulas overestimated GFR in the patients with poor function (GFR &lt;40",
"      <span class=\"nowrap\">",
"       mL/min),",
"      </span>",
"      while the formulas underestimated GFR in patients with better function (GFR &gt;40",
"      <span class=\"nowrap\">",
"       mL/min).",
"      </span>",
"      Despite this, the use of the MDRD or the Cockcroft-Gault formulas to estimate GFR may provide a better assessment of kidney function than the serum creatinine concentration alone [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=see_link\">",
"       \"Assessment of kidney function\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A 24-hour collection for the creatinine clearance is also likely to overestimate GFR in patients with renal disease as the contribution of tubular secretion of creatinine to total clearance is increased in this subset of patients. This was best shown in a systematic review and meta-analysis of seven studies of 193 patients with liver cirrhosis in which the measured creatinine clearance was compared with true GFR (as assessed by inulin clearance) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/9\">",
"     9",
"    </a>",
"    ]. Overall, the measured creatinine clearance overestimated inulin clearance by a mean of 13",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2, with the overestimation being highest in those with the lowest true GFRs. Among those with inulin clearance of less than 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 (stage 4 and 5 CKD), the measured creatinine clearance correctly classified 64 percent of patients, incorrectly classified 23 percent of patients as having GFRs between 30 to 59",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2, and incorrectly classified 14 percent as having GFRs &ge;60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2. Another method to help estimate the GFR in these patients is to average both the creatinine and urea clearances.",
"   </p>",
"   <p>",
"    More accurate methods of estimating GFR rely on the renal clearance of various radionuclide markers, including 99mTc-labeled DTPA, 51Cr-labeled EDTA, and 125I-labeled iothalamate [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/10\">",
"     10",
"    </a>",
"    ]. However, these methods are of limited availability, usually costly, and require radiation exposure. There is also emerging evidence that cystatin C levels (which are also of limited availability) are a more sensitive indicator of kidney function than the serum creatinine concentration in patients with liver or heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. However, using 51Cr-labeled EDTA-measured GFR as the reference, a study that included 254 blood samples from 65 cirrhotic patients demonstrated that the estimated GFR using cystatin C-based formulas was no better than creatinine-based equations [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=see_link\">",
"     \"Assessment of kidney function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urinalysis &mdash; A urinalysis should be performed to assess the presence of microscopic hematuria and proteinuria. A spot urine sample should also be analyzed for protein and creatinine. The presence of significant proteinuria, as determined by a ratio of greater than 500 mg of",
"      <span class=\"nowrap\">",
"       protein/gram",
"      </span>",
"      of creatinine, should also prompt a full evaluation to elucidate the nature and the prognosis of the kidney disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=see_link\">",
"       \"Urinalysis in the diagnosis of kidney disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/32/521?source=see_link\">",
"       \"Epidemiology of chronic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      24 hour urine collection &mdash; A 24-hour urine collection for protein and creatinine may be undertaken when a better characterization of kidney function is needed [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with abnormal kidney function, the following additional studies should be performed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anatomic evaluation &mdash; An imaging study (CT scan, MRI, or ultrasound) of the kidneys should be performed to exclude obstruction, stone disease, or cysts, as well as to evaluate renal size and cortical thickness [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/15\">",
"       15",
"      </a>",
"      ]. A renal ultrasound can also provide information regarding echogenicity. Echogenic kidneys less than 10 cm in length usually indicate irreversible.",
"     </li>",
"     <li>",
"      Urinary electrolytes and osmolarity &mdash; Urinary electrolytes are useful for assessing the effective volume status of patients and renal concentrating ability of patients with abnormal renal function. We obtain urinary sodium or fractional excretion of sodium, which may also provide important diagnostic information for hepatorenal syndrome in patients awaiting liver transplantation, or for low cardiac output states in heart transplant candidates. Such conditions represent situations in which the renal hemodynamic state usually improves with appropriate organ transplantation and where kidney function may be expected to likewise undergo some degree of recovery. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8472?source=see_link\">",
"       \"Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/50/29482?source=see_link\">",
"       \"Hepatorenal syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Renal biopsy &mdash; Renal biopsy should be considered when urinary abnormalities are detected (the presence of microscopic hematuria, proteinuria, red blood cell casts) or in the event of renal failure in which the cause is not evident from routine clinical data [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. Biopsy may be performed percutaneously under ultrasound or CT guidance if the patient condition allows. In a retrospective series in which 44 liver transplant candidates with abnormal kidney function of undetermined etiology for less than eight weeks duration underwent percutaneous renal biopsy, bleeding complications requiring at least one unit of blood occurred in 30 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/18\">",
"       18",
"      </a>",
"      ]. More than half of the complications were major, defined by the requirement for two or more units of blood",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      intervention. By multivariable analysis, only INR at the time of biopsy was an independent predictor of complication. A transjugular kidney biopsy should therefore be considered in patients with severe coagulopathy or on mechanical ventilation in whom a percutaneous approach may not be feasible or safe [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/19-21\">",
"       19-21",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21690?source=see_link\">",
"       \"Indications for and complications of renal biopsy\"",
"      </a>",
"      .) In a series of 30 heart transplant candidates that underwent kidney biopsy for an eGFR &lt;40",
"      <span class=\"nowrap\">",
"       ml/min/1.73",
"      </span>",
"      m",
"      <sup>",
"       2",
"      </sup>",
"      or proteinuria &gt;500",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      only one patient had bleeding to the point of needing a blood transfusion or intervention to stop the bleeding [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A renal biopsy, which often helps elucidate the cause of the impaired kidney function, may also help to differentiate intrinsic renal disease from renal hypoperfusion as well as reveal the extent of glomerular and interstitial fibrosis. Some authors have suggested that combined liver and kidney transplantation, for example, may be undertaken in patients with liver failure and more than 40 percent glomerulosclerosis or more than 30 percent interstitial fibrosis on kidney biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/16,23\">",
"     16,23",
"    </a>",
"    ]. Although this may represent useful information regarding chronicity of kidney injury, evidence supporting the prognostic value of renal histology, or its advantage over kidney function studies alone, is lacking.",
"   </p>",
"   <p>",
"    Glomerulonephritis may be clinically silent and biopsy evidence of glomerulonephritis in the absence of clinical signs of renal disease may be common in liver transplant candidates, especially those with hepatitis C infection. A single-center study, for example, reported the kidney histology and renal outcomes of 30 liver transplant patients with hepatitis C virus infection who underwent liver transplantation alone and had a kidney biopsy at the time of transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/24\">",
"     24",
"    </a>",
"    ]. Immune-complex glomerulonephritis was noted in 25 patients, with 12 having membranoproliferative glomerulonephritis, seven had IgA nephropathy, and six had mesangial glomerulonephritis. Only one had a normal kidney biopsy. Of these patients, 10 had normal serum creatinine levels, normal urinalysis results, and normal quantitative proteinuria. For five others, the only renal abnormality was an increased serum creatinine level. No patient had cryoglobulins in the blood or kidney. This study, together with others [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/18,22\">",
"     18,22",
"    </a>",
"    ], highlights the lack of correlation between clinical parameters and renal histology in patients with decompensated liver or heart disease. However, whether post-liver or heart transplant progression of kidney disease is better predicted by histological damage or clinical judgment has not been established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Liver failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;In this section, clinical scenarios are considered that are specific to patients with end stage liver disease and varying degrees of kidney disease. Unfortunately, these settings are difficult to extrapolate to recipients of other nonrenal solid organ transplants given the absence of data. Issues surrounding combined renal and liver disease in patients infected with hepatitis B or C viruses or in patients with primary hyperoxaluria are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12154?source=see_link\">",
"     \"Primary hyperoxaluria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because serum creatinine is a component of the Model for End-Stage Liver Disease (MELD) scoring system (adopted in 2002 to prioritize patients for liver transplantation), the number of candidates for liver transplantation with kidney dysfunction has increased [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/25\">",
"     25",
"    </a>",
"    ]. The proportion of all liver transplants done as combined liver-kidney transplants has expanded from 2.2 percent in 1999 to just over 6 percent in 2007",
"    <a class=\"external\" href=\"file://www.unos.org/\">",
"     www.unos.org",
"    </a>",
"    . This has led to concern that some recipients who receive combined liver and kidney transplantation may have reversible renal injury and that some patients with ESRD receive liver transplants prematurely [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most important determinant of the need for combined liver and kidney transplant in patients with advanced liver and varying degrees or renal disease is the ability to understand the nature and the anticipated course of the renal disease. In patients with end stage liver disease and renal failure, it is important to distinguish patients with functional renal failure such as those with hepatorenal syndrome from patients with advanced irreversible disease.",
"   </p>",
"   <p>",
"    When evaluating the renal function of liver transplant candidates, one of the following scenarios is possible:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient with acute kidney injury (AKI). Most patients with AKI and end stage liver disease do not require combined liver and kidney transplantation. As an example, one of the most common causes of AKI in this setting is hepatorenal syndrome, which does not constitute an indication for combined liver and kidney transplant [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/26\">",
"       26",
"      </a>",
"      ]. However, hepatorenal syndrome may not be totally reversible, especially in patients who experience a prolonged course requiring renal replacement therapy. Similarly, prolonged acute tubular necrosis may be associated with limited recovery of kidney function after liver transplantation. Regardless of the cause of AKI, it is relatively unknown at what point of the disease process irreversible kidney injury occurs. A consensus conference comprising hepatologists, transplant surgeons, nephrologists, and coordinators reached agreement that the duration of dialysis prior to transplant was an appropriate criterion to use in determining who should get a combined liver and kidney transplant [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/15\">",
"       15",
"      </a>",
"      ]. Although the consensus group eventually agreed on a six-week course of dialysis as the threshold for combined liver and kidney transplantation, others have proposed a more prolonged duration of time (more than eight weeks) [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]. The requirement for a longer duration is supported by an analysis of the US OPTN and USRDS databases that indicated that, among liver recipients on renal replacement therapy pre-transplant, post-operative removal from this treatment modality occurred in about 71, 56, and 24 percent of patients dialyzed for less than 30, 31 to 60 and 61 to 90 days respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/29\">",
"       29",
"      </a>",
"      ]. By the NKF-KDOQI definition, patients with AKI for greater than 8 to 12 weeks duration have CKD and should be considered for combined liver and kidney transplantation.",
"     </li>",
"     <li>",
"      The patient has normal kidney function or a mild degree of CKD. In this setting, generally there is no indication to consider renal transplant.",
"     </li>",
"     <li>",
"      The patient has a moderate to severe degree of CKD. The major determinant of the need for combined liver and kidney transplant in this case is the projected rate of decline of renal function. Kidney transplants should be offered only to patients who are projected to require some form of renal replacement therapy within three years of transplant [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/16,23\">",
"       16,23",
"      </a>",
"      ]. It is generally accepted that patients with primary renal disease and an estimated GFR less than 30",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      be listed for combined liver and kidney transplant [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/15,30\">",
"       15,30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The patient with a history of multiple bouts of recurrent AKI. Generally, these patients do not need a combined liver and kidney transplant. However, they may develop progressive disease with less and less renal functional reserve with each episode of acute renal failure; renal replacement therapy may eventually be required. Patients in this category who require extended periods of renal replacement therapy (greater than eight weeks) may be considered for combined liver and kidney transplant [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/15,27,31\">",
"       15,27,31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The patient with preexisting chronic kidney disease and superimposed AKI. In this patient subset, it is important to consider the quantitative relevance of each form of injury. A kidney biopsy may be helpful to establish the extent of chronicity and the contribution of acute lesions to the renal dysfunction. Patients who develop hepatorenal syndrome on a background of preexisting renal disease may not fully recover renal function and may require renal replacement therapy. If they require renal replacement therapy for more than six weeks, combined renal and liver transplant may be considered [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/15,27,31\">",
"       15,27,31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In 2008, the proceedings of a consensus conference on simultaneous liver-kidney transplantation were published [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/32\">",
"     32",
"    </a>",
"    ]. It was recommended that automatic approval for listing for simultaneous liver-kidney transplantation be given for the following patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ESRD with cirrhosis and symptomatic portal hypertension or hepatic vein wedge pressure gradient &ge;10 mmHg",
"     </li>",
"     <li>",
"      Hepatic failure and GFR &le;30",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      due to chronic kidney disease",
"     </li>",
"     <li>",
"      AKI or hepatorenal syndrome with serum creatinine &ge;2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (177",
"      <span class=\"nowrap\">",
"       &micro;mol/L)",
"      </span>",
"      and dialysis &ge;8 weeks",
"     </li>",
"     <li>",
"      Hepatic failure and chronic kidney disease with a kidney biopsy showing &gt;30 percent glomerulosclerosis or &gt;30 percent fibrosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The data on the evaluation of renal function prior to orthotopic heart transplant are less well defined. However, the following general principles may help guide the evaluation process:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Given that the combination of renal failure and severe heart failure is common, the nature of the kidney disease, in terms of chronicity and reversibility, must be determined. Patients with mainly hemodynamically mediated renal failure and without obvious intrinsic kidney disease (as determined by the lack of proteinuria, normal kidney size on ultrasonography, and the absence of severe histopathology in renal biopsy specimen) can recover sufficient native kidney function after restoration of renal perfusion to not need subsequent kidney replacement therapy for several years.",
"     </li>",
"     <li>",
"      For heart transplant candidates with renal failure that appears to be due to irreversible kidney disease, combined heart-kidney transplantation is a viable option. Pre-transplant kidney biopsy may be useful in determining chronicity of kidney injury, although the prognostic value of these findings is not established [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/22\">",
"       22",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/15/22775?source=see_link&amp;anchor=H12#H12\">",
"       \"Prognosis after cardiac transplantation\", section on 'Heart-kidney transplantation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A separate issue is kidney after heart transplantation when renal failure develops after heart transplantation. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Cardiac transplantation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     General summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a general rule, the preoperative evaluation of renal function in candidates for nonrenal SOT should focus on an assessment for a past history of renal injury and dysfunction, the degree of current kidney function, and the likelihood and rate of progression after SOT. The evaluation of renal function in individuals who are to undergo a nonrenal SOT begins with a complete history and physical examination, an accurate measure of renal function, a urinalysis, and renal ultrasonography. Based on findings from this initial evaluation, renal biopsy and other studies may be considered. Further options will depend on the particular clinical scenario and the particular organ that is failing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CKD AFTER NON-RENAL ORGAN TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree of renal functional impairment post-transplant and the rate of progression of CKD depend to a large degree on the extent of pre-transplant CKD, the nature of the organ transplanted, and the immunosuppressive regimen and individual clinical features that determine susceptibility to renal injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcineurin inhibitor (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ) therapy, still the cornerstone of immunosuppression in most organ recipients, has been implicated as a principal cause of post-transplantation CKD [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/33-52\">",
"     33-52",
"    </a>",
"    ]. The histopathologic characteristic of calcineurin inhibitor nephrotoxicity is similar among patients with renal and nonrenal solid organ transplants. These include vascular obliteration, focal hyalinosis of small renal arteries and arterioles, global or segmental glomerulosclerosis, tubular atrophy, and striped interstitial fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/53-56\">",
"     53-56",
"    </a>",
"    ]. A retrospective report of 105 for-cause kidney biopsies performed in a cohort of 101 bone marrow, liver, lung and heart recipients demonstrated histological findings of primary glomerulonephritis in 17 percent and thrombotic microangiopathy in 10 percent of patients respectively, in addition to non-specific chronic changes, hypertension-related damage, and calcineurin inhibitor toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/57\">",
"     57",
"    </a>",
"    ]. Patients with thrombotic microangiopathy had the worst post-biopsy kidney outcomes. A review of calcineurin inhibitor nephrotoxicity is available in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=see_link\">",
"     \"Cyclosporine and tacrolimus nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to calcineurin inhibitor nephrotoxicity, a number of other factors appear to underlie decreased kidney function post nonrenal solid organ transplant. These include pretransplant kidney function, the specific immunosuppressive regimen, presence of comorbid conditions (particularly diabetes, hypertension, and HCV infection), older age, particular organ transplanted, and surgical issues [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/5\">",
"     5",
"    </a>",
"    ]. Nephropathy resulting from BK virus infection has also been reported in nonrenal organ transplants [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/31,58-60\">",
"     31,58-60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/7/6266?source=see_link\">",
"     \"Clinical manifestations and diagnosis of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/45/42712?source=see_link\">",
"     \"Management of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The best general data on underlying independent pathogenic factors and overall incidence of CKD in nonrenal solid organ transplant patients come from a study that described a population-based cohort of 69,321 persons who received nonrenal transplants (heart, lung, liver, and intestine) in the United States between 1990 and 2000 [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/5\">",
"     5",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    were given to 60 and 28 percent, respectively. In this report, 11,426 patients (16.5 percent) developed stage 4 or 5 CKD (defined as a glomerular filtration rate [GFR] of 29 mL per minute per 1.73 m2 of body-surface area or less) during a median follow up of 36 months. Maintenance dialysis or renal transplantation was required in 29 percent of those who developed stage 4 or 5 CKD.",
"   </p>",
"   <p>",
"    The cumulative incidence of stage 4 or 5 CKD at five years ranged from 6.9 percent among recipients of heart&ndash;lung transplants to 21.3 percent among recipients of intestine transplants. Independent risk factors for chronic renal failure included calcineurin inhibitor therapy, older age, lower pretransplant GFR, female gender, postoperative acute renal failure, baseline diabetes mellitus and hypertension, and hepatitis C virus infection. Among patients who had received liver transplants, the excess risk of chronic renal failure associated with the use of a calcineurin inhibitor was greater with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    than with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    therapy. This association was not statistically significant in recipients of heart, heart-lung or lung transplants.",
"   </p>",
"   <p>",
"    The occurrence of worsening levels of CKD significantly increased the risk of death, with a relatively lower risk of death with subsequent kidney transplantation than with dialysis among those who progress to end stage renal disease. The mortality rate transiently increased perioperatively, which was subsequently followed by a progressive decrease in mortality:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At 141 days, the relative risk of death in patients who received a kidney transplant was the same as those on the waiting list.",
"     </li>",
"     <li>",
"      Beyond 141 days, the relative risk of death was decreased and maintained until the end of the study duration (five years).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mortality incurred from the increased relative risk of death in the perioperative period was offset by the decreased relative risk of death at 506 days after kidney transplantation.",
"   </p>",
"   <p>",
"    For non-renal SOT recipients with advanced CKD deemed healthy enough to potentially receive a subsequent kidney transplant, the risk of dying or being de-listed while awaiting a kidney is elevated. Timely referral of medically appropriate patients for kidney transplantation should be done.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Liver transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although immunosuppressive therapy with calcineurin inhibitors has dramatically improved patient and graft survival after orthotopic liver transplantation, the nephrotoxic effects of calcineurin inhibitors is being increasingly recognized in liver transplant patients [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. Many studies have described a gradual decline in renal function following orthotopic liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/48,50,62-65\">",
"     48,50,62-65",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Using the Kidney Disease Outcomes Quality Initiatives (KDOQI) classification system, one study examined the risk of CKD by stage among 230 liver recipients followed for a mean period of approximately six years [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/4\">",
"       4",
"      </a>",
"      ]. Overall prevalences of CKD at 10 years was 2 percent with stage 5, 6 percent with stage 4, 57 percent with stage 3, 24 percent with stage 2, and the rest with minimal or no renal function deficit.",
"     </li>",
"     <li>",
"      A single-center retrospective study of 883 consecutive adult patients receiving a first liver transplant reported that 8 percent of 10-year survivors of orthotopic liver transplants had developed severe chronic kidney disease (CKD) (defined in this study as creatinine greater than 2.8",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [248",
"      <span class=\"nowrap\">",
"       micromol/L]),",
"      </span>",
"      with 50 percent of these developing ESRD [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of impaired renal function prior to liver transplantation is associated with decreased patient survival post-transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A group of investigators used the United Network for Organ Sharing (UNOS) database to determine the impact of pretransplant renal function on graft and patient survival rates after orthotopic liver transplantation (OLT) [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/66\">",
"       66",
"      </a>",
"      ]. Up to 33 percent of patients undergoing liver transplantation had some degree of kidney injury, with even mild renal dysfunction (GFR of 40 to 70",
"      <span class=\"nowrap\">",
"       mL/min)",
"      </span>",
"      being associated with increased 30 day and two year mortality. Creatinine clearance was the sole variable retaining post-transplant mortality predictive power in liver transplant recipients.",
"     </li>",
"     <li>",
"      The impact of preoperative renal function on outcome after OLT was assessed using the",
"      <span class=\"nowrap\">",
"       UNOS/OPTN",
"      </span>",
"      database for the period 1999 to 2004 [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/67\">",
"       67",
"      </a>",
"      ]. Compared with those with a preoperative serum creatinine concentration less than 1.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (88.4",
"      <span class=\"nowrap\">",
"       micromol/L),",
"      </span>",
"      the relative risk of death was 1.11, 1.48, 1.77, and 1.44 for those with levels between 1.0 and 2.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (88.4 to 176.8",
"      <span class=\"nowrap\">",
"       micromol/L),",
"      </span>",
"      those with levels &ge;2.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (176.8",
"      <span class=\"nowrap\">",
"       micromol/L),",
"      </span>",
"      patients requiring renal replacement therapy, and those who received a",
"      <span class=\"nowrap\">",
"       liver/kidney",
"      </span>",
"      transplant, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Not surprisingly, the presence of kidney dysfunction prior to surgery, particularly the diagnosis of hepatorenal syndrome, is a significant risk factor for post-transplantation kidney dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/63,68-73\">",
"     63,68-73",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study retrospectively examined 724 orthotopic liver transplant recipients and identified preoperative serum creatinine greater than 1.9",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      preoperative blood urea nitrogen greater than 27",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      intensive care unit stay more than three days, and Model for End-Stage Liver Disease (MELD) score greater than 21 as important predictors of the need for renal replacement therapy post-operatively [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the study previously discussed [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/63\">",
"       63",
"      </a>",
"      ], patients who developed severe renal failure post-liver transplant had a greater likelihood of having had hepatorenal syndrome preoperatively when compared with those who maintained normal renal function.",
"     </li>",
"     <li>",
"      In another study, the incidence of end-stage renal disease after liver transplantation in patients who had preoperative hepatorenal syndrome was seven percent, compared with two percent in those without the syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On average, approximately 10 percent of patients who have hepatorenal syndrome preoperatively eventually develop ESRD [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/63,69,70\">",
"     63,69,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with significant preoperative kidney disease may benefit from combined liver and kidney transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/70,74\">",
"     70,74",
"    </a>",
"    ]. Analysis of the United Network of Organ Sharing (UNOS) data revealed that the five year survival in patients with a serum creatinine concentration &gt;2.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (177",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    was 62 and 50 percent in patients who received a combined liver-kidney transplant and liver transplant alone, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/70\">",
"     70",
"    </a>",
"    ]. Additional analysis from the UNOS database suggests that renal allograft half-life is superior with combined liver-kidney transplantation versus that associated with kidney after liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/74\">",
"     74",
"    </a>",
"    ]. However, the findings from both of these retrospective studies were derived from registry data and therefore need to be cautiously interpreted. Analysis of the margin of benefit offered from combined kidney and liver transplantation must be tested in properly designed studies.",
"   </p>",
"   <p>",
"    As with the general population with ESRD, kidney transplantation provides superior survival outcomes to dialysis in recipients of liver transplants who develop end stage renal disease. In one study of patients who developed end stage renal disease following liver transplant, survival at six years was significantly higher in those who received a kidney transplant versus patients who were on dialysis (71 and 21 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/63\">",
"     63",
"    </a>",
"    ]. Patient survival in recipients of sequential kidney after liver transplants was compared to the survival of those who received a primary kidney transplant at the same center during the same period. The investigators showed that the patients receiving a primary kidney transplant only had a superior 10-year patient survival compared with those receiving a kidney transplant after liver transplant (75 versus 43 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pancreas transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on renal function following pancreas transplantation alone performed for diabetes mellitus are scant. In this setting, post-transplant renal function is principally influenced by two competing factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Beneficial effects of sustained normoglycemia",
"     </li>",
"     <li>",
"      Nephrotoxic effects associated with transplantation, particularly those resulting from calcineurin inhibitors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It had been previously noted that normoglycemia following pancreas transplantation alone that persisted for five years failed to ameliorate renal dysfunction or glomerular lesions in type 1 diabetic patients with their own kidneys [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/75\">",
"     75",
"    </a>",
"    ]. The absence of observed benefit with normoglycemia was attributed to the adverse effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Subsequently, the relationship of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    dose and blood levels to changes in renal function was examined in type 1 diabetic patients who underwent pancreas transplantation alone [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/76\">",
"     76",
"    </a>",
"    ]. In this study, creatinine clearance decreased from 108",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    at baseline to 74",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    at five years post-transplantation in those who received pancreas transplantation, while kidney function did not change appreciably in diabetic controls. The decrement in creatinine clearance correlated with cyclosporine blood levels and dose. The investigators concluded that, among patients with type I diabetes mellitus who do not have renal dysfunction and have not received a kidney transplant, pancreas transplantation does not improve kidney function. In addition, it may contribute to a significant decrement in creatinine clearance within five years after transplantation.",
"   </p>",
"   <p>",
"    It was postulated that the relatively short follow-up in this study may have prevented the renoprotective effects of normoglycemia, if present, from emerging. To address this limitation, the same investigators conducted a longer 10 year study to discern the quantitative relevance of the competing factors of normoglycemia and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    nephrotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/77\">",
"     77",
"    </a>",
"    ]. The creatinine clearance in recipients of pancreas transplants significantly declined at five years but stabilized thereafter. Ultrastructural examination of kidney tissue from these patients revealed that the thickness of the glomerular and tubular basement membranes was similar at five years and at baseline but had decreased by ten years. It was concluded that pancreas transplantation can reverse the lesions of diabetic nephropathy, but reversal requires more than five years of normoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/77,78\">",
"     77,78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The natural history of kidney function following pancreas transplantation alone is characterized by an initial decline in renal function, due most likely to the untoward effect of calcineurin inhibitors. However, kidney function later stabilizes so that, when compared to a cohort of non-transplant patients with diabetes mellitus type 1, those who received a pancreas transplant have a higher creatinine clearance and less albuminuria at 10 years of follow up.",
"   </p>",
"   <p>",
"    Practically all patients listed for pancreas transplantation alone have normal or near normal kidney function. The majority of patients with diabetes mellitus type 1 and CKD are considered for either kidney transplant alone or combined kidney and pancreas transplantation either simultaneously or sequentially. A",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    challenge test may be administered pretransplant to pancreas alone candidates to determine the degree of kidney injury induced by the calcineurin inhibitor when deciding whether to proceed with pancreas alone, simultaneous kidney-pancreas, or kidney transplant alone, followed by subsequent pancreas transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues surrounding simultaneous kidney-pancreas transplantation, kidney followed by pancreas transplantation, and pancreas transplantation alone are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/19/41272?source=see_link\">",
"     \"Benefits and complications associated with kidney-pancreas transplantation in diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/16/7434?source=see_link\">",
"     \"Patient selection for and immunologic issues relating to kidney-pancreas transplantation in diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/63/7162?source=see_link\">",
"     \"Pancreas and islet transplantation in diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cardiac transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least 25 percent of cardiac transplant recipients will develop CKD within the first year after transplant. Cardiac transplant recipients usually suffer an initial rapid decline in renal function in the first two years post-transplant, which is followed by a less pronounced decline afterwards [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/40,43,80-91\">",
"     40,43,80-91",
"    </a>",
"    ]. In one study, 200 patients were followed for up to nine years post heart transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/80\">",
"     80",
"    </a>",
"    ]. The average loss of GFR in the first year post-transplant was 14",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    while the average loss of GFR in the subsequent eight years was 14",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    Severe kidney dysfunction (GFR &lt;20",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2) developed in 20 percent of the patients, which was predicted by the recipient age at time of transplantation plus the GFR one year after transplantation.",
"   </p>",
"   <p>",
"    The natural history of renal function following orthotopic heart transplant was also evaluated in another report [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/92\">",
"     92",
"    </a>",
"    ]. To assess the effect of heart transplantation and exposure of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    on long-term kidney function, statistical analysis was restricted to patients who survived the first year post-transplantation. Heart transplant survivors beyond the first year post-transplant have a significant decrease in kidney function over time:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The cumulative incidence of chronic renal failure as defined by a GFR &le;29",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2 at 5, 10 and 15 year was 4.2, 10.4 and 12.5 percent, respectively",
"     </li>",
"     <li>",
"      The cumulative incidence of severe chronic renal failure as defined by a GFR &le;15",
"      <span class=\"nowrap\">",
"       mL/min/1.73",
"      </span>",
"      m2 at 5, 10 and 15 years was 2.1, 8.3 and 8.3 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Age, pretransplantation estimated GFR, pretransplantation diabetes, and pretransplantation hypertension were risk factors associated with a &ge;10",
"    <span class=\"nowrap\">",
"     mL/min/1.73",
"    </span>",
"    m2 decrement in estimated GFR.",
"   </p>",
"   <p>",
"    Pooled weighted average serum creatinine concentrations",
"    <span class=\"nowrap\">",
"     (mg/dL)",
"    </span>",
"    derived from published studies describing renal function in heart transplant recipients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    based immunosuppressive therapy reveals a biphasic pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/40,80,83-88\">",
"     40,80,83-88",
"    </a>",
"    ]. During the first two years following heart transplantation there is a steep decline in kidney function, followed by a less pronounced decline afterwards (",
"    <a class=\"graphic graphic_figure graphicRef58337 \" href=\"UTD.htm?8/52/9038\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The mechanism for this biphasic pattern appears to be due to the renal response to early versus late effects. The GFR rapidly declines in the first few months after transplant mainly as a result of exposure to perioperative and postoperative insults plus exposure to calcineurin inhibitors. Renal function later stabilizes. In general, the GFR at one year is a better reflection of renal functional reserve, which is also predictive of long term renal outcome and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Renal replacement therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a report from the International Society for Heart and Lung Transplantation (ISHLT) registry, 4.4 percent of heart transplant recipients were on chronic dialysis and 0.9 percent of patients received a renal transplant within eight years after heart transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/93\">",
"     93",
"    </a>",
"    ]. Survival in patients receiving kidney transplant after heart transplant was significantly lower than for heart-only recipients at the same time-points after heart transplant.",
"   </p>",
"   <p>",
"    Findings related to end-stage renal disease post-heart transplantation were also reported in a study from the Canadian Organ Replacement registry [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/94\">",
"     94",
"    </a>",
"    ]. The incidence of dialysis after heart transplantation was four percent, with survival on dialysis being significantly worse than a matched dialysis cohort. By comparison, survival was similar in those who received a kidney transplant after heart transplantation versus those in the matched dialysis cohort who had received a kidney transplant.",
"   </p>",
"   <p>",
"    Similar findings as those noted from the Canadian registry were reported in a study from France. Survival among heart transplant patients who initiated dialysis was significantly lower than non-heart transplant dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among those who require renal replacement therapy, survival with a kidney transplant is superior to those who continue dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. In a study using UNOS data, for example, the risk of death was decreased by 43 percent in patients who received a kidney transplant compared to heart recipients maintained on dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/96\">",
"     96",
"    </a>",
"    ]. Another analysis of UNOS data demonstrated that the annual number of kidney after heart transplants has quadrupled over the past decade [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/98\">",
"     98",
"    </a>",
"    ]. Increasing dialysis duration was associated with worse outcomes after the kidney transplant, with patient death accounting for over 75 percent of kidneys that were lost. The fact that kidney quality, (living versus deceased donors; standard criteria versus expanded criteria) was not a determinant of survival, suggests that use of non-standard kidneys should be readily considered in this population rather than spending more time on the list waiting for a standard criteria kidney.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Lung transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;CKD is common following lung transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/42,49,52,65,99-104\">",
"     42,49,52,65,99-104",
"    </a>",
"    ]. The decline in renal function is usually biphasic, with a steep decline in the first year post transplant and a slower decline afterwards [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest study examined renal function in 219 patients who underwent lung or heart-lung transplantation and survived the first six months post-transplant [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/104\">",
"       104",
"      </a>",
"      ]. Over one-half of the patients who survived the first post-transplant year had developed stage 3 CKD by that time [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/105\">",
"       105",
"      </a>",
"      ]. During a median follow-up of 44 months, 7.3 percent of patients had developed end-stage renal disease. The cumulative incidence of doubling of the serum creatinine concentration was 34, 43, and 53 percent at one, two, and five years. However, these incidences were from basic descriptive statistics and not survival-analysis statistics, which would account for patient death. Thus, the true incidences of end-stage renal disease are much greater. Elevated diastolic blood pressure and elevated serum creatinine at one month post-transplant were associated with poor renal function.",
"      <br/>",
"      <br/>",
"      In this report, significantly less nephrotoxicity was observed with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      versus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/104\">",
"       104",
"      </a>",
"      ]. The use of tacrolimus during the first six months after transplantation was associated with a significant decrease in the risk for time to doubling of serum creatinine concentration and a lower rate of acute rejection. However, these results are somewhat difficult to interpret as cyclosporine was used in an earlier era of lung transplantation when overall results were not as good. Additional analysis of these patients found that predictors of a shorter time to doubling of the serum creatinine concentration included older age, lower GFR at one month post-transplant, and cyclosporine use during the first one-half year post-transplant [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/105\">",
"       105",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second study also illustrated the initial steep decline in kidney function, which is followed by a less vigorous decline. In this report of 124 patients, the serum creatinine concentration at baseline one year and five years post-transplant was 0.8, 1.6, and 1.9",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As observed with other solid organ transplants, the tapering and withdrawal of calcineurin-inhibitors can be associated with improved renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among those who require renal replacement therapy, survival with a kidney transplant is superior to those who continue dialysis. In a study from the UNOS, for example, the risk of death was decreased by 54 percent in patients who received a kidney transplant compared to lung recipients maintained on dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Islet cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A paucity of data exists concerning the post-transplant effect on the kidney function of islet cell transplantation alone in patients with normal or near-normal function [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/107-109\">",
"     107-109",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an early report on seven patients with diabetes type 1 and normal kidney function who underwent islet transplantation with an average follow up period of 10 months, the serum creatinine was not found to be significantly different than pretransplant serum creatinine with an average follow-up period of 10 months (1.2 and 1.3",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/107\">",
"       107",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A subsequent report elaborated on the experience with 47 patients who had diabetes type 1 and underwent islet cell transplant [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/108\">",
"       108",
"      </a>",
"      ]. After an average follow up of five years, the serum creatinine was mildly but significantly elevated when compared to pretransplant serum creatinine (1.1 and 0.9",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      respectively). Creatinine clearance nonsignificantly decreased over the course of the study period (108 to 84",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      at the end of follow up). In addition, increasing proteinuria appeared to occur, with 45 percent of patients with pretransplant microalbuminuria progressing to overt proteinuria and 10 percent those with no pretransplant microalbuminuria progressing to overt proteinuria. In this study, patients were induced with daclizumab and subsequently maintained on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      . Proteinuria in patients with clinical islet cell transplantation has been attributed to the use of sirolimus as the discontinuation of sirolimus has led to the resolution of proteinuria [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/110\">",
"       110",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/9/17562?source=see_link\">",
"       \"Mammalian target of rapamycin (mTOR) inhibitors in renal transplantation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While studies on whole pancreas transplantation have shown that metabolic control in recipients with normal kidney function resulted in stabilization and reversal of diabetic lesions in the native kidney, limited data suggest that successful islet transplant may have a similar positive impact on diabetic renal lesions.",
"   </p>",
"   <p>",
"    As an example, the effect of islet transplantation on the renal function of 36 patients with type I diabetes mellitus, kidney transplants, and some degree of kidney allograft dysfunction was reported [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/111\">",
"     111",
"    </a>",
"    ]. The study compared parameters of renal function in patients with successful islet transplantation versus those who had an unsuccessful islet transplant (success was defined as fasting C-peptide levels of &gt;0.5",
"    <span class=\"nowrap\">",
"     ng/ml",
"    </span>",
"    for &gt;1 year). Patients with successful islet transplant had better kidney graft survival rates at seven years when compared to those with unsuccessful islet transplant (83 versus 51 percent, respectively). Microalbuminuria increased significantly in patients with an unsuccessful transplant but did not change appreciably in those with successful islet transplant. Thus, islet transplantation, probably by partially restoring pancreatic endocrine function, not only improves the metabolic control of diabetes mellitus but also is associated with improvements in renal function and kidney graft life span.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Heart-lung transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart-lung transplantation is now an uncommon procedure that should be reserved for patients who cannot be treated by lung transplantation alone [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/93\">",
"     93",
"    </a>",
"    ]. Suitable candidates include patients with severe, irreversible disease of the lung parenchyma or vasculature who also have severely compromised left ventricular function or other cardiac diseases that would preclude a successful outcome with lung transplantation alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/6/99?source=see_link\">",
"     \"Heart-lung transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2005 report from the International Society for Heart and Lung Transplantation included data on renal function after heart-lung transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/93\">",
"     93",
"    </a>",
"    ]. Within one year after transplantation, 17.8 percent of recipients developed some degree of renal dysfunction, 3.6 percent required maintenance dialysis, and 0.4 percent received a renal transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/93\">",
"     93",
"    </a>",
"    ]. Within five years, approximately 25 percent developed severe CKD, which was defined in the registry as a serum creatinine concentration &gt;2.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (221",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    requirement for dialysis, or a renal transplant.",
"   </p>",
"   <p>",
"    The incidence of and risk factors associated with CKD post-heart-lung transplant were also assessed in the previously cited population-based cohort study of 69,321 patients who received nonrenal transplants in the United States between 1990 and 2000, of whom 576 received a heart-lung transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/112\">",
"     112",
"    </a>",
"    ]. The cumulative incidence of CKD in recipients of heart-lung transplant as defined by GFR of less than 29",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 was 1.7, 4.2, and 6.9 percent at one, three, and five years, respectively.",
"   </p>",
"   <p>",
"    Because these findings were nearly identical between heart transplant patients and heart-lung transplant patients, the investigators used a combined regression model for both patient groups [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/112\">",
"     112",
"    </a>",
"    ]. In this model, the presence of pretransplantation kidney disease, post-operative acute renal failure, a positive serologic test for hepatitis C prior to transplant, pretransplant diabetes and pretransplant hypertension were all associated with increased risk of chronic renal failure after the transplant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Intestinal transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although data are minimal, studies suggest that kidney function deteriorates among intestinal transplant patients [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/113-116\">",
"     113-116",
"    </a>",
"    ]. This was best shown in a report of 10 patients (eight adults) in whom the GFR was assessed at baseline, three months posttransplantation, and yearly thereafter using chromium EDTA clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/116\">",
"     116",
"    </a>",
"    ]. Among all adults, the median GFR decreased by approximately 50 percent at three months posttransplant. In addition, among the five adults with greater than one-year follow-up, the median GFR decreased by nearly 75 percent compared with baseline levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PREVENTION AND TREATMENT STRATEGIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attenuation of the risk of nephrotoxicity post-transplantation should focus on modifiable risk factors that are common to all patients at risk of chronic kidney disease and those that are specific to the transplant setting. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Attempts should be made to minimize perioperative and post operative hypotension.",
"     </li>",
"     <li>",
"      The use of nephrotoxic agents should be avoided. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18072?source=see_link\">",
"       \"Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=see_link\">",
"       \"NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      It is generally advisable to achieve good control of blood pressure. In the absence of specific guidelines, general guidelines for treatment in renal transplant recipients should be followed for nonrenal transplant recipients (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/23/16761?source=see_link\">",
"       \"Hypertension after renal transplantation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/26/40362?source=see_link&amp;anchor=H3#H3\">",
"       \"Long-term management of adult liver transplant recipients\", section on 'Hypertension'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The use of therapeutic modalities to attenuate the degree of proteinuria may help delay the progression of renal failure. This includes the use of ACE inhibitors or ARBs as extrapolated from evidence related to non-transplant as well as renal transplant patients with renal dysfunction. These agents reduce the incidence and degree of proteinuria, with potential to slow the progression of renal insufficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/117-121\">",
"       117-121",
"      </a>",
"      ]. However, the effectiveness of RAAS blockade in this population is yet to be established and has to be balanced against the risk of acute kidney injury and hyperkalemia.",
"     </li>",
"     <li>",
"      Tight control of diabetes and hyperlipidemia are important. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/26/25000?source=see_link\">",
"       \"Lipid abnormalities after cardiac transplantation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/26/40362?source=see_link&amp;anchor=H154134594#H154134594\">",
"       \"Long-term management of adult liver transplant recipients\", section on 'Diabetes mellitus'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Some investigators have also suggested the use of calcium antagonists to counteract the hemodynamic effects of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      on the afferent arteriole and its effect on the glomerular filtration rate [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/122-124\">",
"       122-124",
"      </a>",
"      ]. Others have suggested the use of angiotensin converting enzyme inhibitors [",
"      <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/125\">",
"       125",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Immunosuppression regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attention should also be directed toward transplant specific factors such as type and dose of immunosuppressive agent used. Calcineurin inhibitor nephrotoxicity as well as therapeutic strategies to reduce exposure to calcineurin inhibitors in renal and non-renal transplant are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=see_link\">",
"     \"Cyclosporine and tacrolimus nephrotoxicity\"",
"    </a>",
"    .) Although a negative correlation between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    level and the level of renal function in nonrenal organ recipients has not been universally demonstrated in clinical studies, it is generally accepted that careful management of immunosuppression may attenuate the risk of chronic renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/38,80,83,86,126\">",
"     38,80,83,86,126",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are now single and multi-center retrospective and prospective studies, as well as registry analyses, suggesting that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    is associated with less nephrotoxicity in both conversion and de novo settings in heart, lung, and liver recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/5,104,105,127-133\">",
"     5,104,105,127-133",
"    </a>",
"    ]. This may be related to less renal vasoconstriction with tacrolimus than occurs with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/134,135\">",
"     134,135",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on the foregoing emerging data, we personally favor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    over",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    from a renal function-sparing standpoint, however, the choice of calcineurin inhibitor ultimately has to be individualized to balance the overall risks and benefits of one therapy versus another.",
"   </p>",
"   <p>",
"    There has been some reluctance to pursue calcineurin inhibitor-free immunosuppressive protocols in recipients of heart, lung, or liver transplants, since a back-up analogous to dialysis is not available if catastrophic rejection occurs. A novel chemically modified",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , ISA (TX)247, which may prove to be less nephrotoxic is currently being tested in non-human primates [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/136\">",
"     136",
"    </a>",
"    ]. The role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    and its role as potentially less nephrotoxic calcineurin inhibitor also need to be examined in prospective studies.",
"   </p>",
"   <p>",
"    Calcineurin inhibitor-free induction protocols have been cautiously used with some success in liver transplant patients, although this has not been a universal finding.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    induced nephrotoxicity may cause progressive, irreversible kidney disease and reduction of cyclosporine exposure by addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil may result in long-term renal functional improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/137\">",
"     137",
"    </a>",
"    ]. The therapeutic strategy of converting non-renal transplant recipients with chronic renal failure from calcineurin inhibitor based immunosuppression to mycophenolate mofetil",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    or a switch from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    to mycophenolate mofetil to achieve cyclosporine dose reduction has been shown in some small studies to lead to improved renal function without an increase in the rate of allograft rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?33/28/34250/abstract/106,137-144\">",
"     106,137-144",
"    </a>",
"    ]. However, the use of sirolimus also has significant adverse effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/9/17562?source=see_link\">",
"     \"Mammalian target of rapamycin (mTOR) inhibitors in renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Renal dysfunction following nonrenal solid organ transplant (SOT) is a significant issue. Approximately 15 percent of nonrenal SOT recipients eventually develop significant CKD post-transplantation. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The preoperative evaluation of renal function in candidates for nonrenal SOT should focus on establishing the probability of reversibility and the chance of progression to end stage renal disease. The evaluation of renal function begins with a complete history and physical examination, an accurate measure of renal function, a urinalysis, and renal ultrasonography. Based on findings from this initial evaluation, renal biopsy and other studies may be required. Further options depend upon the particular clinical scenario and the particular nonrenal solid organ that is failing. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Preoperative evaluation of kidney function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Calcineurin inhibitor therapy has been implicated as an important cause of post-transplantation chronic kidney disease (CKD) in non-renal SOT recipients. An increased risk of CKD in this population is also associated with pre-transplant kidney injury and damage, increasing age, African-American race, female gender, pretransplantation hypertension and diabetes mellitus, type of organ transplanted, surgical issues,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hepatitis C infection. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'CKD after non-renal organ transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cumulative incidence of ESRD requiring some form of renal replacement therapy in nonrenal SOT ranges from 3 to 10 percent in liver transplant patients, 0 to 20 percent in heart transplant patients, 5 to 15 percent in lung transplant patients and 3 percent in heart-lung transplant patients. There are limited data concerning islet cell and intestinal transplantation. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'CKD after non-renal organ transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Attenuation of the risk of nephrotoxicity post-transplantation should focus on modifiable risk factors that are common to all patients at risk of CKD and those that are specific to the transplant setting. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Prevention and treatment strategies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For non-renal SOT recipients with advanced CKD deemed healthy enough to potentially receive a subsequent kidney transplant, the risk of dying or being de-listed while awaiting a kidney is elevated. We recommend the timely referral of medically appropriate patients for kidney transplantation. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/1\">",
"      Miller BW. Chronic kidney disease in solid-organ transplantation. Adv Chronic Kidney Dis 2006; 13:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/2\">",
"      Chandrakantan A, de Mattos AM, Naftel D, et al. Increasing referral for renal transplant evaluation in recipients of nonrenal solid-organ transplants: a single-center experience. Clin J Am Soc Nephrol 2006; 1:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/3\">",
"      Srinivas TR, Stephany BR, Budev M, et al. An emerging population: kidney transplant candidates who are placed on the waiting list after liver, heart, and lung transplantation. Clin J Am Soc Nephrol 2010; 5:1881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/4\">",
"      O'Riordan A, Wong V, McCormick PA, et al. Chronic kidney disease post-liver transplantation. Nephrol Dial Transplant 2006; 21:2630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/5\">",
"      Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/6\">",
"      Bloom RD, Reese PP. Chronic kidney disease after nonrenal solid-organ transplantation. J Am Soc Nephrol 2007; 18:3031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/7\">",
"      Gonwa TA, Jennings L, Mai ML, et al. Estimation of glomerular filtration rates before and after orthotopic liver transplantation: evaluation of current equations. Liver Transpl 2004; 10:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/8\">",
"      Skluzacek PA, Szewc RG, Nolan CR 3rd, et al. Prediction of GFR in liver transplant candidates. Am J Kidney Dis 2003; 42:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/9\">",
"      Proulx NL, Akbari A, Garg AX, et al. Measured creatinine clearance from timed urine collections substantially overestimates glomerular filtration rate in patients with liver cirrhosis: a systematic review and individual patient meta-analysis. Nephrol Dial Transplant 2005; 20:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/10\">",
"      Tanriover B, Mejia A, Weinstein J, et al. Analysis of kidney function and biopsy results in liver failure patients with renal dysfunction: a new look to combined liver kidney allocation in the post-MELD era. Transplantation 2008; 86:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/11\">",
"      Orlando R, Mussap M, Plebani M, et al. Diagnostic value of plasma cystatin C as a glomerular filtration marker in decompensated liver cirrhosis. Clin Chem 2002; 48:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/12\">",
"      Samyn M, Cheeseman P, Bevis L, et al. Cystatin C, an easy and reliable marker for assessment of renal dysfunction in children with liver disease and after liver transplantation. Liver Transpl 2005; 11:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/13\">",
"      Artunc FH, Fischer IU, Risler T, Erley CM. Improved estimation of GFR by serum cystatin C in patients undergoing cardiac catheterization. Int J Cardiol 2005; 102:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/14\">",
"      Xirouchakis E, Marelli L, Cholongitas E, et al. Comparison of cystatin C and creatinine-based glomerular filtration rate formulas with 51Cr-EDTA clearance in patients with cirrhosis. Clin J Am Soc Nephrol 2011; 6:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/15\">",
"      Davis CL, Feng S, Sung R, et al. Simultaneous liver-kidney transplantation: evaluation to decision making. Am J Transplant 2007; 7:1702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/16\">",
"      Davis CL, Gonwa TA, Wilkinson AH. Identification of patients best suited for combined liver-kidney transplantation: part II. Liver Transpl 2002; 8:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/17\">",
"      Davis CL, Gonwa TA, Wilkinson AH. Pathophysiology of renal disease associated with liver disorders: implications for liver transplantation. Part I. Liver Transpl 2002; 8:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/18\">",
"      Wadei HM, Geiger XJ, Cortese C, et al. Kidney allocation to liver transplant candidates with renal failure of undetermined etiology: role of percutaneous renal biopsy. Am J Transplant 2008; 8:2618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/19\">",
"      Thompson BC, Kingdon E, Johnston M, et al. Transjugular kidney biopsy. Am J Kidney Dis 2004; 43:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/20\">",
"      Sam R, Leehey DJ, Picken MM, et al. Transjugular renal biopsy in patients with liver disease. Am J Kidney Dis 2001; 37:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/21\">",
"      Sam R, Chebrolu SB, Reyes CV, et al. Transjugular renal biopsy in an unconscious patient maintained on mechanical ventilation. Clin Nephrol 2003; 60:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/22\">",
"      Labban B, Arora N, Restaino S, et al. The role of kidney biopsy in heart transplant candidates with kidney disease. Transplantation 2010; 89:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/23\">",
"      Pham PT, Pham PC, Rastogi A, Wilkinson AH. Review article: current management of renal dysfunction in the cirrhotic patient. Aliment Pharmacol Ther 2005; 21:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/24\">",
"      McGuire BM, Julian BA, Bynon JS Jr, et al. Brief communication: Glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation. Ann Intern Med 2006; 144:735.",
"     </a>",
"    </li>",
"    <li>",
"     www.unos.org www.unos.org (Accessed on June 13, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/26\">",
"      Abbasoglu O, Levy MF, Brkic BB, et al. Ten years of liver transplantation: an evolving understanding of late graft loss. Transplantation 1997; 64:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/27\">",
"      Davis CL. Impact of pretransplant renal failure: when is listing for kidney-liver indicated? Liver Transpl 2005; :S35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/28\">",
"      Ruiz R, Kunitake H, Wilkinson AH, et al. Long-term analysis of combined liver and kidney transplantation at a single center. Arch Surg 2006; 141:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/29\">",
"      Northup PG, Argo CK, Bakhru MR, et al. Pretransplant predictors of recovery of renal function after liver transplantation. Liver Transpl 2010; 16:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/30\">",
"      Pham, P-T, Wilkinson, AH. Transplantation: Impact of pretransplant renal insufficiency. Liver Transplant 2008; 5:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/31\">",
"      Barton TD, Blumberg EA, Doyle A, et al. A prospective cross-sectional study of BK virus infection in non-renal solid organ transplant recipients with chronic renal dysfunction. Transpl Infect Dis 2006; 8:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/32\">",
"      Eason JD, Gonwa TA, Davis CL, et al. Proceedings of Consensus Conference on Simultaneous Liver Kidney Transplantation (SLK). Am J Transplant 2008; 8:2243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/33\">",
"      Devineni R, McKenzie N, Keown P, et al. Cyclosporine in cardiac transplantation. Can J Surg 1984; 27:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/34\">",
"      Bennett WM. Insights into chronic cyclosporine nephrotoxicity. Int J Clin Pharmacol Ther 1996; 34:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/35\">",
"      Bennett WM, DeMattos A, Meyer MM, et al. Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy. Kidney Int 1996; 50:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/36\">",
"      Van Buren DH, Burke JF, Lewis RM. Renal function in patients receiving long-term cyclosporine therapy. J Am Soc Nephrol 1994; 4:S17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/37\">",
"      El Kossi MM, Ibrahim A, Lock TJ, El Nahas AM. Impact of cardiac transplantation on kidney function: a single- center experience. Transplant Proc 2003; 35:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/38\">",
"      van Gelder T, Balk AH, Zietse R, et al. Renal insufficiency after heart transplantation: a case-control study. Nephrol Dial Transplant 1998; 13:2322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/39\">",
"      Waser M, Maggiorini M, Binswanger U, et al. Irreversibility of cyclosporine-induced renal function impairment in heart transplant recipients. J Heart Lung Transplant 1993; 12:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/40\">",
"      Greenberg A, Thompson ME, Griffith BJ, et al. Cyclosporine nephrotoxicity in cardiac allograft patients--a seven-year follow-up. Transplantation 1990; 50:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/41\">",
"      Goldstein DJ, Zuech N, Sehgal V, et al. Cyclosporine-associated end-stage nephropathy after cardiac transplantation: incidence and progression. Transplantation 1997; 63:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/42\">",
"      Zaltzman JS, Pei Y, Maurer J, et al. Cyclosporine nephrotoxicity in lung transplant recipients. Transplantation 1992; 54:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/43\">",
"      Greenberg A, Egel JW, Thompson ME, et al. Early and late forms of cyclosporine nephrotoxicity: studies in cardiac transplant recipients. Am J Kidney Dis 1987; 9:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/44\">",
"      McKenzie N, Keown P, Stiller C, et al. Effects of cyclosporine on renal function following orthotopic heart transplantation. J Heart Transplant 1985; 4:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/45\">",
"      Ziolkowski J, Paczek L, Senatorski G, et al. Renal function after liver transplantation: calcineurin inhibitor nephrotoxicity. Transplant Proc 2003; 35:2307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/46\">",
"      Lynn, M, Abreo, K, Zibari, G, McDonald, J. End-stage renal disease in liver transplants. Clin Transplant 2001; 6:S66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/47\">",
"      Platz KP, Mueller AR, Blumhardt G, et al. Nephrotoxicity after orthotopic liver transplantation in cyclosporin A and FK 506-treated patients. Transpl Int 1994; 7 Suppl 1:S52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/48\">",
"      Platz KP, Mueller AR, Blumhardt G, et al. Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. Transplantation 1994; 58:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/49\">",
"      Pattison JM, Petersen J, Kuo P, et al. The incidence of renal failure in one hundred consecutive heart-lung transplant recipients. Am J Kidney Dis 1995; 26:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/50\">",
"      Fisher NC, Nightingale PG, Gunson BK, et al. Chronic renal failure following liver transplantation: a retrospective analysis. Transplantation 1998; 66:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/51\">",
"      Sehgal V, Radhakrishnan J, Appel GB, et al. Progressive renal insufficiency following cardiac transplantation: cyclosporine, lipids, and hypertension. Am J Kidney Dis 1995; 26:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/52\">",
"      Wilkinson AH, Cohen DJ. Renal failure in the recipients of nonrenal solid organ transplants. J Am Soc Nephrol 1999; 10:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/53\">",
"      Myers BD. Cyclosporine nephrotoxicity. Kidney Int 1986; 30:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/54\">",
"      Puschett JB, Greenberg A, Holley J, McCauley J. The spectrum of ciclosporin nephrotoxicity. Am J Nephrol 1990; 10:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/55\">",
"      Bertani T, Ferrazzi P, Schieppati A, et al. Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients. Kidney Int 1991; 40:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/56\">",
"      Myers BD, Ross J, Newton L, et al. Cyclosporine-associated chronic nephropathy. N Engl J Med 1984; 311:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/57\">",
"      Schwarz A, Haller H, Schmitt R, et al. Biopsy-diagnosed renal disease in patients after transplantation of other organs and tissues. Am J Transplant 2010; 10:2017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/58\">",
"      Schmid H, Burg M, Kretzler M, et al. BK virus associated nephropathy in native kidneys of a heart allograft recipient. Am J Transplant 2005; 5:1562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/59\">",
"      Limaye AP, Smith KD, Cook L, et al. Polyomavirus nephropathy in native kidneys of non-renal transplant recipients. Am J Transplant 2005; 5:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/60\">",
"      Barber CE, Hewlett TJ, Geldenhuys L, et al. BK virus nephropathy in a heart transplant recipient: case report and review of the literature. Transpl Infect Dis 2006; 8:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/61\">",
"      Jain A, Reyes J, Kashyap R, et al. Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg 2000; 232:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/62\">",
"      A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. The U.S. Multicenter FK506 Liver Study Group. N Engl J Med 1994; 331:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/63\">",
"      Gonwa TA, Mai ML, Melton LB, et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation 2001; 72:1934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/64\">",
"      Iwatsuki S, Esquivel CO, Klintmalm GB, et al. Nephrotoxicity of cyclosporine in liver transplantation. Transplant Proc 1985; 17:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/65\">",
"      de Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis 2000; 35:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/66\">",
"      Nair S, Verma S, Thuluvath PJ. Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology 2002; 35:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/67\">",
"      Gonwa TA, McBride MA, Anderson K, et al. Continued influence of preoperative renal function on outcome of orthotopic liver transplant (OLTX) in the US: where will MELD lead us? Am J Transplant 2006; 6:2651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/68\">",
"      Sanchez EQ, Gonwa TA, Levy MF, et al. Preoperative and perioperative predictors of the need for renal replacement therapy after orthotopic liver transplantation. Transplantation 2004; 78:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/69\">",
"      Gonwa TA, Klintmalm GB, Levy M, et al. Impact of pretransplant renal function on survival after liver transplantation. Transplantation 1995; 59:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/70\">",
"      Jeyarajah DR, Gonwa TA, McBride M, et al. Hepatorenal syndrome: combined liver kidney transplants versus isolated liver transplant. Transplantation 1997; 64:1760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/71\">",
"      Marik PE, Wood K, Starzl TE. The course of type 1 hepato-renal syndrome post liver transplantation. Nephrol Dial Transplant 2006; 21:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/72\">",
"      Cabezuelo JB, Ram&iacute;rez P, R&iacute;os A, et al. Risk factors of acute renal failure after liver transplantation. Kidney Int 2006; 69:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/73\">",
"      O'Riordan A, Wong V, McQuillan R, et al. Acute renal disease, as defined by the RIFLE criteria, post-liver transplantation. Am J Transplant 2007; 7:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/74\">",
"      Simpson N, Cho YW, Cicciarelli JC, et al. Comparison of renal allograft outcomes in combined liver-kidney transplantation versus subsequent kidney transplantation in liver transplant recipients: Analysis of UNOS Database. Transplantation 2006; 82:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/75\">",
"      Fioretto P, Mauer SM, Bilous RW, et al. Effects of pancreas transplantation on glomerular structure in insulin-dependent diabetic patients with their own kidneys. Lancet 1993; 342:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/76\">",
"      Fioretto P, Steffes MW, Mihatsch MJ, et al. Cyclosporine associated lesions in native kidneys of diabetic pancreas transplant recipients. Kidney Int 1995; 48:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/77\">",
"      Fioretto P, Steffes MW, Sutherland DE, et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998; 339:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/78\">",
"      Fioretto P, Kim Y, Mauer M. Diabetic nephropathy as a model of reversibility of established renal lesions. Curr Opin Nephrol Hypertens 1998; 7:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/79\">",
"      Brennan DC, Stratta RJ, Lowell JA, et al. Cyclosporine challenge in the decision of combined kidney-pancreas versus solitary pancreas transplantation. Transplantation 1994; 57:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/80\">",
"      Lindel&ouml;w B, Bergh CH, Herlitz H, Waagstein F. Predictors and evolution of renal function during 9 years following heart transplantation. J Am Soc Nephrol 2000; 11:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/81\">",
"      Bourge RC, Naftel DC, Costanzo-Nordin MR, et al. Pretransplantation risk factors for death after heart transplantation: a multiinstitutional study. The Transplant Cardiologists Research Database Group. J Heart Lung Transplant 1993; 12:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/82\">",
"      Radovancevic B, Birovljev S, Frazier OH, et al. Long-term follow-up of cyclosporine-treated cardiac transplant recipients. Transplant Proc 1990; 22:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/83\">",
"      Herlitz H, Lindel&ouml;w B. Renal failure following cardiac transplantation. Nephrol Dial Transplant 2000; 15:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/84\">",
"      Lewis RM, Van Buren CT, Radovancevic B, et al. Impact of long-term cyclosporine immunosuppressive therapy on native kidneys versus renal allografts: serial renal function in heart and kidney transplant recipients. J Heart Lung Transplant 1991; 10:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/85\">",
"      Gonwa TA, Mai ML, Pilcher J, et al. Stability of long-term renal function in heart transplant patients treated with induction therapy and low-dose cyclosporine. J Heart Lung Transplant 1992; 11:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/86\">",
"      Zietse R, Balk AH, vd Dorpel MA, et al. Time course of the decline in renal function in cyclosporine-treated heart transplant recipients. Am J Nephrol 1994; 14:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/87\">",
"      Tinawi M, Miller L, Bastani B. Renal function in cardiac transplant recipients: retrospective analysis of 133 consecutive patients in a single center. Clin Transplant 1997; 11:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/88\">",
"      Goral S, Ynares C, Shyr Y, et al. Long-term renal function in heart transplant recipients receiving cyclosporine therapy. J Heart Lung Transplant 1997; 16:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/89\">",
"      Cirillo M, De Santo LS, Pollastro RM, et al. Creatinine clearance and hemoglobin concentration before and after heart transplantation. Semin Nephrol 2005; 25:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/90\">",
"      Arora S, Andreassen A, Simonsen S, et al. Prognostic importance of renal function 1 year after heart transplantation for all-cause and cardiac mortality and development of allograft vasculopathy. Transplantation 2007; 84:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/91\">",
"      Deuse T, Haddad F, Pham M, et al. Twenty-year survivors of heart transplantation at Stanford University. Am J Transplant 2008; 8:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/92\">",
"      Al Aly Z, Abbas S, Moore E, et al. The natural history of renal function following orthotopic heart transplant. Clin Transplant 2005; 19:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/93\">",
"      Taylor DO, Edwards LB, Boucek MM, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult heart transplant report--2005. J Heart Lung Transplant 2005; 24:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/94\">",
"      Alam A, Badovinac K, Ivis F, et al. The outcome of heart transplant recipients following the development of end-stage renal disease: analysis of the Canadian Organ Replacement Register (CORR). Am J Transplant 2007; 7:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/95\">",
"      Villar E, Boissonnat P, Sebbag L, et al. Poor prognosis of heart transplant patients with end-stage renal failure. Nephrol Dial Transplant 2007; 22:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/96\">",
"      Lonze BE, Warren DS, Stewart ZA, et al. Kidney transplantation in previous heart or lung recipients. Am J Transplant 2009; 9:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/97\">",
"      Gill J, Shah T, Hristea I, et al. Outcomes of simultaneous heart-kidney transplant in the US: a retrospective analysis using OPTN/UNOS data. Am J Transplant 2009; 9:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/98\">",
"      Cassuto JR, Reese PP, Reese P, et al. Kidney transplantation in patients with a prior heart transplant. Transplantation 2010; 89:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/99\">",
"      Broekroelofs J, Stegeman CA, Navis G, de Jong PE. Prevention of renal function loss after non-renal solid organ transplantation--how can nephrologists help to keep the kidneys out of the line of fire? Nephrol Dial Transplant 1999; 14:1841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/100\">",
"      Maurer JR, Tewari S. Nonpulmonary medical complications in the intermediate and long-term survivor. Clin Chest Med 1997; 18:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/101\">",
"      Broekroelofs J, Navis GJ, Stegeman CA, et al. Long-term renal outcome after lung transplantation is predicted by the 1-month postoperative renal function loss. Transplantation 2000; 69:1624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/102\">",
"      Navis G, Broekroelofs J, Mannes GP, et al. Renal hemodynamics after lung transplantation. A prospective study. Transplantation 1996; 61:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/103\">",
"      Tsimaratos M, Viard L, Kreitmann B, et al. Kidney function in cyclosporine-treated paediatric pulmonary transplant recipients. Transplantation 2000; 69:2055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/104\">",
"      Ishani A, Erturk S, Hertz MI, et al. Predictors of renal function following lung or heart-lung transplantation. Kidney Int 2002; 61:2228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/105\">",
"      Canales M, Youssef P, Spong R, et al. Predictors of chronic kidney disease in long-term survivors of lung and heart-lung transplantation. Am J Transplant 2006; 6:2157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/106\">",
"      Groetzner J, Wittwer T, Kaczmarek I, et al. Conversion to sirolimus and mycophenolate can attenuate the progression of bronchiolitis obliterans syndrome and improves renal function after lung transplantation. Transplantation 2006; 81:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/107\">",
"      Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/108\">",
"      Ryan EA, Paty BW, Senior PA, et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005; 54:2060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/109\">",
"      Senior PA, Zeman M, Paty BW, et al. Changes in renal function after clinical islet transplantation: four-year observational study. Am J Transplant 2007; 7:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/110\">",
"      Senior PA, Paty BW, Cockfield SM, et al. Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing. Am J Transplant 2005; 5:2318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/111\">",
"      Fiorina P, Folli F, Zerbini G, et al. Islet transplantation is associated with improvement of renal function among uremic patients with type I diabetes mellitus and kidney transplants. J Am Soc Nephrol 2003; 14:2150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/112\">",
"      Bloom RD, Doyle AM. Kidney disease after heart and lung transplantation. Am J Transplant 2006; 6:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/113\">",
"      Tzakis AG, Kato T, Levi DM, et al. 100 multivisceral transplants at a single center. Ann Surg 2005; 242:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/114\">",
"      Ueno T, Kato T, Gaynor J, et al. Renal dysfunction following adult intestinal transplant under tacrolimus-based immunosuppression. Transplant Proc 2006; 38:1762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/115\">",
"      Ueno T, Kato T, Gaynor J, et al. Renal function after pediatric intestinal transplant. Transplant Proc 2006; 38:1759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/116\">",
"      Herlenius G, F&auml;gerlind M, Krantz M, et al. Chronic kidney disease--a common and serious complication after intestinal transplantation. Transplantation 2008; 86:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/117\">",
"      Stigant CE, Cohen J, Vivera M, Zaltzman JS. ACE inhibitors and angiotensin II antagonists in renal transplantation: an analysis of safety and efficacy. Am J Kidney Dis 2000; 35:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/118\">",
"      Hausberg M, Barenbrock M, Hohage H, et al. ACE inhibitor versus beta-blocker for the treatment of hypertension in renal allograft recipients. Hypertension 1999; 33:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/119\">",
"      Borchhardt K, Haas N, Yilmaz N, et al. Low dose angiotensin converting enzyme inhibition and glomerular permselectivity in renal transplant recipients. Kidney Int 1997; 52:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/120\">",
"      Traindl O, Falger S, Reading S, et al. The effects of lisinopril on renal function in proteinuric renal transplant recipients. Transplantation 1993; 55:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/121\">",
"      Bochicchio T, Sandoval G, Ron O, et al. Fosinopril prevents hyperfiltration and decreases proteinuria in post-transplant hypertensives. Kidney Int 1990; 38:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/122\">",
"      Bunke M, Ganzel B. Effect of calcium channel antagonists on renal function in hypertensive heart transplant recipients. J Heart Lung Transplant 1992; 11:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/123\">",
"      Chan C, Maurer J, Cardella C, et al. A randomized controlled trial of verapamil on cyclosporine nephrotoxicity in heart and lung transplant recipients. Transplantation 1997; 63:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/124\">",
"      Fassi A, Sangalli F, Colombi F, et al. Beneficial effects of calcium channel blockade on acute glomerular hemodynamic changes induced by cyclosporine. Am J Kidney Dis 1999; 33:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/125\">",
"      Elliott WJ, Murphy MB, Karp R. Long-term preservation of renal function in hypertensive heart transplant recipients treated with enalapril and a diuretic. J Heart Lung Transplant 1991; 10:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/126\">",
"      van Gelder T, Balk AH, Zietse R, et al. Survival of heart transplant recipients with cyclosporine-induced renal insufficiency. Transplant Proc 1998; 30:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/127\">",
"      Israni A, Brozena S, Pankewycz O, et al. Conversion to tacrolimus for the treatment of cyclosporine-associated nephrotoxicity in heart transplant recipients. Am J Kidney Dis 2002; 39:E16.",
"     </a>",
"    </li>",
"    <li>",
"     Garlicki, M, Czub, P, Labus, K, et al. Conversion from cyclosporine to.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/129\">",
"      Cantarovich D, Renou M, Megnigbeto A, et al. Switching from cyclosporine to tacrolimus in patients with chronic transplant dysfunction or cyclosporine-induced adverse events. Transplantation 2005; 79:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/130\">",
"      Kobashigawa JA, Miller LW, Russell SD, et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006; 6:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/131\">",
"      Pratschke J, Neuhaus R, Tullius SG, et al. Treatment of cyclosporine-related adverse effects by conversion to tacrolimus after liver transplantation. Transplantation 1997; 64:938.",
"     </a>",
"    </li>",
"    <li>",
"     Lucey, MR, Abdelmalek, MF, Gagliardi, R, et al. A comparison of.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/133\">",
"      Neuberger JM, Mamelok RD, Neuhaus P, et al. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. Am J Transplant 2009; 9:327.",
"     </a>",
"    </li>",
"    <li>",
"     Nankivell, BJ, Chapman, JR, Bonovas, G &amp; Gruenewald, SM. Oral.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/135\">",
"      Klein IH, Abrahams A, van Ede T, et al. Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. Transplantation 2002; 73:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/136\">",
"      Stalder M, B&icirc;rsan T, Hubble RW, et al. In vivo evaluation of the novel calcineurin inhibitor ISATX247 in non-human primates. J Heart Lung Transplant 2003; 22:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/137\">",
"      Sanchez V, Delgado JF, Morales JM, et al. Chronic cyclosporine-induced nephrotoxiciy in heart transplant patients: long-term benefits of treatment with mycophenolate mofetil and low-dose cyclosporine. Transplant Proc 2004; 36:2823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/138\">",
"      Groetzner J, Meiser B, Landwehr P, et al. Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure. Transplantation 2004; 77:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/139\">",
"      Groetzner J, Kaczmarek I, Landwehr P, et al. Renal recovery after conversion to a calcineurin inhibitor-free immunosuppression in late cardiac transplant recipients. Eur J Cardiothorac Surg 2004; 25:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/140\">",
"      Tedoriya T, Keogh AM, Kusano K, et al. Reversal of chronic cyclosporine nephrotoxicity after heart transplantation-potential role of mycophenolate mofetil. J Heart Lung Transplant 2002; 21:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/141\">",
"      Angermann CE, St&ouml;rk S, Costard-J&auml;ckle A, et al. Reduction of cyclosporine after introduction of mycophenolate mofetil improves chronic renal dysfunction in heart transplant recipients--the IMPROVED multi-centre study. Eur Heart J 2004; 25:1626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/142\">",
"      Tr&ouml;sch F, Rothenburger M, Schneider M, et al. First experience with rapamycin-based immunosuppression to improve kidney function after heart transplantation. Thorac Cardiovasc Surg 2004; 52:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/143\">",
"      Bestetti R, Theodoropoulos TA, Burdmann EA, et al. Switch from calcineurin inhibitors to sirolimus-induced renal recovery in heart transplant recipients in the midterm follow-up. Transplantation 2006; 81:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/28/34250/abstract/144\">",
"      Al-Aly Z, Sachdeva A, Philoctete Ashley JM, Bastani B. Preliminary experience with mycophenolate mofetil for preservation of renal function in cardiac transplant patients with documented cyclosporine nephrotoxicity. Nephrology (Carlton) 2006; 11:151.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7331 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-427C511A25-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_28_34250=[""].join("\n");
var outline_f33_28_34250=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREOPERATIVE EVALUATION OF KIDNEY FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Liver failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      General summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CKD AFTER NON-RENAL ORGAN TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pancreas transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Renal replacement therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Islet cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Heart-lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Intestinal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PREVENTION AND TREATMENT STRATEGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Immunosuppression regimens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7331\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7331|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/52/9038\" title=\"figure 1\">",
"      Cr concentration Heart Tx",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/19/41272?source=related_link\">",
"      Benefits and complications associated with kidney-pancreas transplantation in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/7/6266?source=related_link\">",
"      Clinical manifestations and diagnosis of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=related_link\">",
"      Cyclosporine and tacrolimus nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/32/521?source=related_link\">",
"      Epidemiology of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8472?source=related_link\">",
"      Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/6/99?source=related_link\">",
"      Heart-lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/50/29482?source=related_link\">",
"      Hepatorenal syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/23/16761?source=related_link\">",
"      Hypertension after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21690?source=related_link\">",
"      Indications for and complications of renal biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/26/25000?source=related_link\">",
"      Lipid abnormalities after cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/26/40362?source=related_link\">",
"      Long-term management of adult liver transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/9/17562?source=related_link\">",
"      Mammalian target of rapamycin (mTOR) inhibitors in renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/45/42712?source=related_link\">",
"      Management of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=related_link\">",
"      NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/63/7162?source=related_link\">",
"      Pancreas and islet transplantation in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18072?source=related_link\">",
"      Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/16/7434?source=related_link\">",
"      Patient selection for and immunologic issues relating to kidney-pancreas transplantation in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12154?source=related_link\">",
"      Primary hyperoxaluria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/15/22775?source=related_link\">",
"      Prognosis after cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=related_link\">",
"      Urinalysis in the diagnosis of kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_28_34251="Enuresis examination";
var content_f33_28_34251=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80638&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80638&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Important aspects of the physical examination of a child with enuresis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Examination finding",
"       </td>",
"       <td class=\"subtitle1\">",
"        Possible significance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poor growth",
"       </td>",
"       <td>",
"        Renal disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypertension",
"       </td>",
"       <td>",
"        Renal disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wetness in the undergarments",
"       </td>",
"       <td>",
"        Daytime incontinence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Palpation of stool in abdomen",
"       </td>",
"       <td>",
"        Constipation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perianal excoriation or vulvovaginitis",
"       </td>",
"       <td>",
"        Pinworms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abnormalities of lumbosacral spine (midline hair tuft, abnormal gluteal fold)",
"       </td>",
"       <td>",
"        Spinal dysraphism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Incomplete bladder emptying (by percussion or palpation)",
"       </td>",
"       <td>",
"        Urologic abnormality",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Observation of slow urinary stream, straining, dribbling, intermittent stream",
"       </td>",
"       <td>",
"        Urologic abnormality",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Undescended testicles, underdeveloped scrotum, abnormal location of urethral meatus",
"       </td>",
"       <td>",
"        Urologic abnormality",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abnormal neurologic examination of the perineum and lower extremities",
"       </td>",
"       <td>",
"        Spinal cord abnormality",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_28_34251=[""].join("\n");
var outline_f33_28_34251=null;
var title_f33_28_34252="Chronic impairment gas exchange";
var content_f33_28_34252=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78105&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78105&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Social security disability criteria for chronic impairment of gas exchange (any cause)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Arterial PCO2 (mmHg)",
"       </td>",
"       <td class=\"subtitle2\">",
"        AND",
"       </td>",
"       <td class=\"subtitle1\">",
"        Arterial PO2 equal to or less",
"than (in mmHg, &lt;3,000 ft. above sea level)",
"       </td>",
"       <td class=\"subtitle2\">",
"        OR",
"       </td>",
"       <td class=\"subtitle1\">",
"        Arterial PO2 equal to or less",
"than (in mmHg, 3,000 to 5,000 ft. above sea level)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        30 or below",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        31",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        59",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        58",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        57",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        56",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        55",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        54",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        37",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        53",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        57",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        52",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        51",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        40 or above",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Steady-state exercise blood gases demonstrating values of PaO2 and simultaneously determined PaCO2, measured at a work load (VO2) of approximately 17 ml of O2/kg/min or less of exercise, equal to or less than the values specified.",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from *Disability Evaluation Under Social Security. U.S. Department of Health and Human Services, SSA Publication No. 05-10089, February 1986.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_28_34252=[""].join("\n");
var outline_f33_28_34252=null;
var title_f33_28_34253="NYHA class and survival HF";
var content_f33_28_34253=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F63748&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F63748&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    New York Heart Association (NYHA) class predicts survival in heart failure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 240px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patient survival according to functional class in heart failure. Survival varies markedly with functional class, from as high as 81 percent at four years in asymptomatic patients (NYHA class I) to as low as 36 percent at one year in patients with NYHA class IV.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <br>",
"       <ol>",
"        <li>",
"         The SOLVD Investigators, N Engl J Med 1992; 327:685.",
"        </li>",
"        <li>",
"         The SOLVD Investigators, N Engl J Med 1991; 325:293.",
"        </li>",
"        <li>",
"         The CONSENSUS Trial Study Group 1987; 316:1429.",
"        </li>",
"       </ol>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_28_34253=[""].join("\n");
var outline_f33_28_34253=null;
var title_f33_28_34254="Contents: Cardiovascular disease";
var content_f33_28_34254=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?43/6/44141\">",
"       Geriatrics",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Cardiovascular disease",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Cardiovascular disease",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Atrial fibrillation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/54/28522\">",
"           Epidemiology of and risk factors for atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/6/39016\">",
"           Management of new onset atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/22/361\">",
"           Overview of atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/41/31384\">",
"           Paroxysmal atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/29/39383\">",
"           Stroke in patients with atrial fibrillation",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Coronary artery disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/18/17705\">",
"           Cardiac rehabilitation: Exercise training and secondary prevention of coronary heart disease in older adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/59/16314\">",
"           Coronary reperfusion for acute myocardial infarction in older adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/41/44697\">",
"           Overview of the acute management of ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/20/37193\">",
"           Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/28/3529\">",
"           Overview of the care of patients with stable ischemic heart disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         General",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/52/27463\">",
"           Indications for permanent cardiac pacing",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Heart failure",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/45/16090\">",
"           ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/30/24042\">",
"           Atrial fibrillation in patients with heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/56/18314\">",
"           Cardiac resynchronization therapy in heart failure: Indications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/22/43368\">",
"           Clinical manifestations and diagnosis of diastolic heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/37/2650\">",
"           End of life considerations for heart failure patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/8/15497\">",
"           Epidemiology and causes of heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/59/28601\">",
"           Evaluation and management of asymptomatic left ventricular systolic dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/28/39369\">",
"           Evaluation of the patient with heart failure or cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/30/19945\">",
"           Evaluation of the patient with suspected heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/55/25465\">",
"           Heart failure self management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/56/7048\">",
"           Indications for antithrombotic therapy in heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/40/4743\">",
"           Management of refractory heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/63/38906\">",
"           Overview of the therapy of heart failure due to systolic dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/61/4058\">",
"           Prognosis of heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/55/19322\">",
"           Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/56/24453\">",
"           Statin therapy in patients with heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/20/35143\">",
"           Surgical management of heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/54/7018\">",
"           Treatment and prognosis of diastolic heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/7/41079\">",
"           Treatment of acute decompensated heart failure: General considerations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/22/29031\">",
"           Treatment of hypertension in patients with heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/38/12905\">",
"           Use of beta blockers in heart failure due to systolic dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/47/21241\">",
"           Ventricular arrhythmias in heart failure and cardiomyopathy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Valvular disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/11/1208\">",
"           Aortic valve area in aortic stenosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/24/38279\">",
"           Aortic valve sclerosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/12/21706\">",
"           Clinical features and evaluation of aortic stenosis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/8/31881\">",
"           Indications for valve replacement in aortic stenosis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/62/2025\">",
"           Medical management of asymptomatic aortic stenosis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/43/41654\">",
"           Medical management of symptomatic aortic stenosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/58/37801\">",
"           Mitral annular calcification",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/53/30551\">",
"           Natural history of aortic stenosis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/14/13544\">",
"           Noncardiac surgery in patients with aortic stenosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/31/39411\">",
"           Percutaneous aortic valvotomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/37/11865\">",
"           Surgical valve replacement in aortic stenosis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/29/34264\">",
"           Transcatheter aortic valve replacement",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/36/34377\">",
"           Valvular heart disease in elderly adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Vascular disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/17/13592\">",
"           Clinical evaluation of lower extremity chronic venous disease",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-A529210E0E-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f33_28_34254=[""].join("\n");
var outline_f33_28_34254=null;
var title_f33_28_34255="WHO MEC for reproductive tract infections and disorders";
var content_f33_28_34255=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F60832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F60832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    World Health Organization medical eligibility for contraceptive use: Reproductive tract infections and disorders",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        COC",
"       </td>",
"       <td class=\"subtitle1\">",
"        CIC",
"       </td>",
"       <td class=\"subtitle1\">",
"        P/R",
"       </td>",
"       <td class=\"subtitle1\">",
"        POP",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         DMPA",
"        </p>",
"        <p>",
"         NET-EN",
"        </p>",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         LNG/ETG",
"        </p>",
"        <p>",
"         Implants",
"        </p>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cu-IUD",
"       </td>",
"       <td class=\"subtitle1\">",
"        LNG-IUD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"9\">",
"        Vaginal bleeding patterns",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Irregular pattern without heavy bleeding",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        2",
"       </td>",
"       <td rowspan=\"2\">",
"        2",
"       </td>",
"       <td rowspan=\"2\">",
"        2",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td>",
"        Initiation: 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Continuation: 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Heavy or prolonged bleeding (includes regular and irregular patterns)",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        2",
"       </td>",
"       <td rowspan=\"2\">",
"        2",
"       </td>",
"       <td rowspan=\"2\">",
"        2",
"       </td>",
"       <td rowspan=\"2\">",
"        2",
"       </td>",
"       <td>",
"        Initiation: 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Continuation: 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"9\">",
"        Unexplained vaginal bleeding (suspicious for serious condition)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Before evaluation",
"       </td>",
"       <td rowspan=\"2\">",
"        2",
"       </td>",
"       <td rowspan=\"2\">",
"        2",
"       </td>",
"       <td rowspan=\"2\">",
"        2",
"       </td>",
"       <td rowspan=\"2\">",
"        2",
"       </td>",
"       <td rowspan=\"2\">",
"        3",
"       </td>",
"       <td rowspan=\"2\">",
"        3",
"       </td>",
"       <td>",
"        Initiation: 4",
"       </td>",
"       <td>",
"        Initiation: 4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Continuation: 2",
"       </td>",
"       <td>",
"        Continuation: 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Endometriosis",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Benign ovarian tumors (including cysts)",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Severe dysmenorrhoea",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"9\">",
"        Gestational trophoblastic disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Decreasing or undetectable human chorionic gonadotropin levels",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Persistently elevated human chorionic gonadotropin levels or malignant disease",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Cervical ectropion",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Cervical intraepithelial neoplasia (CIN)",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" rowspan=\"2\">",
"        Cervical cancer (awaiting treatment)",
"       </td>",
"       <td rowspan=\"2\">",
"        2",
"       </td>",
"       <td rowspan=\"2\">",
"        2",
"       </td>",
"       <td rowspan=\"2\">",
"        2",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        2",
"       </td>",
"       <td rowspan=\"2\">",
"        2",
"       </td>",
"       <td>",
"        Initiation: 4",
"       </td>",
"       <td>",
"        Initiation: 4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Continuation: 2",
"       </td>",
"       <td>",
"        Continuation: 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"9\">",
"        Breast disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Undiagnosed mass",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Benign breast disease",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Family history of cancer",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"9\">",
"        Cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Current",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Past and no evidence of current disease for 5 years",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" rowspan=\"2\">",
"        Endometrial cancer",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td>",
"        Initiation: 4",
"       </td>",
"       <td>",
"        Initiation: 4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Continuation: 2",
"       </td>",
"       <td>",
"        Continuation: 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" rowspan=\"2\">",
"        Ovarian cancer",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td>",
"        Initiation: 3",
"       </td>",
"       <td>",
"        Initiation: 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Continuation: 2",
"       </td>",
"       <td>",
"        Continuation: 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"9\">",
"        Uterine fibroids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Without distortion of the uterine cavity",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        With distortion of the uterine cavity",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"9\">",
"        Anatomical abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        That distort the uterine cavity",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        That do not distort the uterine cavity",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"9\">",
"        Pelvic inflammatory disease (PID)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"9\">",
"        Past PID (assuming no current risk factors of STIs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" rowspan=\"2\">",
"        With subsequent pregnancy",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td>",
"        Initiation: 1",
"       </td>",
"       <td>",
"        Initiation: 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Continuation: 1",
"       </td>",
"       <td>",
"        Continuation: 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" rowspan=\"2\">",
"        Without subsequent pregnancy",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td>",
"        Initiation: 2",
"       </td>",
"       <td>",
"        Initiation: 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Continuation: 2",
"       </td>",
"       <td>",
"        Continuation: 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        PID - current or within last three months",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td>",
"        Initiation: 4",
"       </td>",
"       <td>",
"        Initiation: 4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Continuation: 2",
"       </td>",
"       <td>",
"        Continuation: 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"9\">",
"        STIs (sexually transmitted infections)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Current purulent cervicitis or chlamydial infection or gonorrhoea",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td>",
"        Initiation: 4",
"       </td>",
"       <td>",
"        Initiation: 4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Continuation: 2",
"       </td>",
"       <td>",
"        Continuation: 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Other STIs (excluding HIV and hepatitis)",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td>",
"        Initiation: 2",
"       </td>",
"       <td>",
"        Initiation: 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Continuation: 2",
"       </td>",
"       <td>",
"        Continuation: 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Vaginitis (including trichomonas vaginalis and bacterial vaginosis)",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td>",
"        Initiation: 2",
"       </td>",
"       <td>",
"        Initiation: 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Continuation: 2",
"       </td>",
"       <td>",
"        Continuation: 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Increased risk of STIs",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td>",
"        Initiation: 2/3",
"       </td>",
"       <td>",
"        Initiation: 2/3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Continuation: 2",
"       </td>",
"       <td>",
"        Continuation: 2",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    1: A condition for which there is no restriction for the use of the contraceptive method.",
"    <br>",
"     2: A condition where the advantages of using the method generally outweigh the theoretical or proven risks.",
"     <br>",
"      3: A condition where the theoretical or proven risks usually outweigh the advantages of using the method.",
"      <br>",
"       4: A condition which represents an unacceptable health risk if the contraceptive method is used.",
"       <div class=\"footnotes\">",
"        COC: low-dose combined oral contraceptive; CIC: combined injectable contraceptives; P: combined patch; R: combined vaginal ring; POP: progestogen-only pill; DMPA: depot medroxyprogesterone acetate; NET-EN: norethisterone enantate; LNG: levonorgestrel; ETG: etonogestrel; ECP: emergency contraceptive pill; Cu-IUD: copper intrauterine device; LNG-IUD: levonorgestrel-releasing IUDs; E-IUD: copper-IUD for emergency contraception; BARR: barrier methods; FAB: fertility awareness-based methods; LAM: lactational amenorrhoea method; CI: coitus interruptus; STER: female and male sterilization.",
"       </div>",
"       <div class=\"reference\">",
"        Reproduced with permission from: file://www.who.int/reproductive-health/publications/mec/summary.html. Copyright &copy; 2006 World Health Organization. Updated and revised 2009.",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_28_34255=[""].join("\n");
var outline_f33_28_34255=null;
